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Abstract
Strained-ring systems including vinylcyclopropanes, phenyl- and vinylaziridines were utilised to
undergo ring-opening reactions under the catalysis of organotransition-metals in this research. Firstly,
PdCl2(MeCN)2 catalysed the formal [3+2] annulations of N-activated aziridines to construct a number
of potentially bioactive pyrroloindolines in one-pot with C3-substituted indoles. Furthermore,
C3-unsubstituted indoles were treated with N-tosyl arylaziridines in the presence of PdCl2(MeCN)2
via a Friedel–Crafts pathway. The resulting β-substituted tryptamines then undergo the ring-closure
with N-fluorobenzenesulfonimide to produce C3-fluorinated pyrroloindolines in moderate yields and
selectivities. In chapter 2, the palladium(II)-catalysed addition of arylboronic acids to N-activated
vinylaziridines has been developed. This reaction proceeds via a redox-neutral insertion/ring-opening
process to provide unusual (Z)-allylsulfonamides preferentially. Finally, a highly efficient
ring-opening reaction of vinylcyclopropanes by boronic acids was reported in the chapter 3, using
palladium nanoparticles formed from Pd(OAc)2 and boronic acids in neat water. Linear and branched
regioselectivities were obtained using vinylcyclopropanes and aryl-substituted vinylcyclopropanes
respectively under these ligandless conditions.
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Abbreviations
Ac

acetate

Ar

aromatic ring

9-BBN

9-borabicyclo(3.3.1)nonane

BINAP

2,2'-bis(diphenylphosphino)-1,1'-binaphthyl

Bn

benzyl

BQ

1,4-benzoquinone

BPO

benzoyl peroxide

Bz

benzoyl

13

carbon nuclear magnetic resonance spectroscopy

COD

1,5-cyclooctadiene

DABCO

1,4-diazabicyclo[2.2.2]octane

dba

dibenzylideneacetone

DCE

1,2-dichloroethane

DCM

dichloromethane

DMA

dimethylacetamide

DMAP

4-dimethylaminopyridine

DMB

dimethoxybenzene

DMF

dimethylformamide

DMSO

dimethylsulfoxide

Dpp

diphenylphosphine oxide

1

proton nuclear magnetic resonance spectroscopy

hfacac

hexafluoroacetylacetone

LA

Lewis acid

LAH

lithium aluminium hydride

LDA

lithium diisopropylamide

Mes

methanesulfonyl

MS

mass spectrometry

NFSI

N-fluorobenzenesulfonimide

C NMR

H NMR
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NOESY

nuclear overhauser enhancement spectroscopy

Ns

4-nitrobenzenesulfonyl

NMO

N-Methylmorpholine-N-Oxide

OBoc

tert-butyl carbonate

Phen

1,10-phenanthroline

PMB

p-methoxybenzyl

PTAB

phenyltrimethylammonium perbromide

TBAB

tetrabutylammonium bromide

TBS

tert-butyldimethylsilyl

TFA

trifluoroacetic acid

Tf

trifluoromethanesulfonate

THF

tetrahydrofuran

TMS

trimethylsilyl

Ts

p-toluenesulfonyl

ηn

(ligand) coordinated through n adjacent atoms
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Chapter 1. The Reactivity and Synthesis of Indoles, Tryptamines and
Pyrrolindolines

Introduction

The transition-metal-catalysed synthesis of two nitrogen-containing heterocyclic classes:
pyrroloindolines and tryptamines were developed in this chapter. These two indole-derived
compounds have been frequently investigated due to their biological activities in the pharmacological
area. For example, sumatriptan 1 is used for migraine treatment1, and melatonin 5 has shown
promising bioactivity in treating insomnia in older adults (Figure 1a).2 In addition, it has been found
that pyrroloindolines such as physostigmine 2 and its analogues 3 and 4 have promising bioactivities
in the treatment of Alzheimer’s disease and function as anticholinesterase and insecticidal agents
(Figure 1b).345

Figure 1: a) Medicinally valuable indole-fused molecules b) Bioactive pyrroloindolines

Synthesis of Pyrroloindolines via the Lewis Acid-Catalysed [3+2] Cycloaddition of
C3-Substituted Indoles with Aziridines

It has been known that the synthesis of pyrroloindolines previously required multiple-step methods,
for example, a 3,3'-disubstituted indolenine 7, synthesised via the enantioselective Pd-catalysed
8

C3-allylation of C3-substitited indole 6, was treated with tetrabutylammonium oxone and acetic acid
to give enantiopure oxindole 8 in a good yield (Scheme 1). Subsequently, after sequential
methylation and oxidative cleavage of oxindole 8, a reductive amination-cyclisation process occurred
to convert previously generated aldehyde 9 to (–)-esermethole 10, which was then subjected to the
synthesis of (–)-phenserine 11 for treatment of Alzheimer’s disease.

Scheme 1: Synthesis of (_)-Phenserine 11

In this project, a more efficient method to synthesise the pyrroloindoline was developed using a
formal [3+2] cycloaddition of aziridines to indoles (Scheme 2). In the presence of Lewis acids, a
zwitterionic 1,3-dipole 13 could be given via the C-N bond cleavage of the aziridine 12 to undergo
nucleophilic attack of the indole 14 to give an iminium 15. As the indole 14 is C3-substituted by an
electron-donating group such as methyl, the anionic amide branch of the iminium intermediate 15
could intramolecularly attack the C2-position to achieve the ring-closure. Finally, the pyrroloindoline
skeleton 16 bearing three contiguous stereogenic centers is released. It is worth noting that an
electron-withdrawing N-protecting group such as tosyl is generally required to facilitate the C-N bond
breaking of 12 (Scheme 2a).6 Furthermore, a cation-stabilising R1 group of the aziridine 12 is
introduced to the final product 16 in the reaction, making the pyrroloindoline products 16 highly
functionalised.

9

Scheme 2: Lewis acid-catalysed synthesis of the pyrroloindoline 16 via the 1,3-dipole 13

This formal [3+2] dearomative cycloaddition of indole derivative has not been developed as a
general method for pyrroloindoline synthesis (Scheme 2), 7 with only a single report by the
Nakagawa group using a stoichiometric amount of Sc(OTf)3 and TMSCl as a cocatalyst system to
synthesise the pyrroloindoline skeleton 19 via the C-N bond cleavage of N-benzyloxycarbonyl
(Z)-aziridine 18 (Scheme 3). This is an efficient synthetic route to the insecticidal
compound–physostigmine 2, where the key step is alkylative cyclisation of 1,3-dimethylindole 17
with the aziridine 18 mediated by Sc(OTf)3 and TMSCl to give the cycloadduct 19 in a 90% yield.8
However, although 19 was directly prepared by this versatile methodology, a stoichiometric amount
of Lewis acid and flammable TMSCl are required, severely limiting its application. In addition, no
substrate scope for this reaction was explored. Arylaziridines, which stabilise the carbonium ion in 13,
should facilitate this process and increase the functionality of the targeted pyrroloindoline skeleton.
Reactivity of various arylaziridines in the presence of different metal-catalysts will therefore be
examined in this reaction.
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Scheme 3: A concise synthesis of physostigmine 15 from skatole 17 and activated aziridine 18 via formal [3+2]
cycloaddition

In conclusion, a catalytic process to construct the highly functionalised pyrroloindoline skeleton
first diastereoselectively and then enantioselectively with arylaziridines in the presence of Lewis
acids under the mild conditions is the goal of the project (Scheme 2).

Lewis Acid-Catalysed Synthesis of Tryptamines by C3-Unsubstituted Indoles and
Aziridines

The proposal in Scheme 2 demonstrates the potential application of C3-substituted indoles in the
synthesis of pyrroloindolines. In addition, it was envisioned that skeletons of indole-derived bioactive
tryptamines such as sumatriptan (Figure 1) could be synthesised via the substitution of
C3-unsubstituted indoles with 1,3-dipole 13 (Scheme 4). This Friedel–Crafts process would involve
the generation of 1,3-dipole 13 under Lewis acid conditions and subsequent iminium intermediate 21
resulting from the C3-substitution of 20 with 13. Finally, elimination releases the re-aromatised
β-substituted tryptamines 22 in contrast to the formal [3+2] cycloaddition (Scheme 2).
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Scheme 4: Lewis acid-catalysed synthesis of tryptamines 22

However, as a molecule that is frequently present in biologically active compounds,9 it is
surprising to find only limited examples reported for use of indole and its derivatives 20 in the
ring-opening reaction of the N-activated aziridines 12 (Scheme 4). For example, the Yadav group
utilised InCl3 as a mild Lewis acid to catalyse ring-opening of aziridines with 1H-indole 23 (Scheme
5).10 The ring-opening of less reactive symmetric alkylaziridine 24 was successful to give the
product 25 in a good yield under the conditions. However, a mixture of regioisomers 27a and 27b
were given in an excellent combined yield with the low regioselectivity with unsymmetric
arylaziridine 26. To develop a regioselective reaction with 26, appropriate conditions will be
identified in the project.

Scheme 5: InCl3-catalysed opening of aziridines with 1H-indole 23

In 2003, Farr demonstrated that N-nosyl aziridines 29 react with N-H 2-phenylindole 28 to
12

afford β-substituted tryptamines 31 in moderate to excellent yields with high enantioselectivities and
regioselectivities (Scheme 6). 11 Different enantiopure N-nosyl alkyl/phenylaziridines 29 were
selected as substrates for the reaction in the presence of a stoichiometric quantity of BF3.OEt2.
Furthermore, it is worth indicating that this non-catalytic reaction provides a method to synthesise
Gonanotropin releasing hormone (GnRH), which could be used for suppressing gonadal steroid
hormones to castrate levels. However, in addition to being a stoichiometric process, substrate scope
investigated is limited to C2 substituted indoles.

Scheme 6: Ring-opening of 2-alkyl nosylaziridines 29 by indoles 28 mediated by boron trifluoride

More Lewis acids were developed for the ring-opening reaction of aziridines with indoles. For
instance, sulphated zirconia, made by acidifying zirconium isopropoxide with sulfuric acid in
deionised water, could also be used as a Lewis acid to perform the ring-opening reaction of aziridines
with indoles. The Castillon group reported a single example of the ring-opening of phenylaziridine 26
with 1H-indole 23 to give a mixture of two regioisomers 32a and 32b of β-phenyl tryptamine in a
good yield. The nucleophilic attack preferentially occurs at the benzylic position of 26, but the
by-product generated from the C2-N bond breaking of 26 was still observed in the reaction (Scheme
7).12 The heterogeneous sulphated zirconia demonstrated excellent catalytic efficiency for various
acid-sensitive and slightly basic nucleophiles. Moreover, it can be reused for several times with no
loss of activity although the relatively harsh conditions are required for the preparation of the catalyst
(calcinations at 700 oC).
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Scheme 7: Ring-opening of phenylaziridine 26 with 1H-indole 23

Another early example for the ring-opening of aziridines with indole derivatives was reported by
the Tse group.13 They demonstrated a nucleophilic ring-opening reaction of a racemic N-activated
aziridine 34 with various electron-rich indoles 33 in the presence of activated silica gel (Scheme 8).
In this reaction, indoles 33 were utilised as the C-nucleophile to form bisindoles 35, which could be
kinase inhibitors, in excellent yields through an electrophilic aromatic substitution pathway. Notably,
the two N-protecting tert-butyloxycarbonyl groups of starting aziridine 34 could be easily removed
under the reaction conditions Furthermore, this reaction proceeded with excellent regioselectivity at
the C3-position of the indoles and the benzylic position of aziridines. However, a large amount of the
indole 33 (up to 10 equiv.) is required to ensure complete conversion of the aziridine 34 due to the
sublimation of 33, and only one N-tosyl aziridine 34 was utilised as a substrate.

Scheme 8: Ring-opening reaction of aziridine 34 with indoles 33 on activated silica

Subsequently, a diastereo- and enantioselective synthesis of 2-arylethylamines 40 was developed
by Ghorai and co-workers. This route has a single example that was achieved via intermolecular ring
opening of substituted N-activated aziridines with electron-rich arenes and heteroarenes such as the
indole 42 in the presence of a dual catalysts system consisting of Sc(OTf)3 and Zn(OTf)2 (Scheme
9b).14 The nucleophilic attack occurs at the benzylic position of aziridines, which was found to be
electrophilic in the previous research, but only a single example of 42 was demonstrated in this
14

research and some uncharacterised by-products were also produced. Moreover, other enantiopure
aziridines such as 37 and 38 gave significantly reduced enantiomeric excess of the resulting products
compared to 36 (Scheme 9a). To explore the reason behind obtaining reduced enantiomeric excess of
the products a time dependent study of reaction of enantiopure aziridine with the arene was carried
out, and it was observed that the enantiopurity of both aziridine and product decreased over time.
Therefore, the racemisation of aziridine and product by the Lewis acid may be the reason why the
reduced enantiopurity was observed. Furthermore, the authors found the product has a faster
racemisation rate than that of the aziridine.

Scheme 9: Dual Lewis acid catalysed SN2‑type ring opening of N‑activated aziridine 41with electron-rich
arenes

Yadav and co-workers also provided some scattered examples for ring-opening of N-tosyl
arylaziridine 44 with indole 45. The reaction was carried out in the presence of 5M lithium
perchlorate in diethyl ether at room temperature to give a 3-alkylated indole 46 in high yields with
high C3-selectivities (Scheme 10).15 Nevertheless, although a number of examples were provided in
the reaction, LiClO4 is potentially explosive. Therefore, a bench stable catalyst is needed for
synthesis of β-branched tryptamines.
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Scheme 10: LiClO4-catalysed C-alkylation of indole 45 with arylaziridine 44

In conclusion, only a number of examples for the Friedel–Crafts ring-opening of N-activated
aziridines with indoles could be found in the literature. Only a non-catalyic reaction resulted in
enantioretention (Scheme 6), but others such as that in Scheme 9a demonstrated the significant
erosion in the enantiopurity of the ring-opened product as a result of the racemisation caused by
relatively strong Lewis acidity of Sc(OTf)3 and Zn(OTf)2 system. Although the stereospecific
ring-opening reaction of aziridines is synthetically useful, it has relatively limited application due to
the difficulty in preparing a wide range of these systems in an enantioenriched form. It is more
important that no kinetic resolution (dynamic or non-dynamic) has been carried out for this type of
reaction. Nevertheless, after this investigation has been started, Wang and co-workers reported a
kinetic resolution for the first magnesium-catalysed asymmetric desymmetrisation of a meso aziridine
47 with 1-H indole 23 (Scheme 11).16 Both of enantiomers of the ring-opening products were
synthesised with commercially available chiral ligands such as quinine and quinidine respectively.
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Scheme 11: Highly enantioselective ring-opening reactions of aziridine 47 with indole 23

A catalytic process was proposed for explanation of generation of the product 48 and
stereochemistry. After the pre-catalyst was generated from the deprotonation of indole by MgBu2 and
quinine, an intermediate 50 is given from the coordination of the aziridine 47 to the magnesium
center from a less sterically hindered direction that is possibly determined by the effects of
pre-catalyst. Subsequently, the activated indole attacks the aziridine 47 via the 2nd transition state 51
accompanied by the ring-opening reaction to give 52. The indole molecule 23 enters into the process
to donate a proton for releasing the final compound 48 and recovering the pre-catalyst (Scheme 11b).
17

It can be seen from previous examples that a strong electron-withdrawing N-protecting group such
as tosyl or nosyl was required to facilitate C-N bond breaking of aziridines in the presence of Lewis
acids.17 Nevertheless, Lewis acid catalysis was also proved to be effective in the ring-opening of the
less activated aziridines such as N-benzylaziridine. For example, in 2007, Ishikawa and co-workers
reported an InCl3-catalysed ring-opening reaction of 2,3-disubstituted N-benzylaziridine 53 with
1H-indole 23 (Scheme 12).18 The less activated aziridine 53 took part in the reaction and was
activated by InCl3 to accept nucleophilic attack in an SN2 manner from the indole nucleophile.
Notably, the corresponding product 54 was produced in an excellent yield with an absolute
diastereoselectivity. Furthermore, the X-ray crystallographic analysis showed that inversion of
configuration at C3 of the aziridine ring happened during the ring-opening reaction by the aromatic
carbon-based nucleophile.

Scheme 12: Ring-opening reaction of trans-(1,3-benzodioxol-5-yl)aziridine-2-carboxylate 53 with indole 23

In summary, the limited examples above demonstrate that the Lewis-catalysed synthesis of
tryptamines is still under investigated, especially with regard to the dynamic kinetic resolution.
Therefore, a comprehensive study for the catalytic synthesis of β-branched tryptamines via the
ring-opening of N-activated arylaziridines in the presence of Lewis acids and then chiral ligands was
to be performed as one of the goals in the project (Scheme 4).
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C3 Ring-Opening of Aziridines with Electron-Rich Arenes

Although the Lewis acid-catalysed ring-opening of aziridines with indoles have only limited
examples, a large number of electron-rich arenes have been utilised as C-based nucleophiles to open
the aziridine ring for synthesis of nitrogen-containing compounds.19 To obtain a comprehensive
understanding of Lewis acid-catalysed ring-opening process of aziridines, it is necessary to review
those reactions.
The Stamm group provided one early example in 1989, demonstrating an efficient AlCl3-promoted
reaction of the N-sulfonylaziridine 55 with benzene. The reaction proceeds rapidly at room
temperature to yield the desired N-sulfonyl(arylethyl)amine 56 in a good yield, though significant
amounts of two side-products were also given. One (57) resulted from 2,3-diarylation, and the other
is benzenesulfonamide 58, which is generated by decomposition of 55 (Scheme 13).20 The first event
in this ring-opening reaction is the coordination of AlCl3 to the aziridine nitrogen atom or sulfonyl
oxygen, forming a 1,3-dipole 62. A Friedel-Crafts process then occurs to generate an intermediate 63
with benezene. Accompanied with the leaving of AlCl3, the final ring-opened compound 56 is yielded.
The 1,3-dipole 62 may also undergo hydride shift to give the intermediate 59. Benzene then adds to
the intermediate 60, which is the resonance-related structure of 59. The subsequent intermediate 61 is
therefore generated in the reaction. Subsequently, the addition of the second benzene to the
intermediate 61 causes the departure of NH2X and biarene 57 as the by-product.

Scheme 13: Friedel–Crafts reactions with N-sulfonated aziridines
19

The Yadav group then reported an example of C-arylation of N-tosyl phenylaziridine 26 via an
In(OTf)3-promoted Friedel–Crafts reaction. The reaction resulted in an exclusive regioselectivity and
a good yield in the ring-opening of phenylaziridine 26 with benzene in the presence of stoichiometric
amount of In(OTf)3, and substituted arenes such as anisole also gave excellent yield and high
C2-selectivity (Scheme 14).21

Scheme 14: First example of C-arylation of aziridine 26 promoted by indium triflate

Almost all examples shown above are intermolecular reactions, but in 2004, a facile
intramolecular cyclisation was uncovered by the Bergmeier group (Scheme 15).22 The substrates 66
combine an aziridine ring and a π-nucleophile in one molecule. With promotion of a stoichiometric
amount of BF3.OEt2, intramolecular cyclisation reaction of 66 occurred to produce a
nitrogen-containing core structure 67 that could be found in a variety of biologically active
molecules.

Scheme 15: Intramolecular cyclisation reaction of aziridines 66 with π-nucleophiles

More efforts were contributed to the selection of efficient Lewis acid to open the aziridine ring
catalytically. The Roy group developed the synthesis of β-aryl amine derivatives 69 and 70 from
20

N-tosyl aziridines 68 and a variety of arenes and heteroarenes via a Friedel–Crafts reaction pathway
in the presence of 1-2 mol% of silver hexafluorophosphate at room temperature (Scheme 16).23 With
the catalysis of silver hexafluorophosphate, exclusive regioselectivity for attack at the benzylic
position of the aziridine was observed. Moreover, the conditions proved to be efficient with
heteroarenes, such as furan and thiophene, and in all cases, the substitution occurred exclusively at
the C2-position of these heteroarenes. Furthermore, it was also found that electron-rich arylaziridines
are more reactive towards arenes, but the aziridine bearing an alkyl C2-substituent did not give any
visible reaction.

Scheme 16: AgPF6 catalysed regioselective ring opening of N-tosyl aziridines 68 with arenes and heteroarenes

Roy and co-workers also developed an efficient arylation of N-tosylaziridine 26 with arenes and
non-indole heteroarenes under the mild conditions to give the corresponding β-aryl amine derivatives
72 with excellent regioselectivity in the presence of [Ag(COD)2]PF6.24 For ring-activated arenes such
as anisole (Scheme 17a), the benzylic position of the N-tosylaziridine 26 was attacked to afford the
product in an excellent yield. In addition, heteroarenes such as benzofuran and benzothiophene are
also able to participate in the reaction with exclusive C2 regioselectivity (Scheme 17b). However,
benzene and ring-deactivated arenes proved to be inactive substrates, and reactions of alkylaziridines
such as N-tosyl-2-hexylaziridine and N-benzyl-2-phenylaziridine failed.

21

Scheme 17: Silver(I)-diene complexes as versatile catalysts for the C-arylation of N-tosylaziridines (COD =
cyclooctadiene)

The authors proposed a catalytic cycle for the Ag(I)-catalysed arylation reaction of aziridines
(Scheme 17c). First of all, the catalytically active species [Ag(COD)]+ is formed via dissociation of
the PF6- and one COD ligand. The active Ag(I) species, which has coordinative unsaturation, is able
to accept the first coordination from the aziridine 26. It worth noting that this reaction is different
from the cases catalysed by strong Lewis acids because the distinct free benzyl cation does not form
in the resulting transition state 73. Subsequently, additional coordination to the arene gives
intermediate 74. The coupling then occurs between two organic substrates facilitated by their close
proximity in an Ag-centered activated complex intermediate 74 to release the final product 72. A
COD molecule then enters into the cycle to regenerate the active species [Ag(COD)]+.
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Synthesis of Pyrroloindolines by the Ring-Closure of Tryptamine Derivatives

It has been shown in Scheme 2 that a dearomative Lewis acid-catalysed [3+2] cycloaddition of
C3-substituted indoles with N-activated aziridines has been proposed for synthesis of
pyrroloindolines. However, this method is limited to C3-substituted indoles 14, otherwise, the
tryptamines 22 could be generated via the substitution of C3-unsubstituted indoles 20 in the presence
of Lewis acids (Scheme 4).
Several groups have developed methods where pyrolloindolines can be formed by the C3 arylation
of tryptamine derivatives and subsequent cycloaddition, realising the synthesis of the bioactive
pyrroindolines from the tryptamines. For example, the Reisman group explored a reaction utilising
hypervalent iodine species that aimed to construct the pyrroloindoline 76 by using the tryptamine 75
(Scheme 18).25 A Cu(I)-Cu(III) catalytic cycle was proposed for the reaction of this type based on
the C3-arylation of unsubstituted indoles developed by Gaunt and co-workers. 26 First, an in
situ-generated Cu(I) species is considered to be the catalytically active intermediate. A highly
electrophilic Cu(III)-aryl complex 77 is generated via the oxidative addition of the aryliodonium to
the Cu(I) species. Nucleophilic attack of 75 to the electrophilic complex 77 then occurs to give the
complex 78, followed by iminium ion trapping to give the complex 79. Subsequently, reductive
elimination occurs to release an arylated pyrroloindoline 76 as the final product. An alternative
mechanism was also proposed, where the sulfonamide functions as a ligand so that the nucleophilic
attack is promoted by indole at the Cu(I)–aryl complex to give a spiro-metallacycle 80. Furthermore,
the rate of formation of the sp3-sp2 C–C bond is faster than the rate of copper migration due to the
acceleration effect caused by this ligand coordination. Finally, the active Cu(I) species is regenerated
with reductive elimination, and cyclisation of the resulting 81 would afford arylated pyrroloindoline
76.
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Scheme 18: A copper-catalysed arylation of the tryptamine 75

The Reisman and MacMillan groups further investigated the asymmetric synthesis of
pyrroloindolines (Scheme 19). 27 MacMillan and his co-worker prepared a series of arylated
2-oxopyrroloindolines 83 by the catalytic asymmetric arylation of indole-3-carboxamides 82 in the
presence of a phenyl-substituted bisoxazoline-bound Cu(I) complex in high yields and
enantioselectivities (Scheme 19a). The Reisman group also developed a diastereoselective arylation
of tryptophan derivatives via cyclisation of enantioenriched 84 via a similar mechanism of the
reaction demonstrated in Scheme 18 (Scheme 19b). Furthermore, the appropriate carboxylate
functionalities incorporated in the molecules 84 allow a direct elaboration to the natural products
(+)-naseseazine A and B, which both display antibacterial activity (Figure 2).28
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Scheme 19: Two examples of Cu-catalysed C3-arylation-cyclisation towards pyrroloindolines

Figure 2: Natural products synthesised through the methodology from the Scheme 19b

It can be seen that all pyrroloindolines synthesised in the above examples only have aryl groups at
the C3a-position. Recently, pyrroloindolines halogenated at the C3a-position have found increasing
importance in synthetic and medicinal chemistry and so methods for their synthesis have been
investigated.29 For example, the Wang group constructed various C3a-halogenated pyrroloindolines
by using electrophilic halogenating agents (Scheme 20).64 This strategy utilised the enantioenriched
N-H tryptamine 86 as the starting material to synthesise the corresponding C3-halogenated
pyrroloindolines 88, 90 and 91 with the retention of enantiopurity. The enantioenriched starting
materials were prepared by desymmetrisation of a meso aziridine as shown previously in Scheme 11.
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Scheme 20: Applications of the ring-opening reaction towards C3-halogenated pyrroloindolines

Therefore, inspired by the example carried out by the Reisman and MacMillan groups (Schemes
18-19), a proposal was designed (Scheme 21) for the synthesis of the C3-substituted pyrroloindolines
from the β-substituted tryptamines 21. The tryptamine 21 that would be prepared from C2-substituted
aziridines and indoles in the presence of Lewis acids (Scheme 4) could trap an appropriate
electrophile, followed by an intramolecular cycloaddition of the resultant iminium intermediate 92 to
give the skeletons of the pyrroloindolines 93. Furthermore, not only does this strategy allow the
C3-position to be substituted, but the strategy also potentially provides different C3a groups by
varying the external electrophiles. Such substitution patterns had not been reported, so this synthetic
route could provide new pyrroloindolines that may potentially have useful bioactivities.
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Scheme 21: Electrophilic cycloaddition to synthesise highly substituted pyrroloindolines 93
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Research Plan

The overall research plan combining the reactivities of indoles and arylaziridines is summarised
in Scheme 22. Firstly, a catalytic Lewis acid will be identified for achieving the C-N bond cleavage
of N-tosyl arylaziridine 12 to form a zwitterionic 1,3-dipole 13 or an activated aziridine complex,
followed by the SN1 or SN2 nucleophilic substitution respectively of indoles 14 to give an iminium
intermediate 15. Subsequently, an intramolecular ring-closure then occurs to diastereoselectively
synthesise the biologically relevant pyrroloindoline skeleton 16 with a C3-substituted indole
(Pathway b, Scheme 22b). Alternatively, the β-branched tryptamine 22 could be produced via the
intramolecular protonation of 15 when R1 is a proton (Pathway a, Scheme 22). In addition, to show
the synthetic value of tryptamines 22 (Pathway c, Scheme 22), an electrophilic ring closure to prepare
C3, C3a-disubstituted pyrroloindolines 94 was planned to be carried out and its diastereoselectivity
studied (Pathway c, Scheme 22). To determine whether an SN1 or SN2 mechanism is operating
enantioenriched aziridines 95 will be used as starting materials (Scheme 22d). In this case an SN2
mechanism is operating, formally charged intermediate 96 may be generated by the C-N bond
polarisation of an enantioenriched arylaziridine 95, which does not enable the complete C-N cleavage
of 95. Therefore, the enantiopurity could be retained in the tryptamine 97, which is resulted from the
nucleophilic attack of 20 to the intermediate 96 via a SN2 pathway with inversion of configuration. If
an SN1 mechanism is operating then it may be possible to develop catalytic asymmetric processes here a chiral Lewis acid converts racemic aryl aziridines 12 into the zwitterionic dipole 13 and may
then control the facial selectivity of attack of the indole so that the stereogenic centre in 15 is formed
in an enantioselective fashion.
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Scheme 22: Overall research plan for the synthesis of tryptamines and pyrroloindolines

Furthermore, the efficient formation of all-carbon quaternary all-carbon centres remains
particularly challenging in intermolecular reactions because the increased steric repulsion between
the carbon substituents of the resulting product.30 Interestingly, as shown in the survey above, there
have been no examples of the use of 2,2'-disubstituted aziridines in cycloaddition or Friedel–Crafts
reactions. On the basis of Scheme 22a, it is envisioned that an all-carbon quaternary centre could be
created in the tryptamine 100 via the Lewis acid-catalysed C-N bond cleavage of the
2,2'-disubstituted aziridine 98 with the C3-unsubstituted indole 20 (Scheme 23). The formation of the
reactive tertiary carbocation 99 is highly likely, as it has delocalised positive charge that is stabilised
by the surrounding substituents, leads to this favoured SN1 process to give 100. As such it may be
possible to develop a catalytic enantioselective ring-opening process with a chiral Lewis acid.
However, Lewis acid-catalysed E1 reaction of 98 may be a competing side reaction.
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Scheme 23: Proposed synthetic pathways of the tryptamine 100 bearing an all-carbon quaternary centre
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Recent Complementary Reactions

As discussed above there was only an isolated example using an unsubstituted aziridine with the
stoichiometric amount of Lewis acid in [3+2] cycloaddition reactions to indoles when this project
was started (Scheme 1). Nevertheless, towards the end of this project, it was found that other groups
have concurrently studied this topic. Therefore, it is important to introduce those recent reports about
the Lewis-catalysed [3+2] annulation of indoles and aziridines even though they had no influence on
the current study. Firstly, the Chai group realised the first Lewis acid catalysed [3+2] annulation of
the indole 101 and 2-phenyl-N-tosylaziridines 26 in the presence of copper(I)/chiral diphosphine
complexes in a similar manner proposed in Scheme 2 (Scheme 24).31 A multi-functionalised chiral
pyrroloindoline 102 bearing multiple contiguous stereogenic centers were prepared in a high yield
with excellent enantio- and diastereoselectivity under mild conditions.
Excess racemic aziridine 26 (2.2 equiv) was required in the reaction to diastereo- and
enantioselectively give the pyrroloindolines and recover enantiopure unreacted aziridine, indicating a
kinetic resolution process occurs. To probe the stereochemical process of this reaction, a few control
reactions were carried out with enantiopure (S)-aziridine 103 (Scheme 24b). It was then found that
the pyrroloindoline 102 could be synthesised in a comparably excellent yield and a stereoselectivity
with use of either (R)-XylBINAP or racemic Cy3P as the ligand, however, a considerable drop in both
yield and enantioselectivity was observed when (S)-XylBINAP was employed as the ligand.
Moreover, the absolute stereochemistry of the resultant major pyrroloindoline isomer 102 was found
to be determined by the structure of the aziridine. It is therefore concluded that the C2-position of the
aziridine is attacked by the nucleophilic indole 101 via an SN2 pathway with a stereoinvertive manner.
Furthermore, the racemic aziridine 26 should undergo a kinetic resolution process in this asymmetric
catalytic reaction to ensure the high enantiopurity in the product 102 (Scheme 24a). In addition, a
significant decrease in the enantiopurity of product was found when the reaction was completed
without any ligand, suggesting a slight racemisation of the aziridine (Scheme 24b).
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Scheme 24: Copper(I)-catalysed kinetic resolution of N-sulfonylaziridines with indoles

The [3+2] cycloaddition reaction to construct C3-substituted pyrroloindoline skeletons using
achiral or chiral 2-arylaziridines was also developed by the Zhao group (Scheme 25).32a After
carrying out an Lewis acid catalyst screening at room temperature, Pd(PhCN)2Cl2 and toluene were
selected as the optimum Lewis acid and solvent respectively, since they were found to give the best
yield and diastereoselectivity (up to 81% and 10:1 for trans:cis) (Scheme 25a). However, the reaction
did not occur when 2-benzylaziridine and Pd(0)-catalysts such as Pd(PPh3)4 and Pd2(dba)3 were
subjected to the reaction, verifying the C-N bond cleavage is likely being promoted by a Lewis acid
pathway. In addition, the enantioenriched (S)-aziridine 26’ was employed as the substrate, affording
the corresponding pyrroloindoline 104 in the enantiopure form in a high yield and a good
diastereoselectivity (Scheme 25b). Moreover, the single crystal X-ray analysis clearly indicated the
absolute configuration of the product is (S, S, S), confirming the aforementioned stereoinversion at
the C2-position of aziridine 26. Mechanistically, aziridine 26’ initially coordinates to the
Pd(II)-centre with either nitrogen atom or sulfonyl oxygen atom, giving a reactive complex 105 as the
intermediate, which then accepts SN2 nucleophilic attack from 103 to generate a stereoinverted
iminium ion 106. Subsequently, the ring closure occurs to release the targeted product 104 (Scheme
25c).
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Scheme 25: Palladium(II)-catalysed formal [3+2] cycloaddition of aziridines with 3‑substituted indoles
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Results and Discussion

Synthesis of Pyrroloindolines via the Lewis Acid-Catalysed [3+2] Cycloaddition of
C3-Substituted Indoles with Aziridines

At the beginning of the project, the catalytic efficiency of various Lewis acids in the [3+2]
cyclisation of N-tosyl phenylaziridine 26 with 1,3-dimethylindole 101 under the different conditions
was examined (Table 1). The aziridines 26 can be obtained by aziridination of the corresponding
alkene and this will be discussed in detail in the next section. Cu(OTf)2 was first identified as an
effective Lewis acid to promote the formation of pyrroloindole 102, however, only DCE and DCM
gave moderate yields with relatively low trans-selectivities when 101 was limiting agent (entries 1-5).
This successful [3+2] cyclisation reaction was evidenced by a singlet associated with C8a proton at
5.37 ppm and a triplet corresponding to C3 proton at 3.39 ppm (major product). Additionally, C3a
methyl of 102 at 1.27 ppm is upfield in comparison to C3 methyl of 101 at 2.36 ppm. Six aliphatic
carbon signals of major product were found in the 13C NMR of 102, suggesting the coupling reaction
between 101 and 26 has successfully occurred. High-resolution mass spectrometry indicated the
molecular weight of isolated product is 441.1620 g mol-1, which is agreement with the molecular
weight of expected cycloadduct 102. Furthermore, the 1D-NOESY indicates the major
diastereoisomer of the resulting pyrroloindoline 102 was trans, which is in accordance with the
subsequent result of the Chai group.33 Therefore, 1.0 equivalent of 26 and 1.5 equivalents of 101
were then added in the presence of Cu(OTf)2, and the reaction gave 102 in a moderate yield (47%)
with significantly increased trans-selectivity (entry 6). Next, 3.0 equivalents of 26 was added to the
reaction to enhance the yield and trans-selectivity (entry 7). Other Lewis acids such as Sc(OTf)3 and
Ni(acac)2 were also evaluated but no improved results were obtained (entries 8-9), while addition of
PdCl2(MeCN)2 considerably increased both yield (82%) and diastereoselectivity (entry 10). Reducing
the catalyst loading and equivalents of 101 were detrimental since 102 was isolated in depressed yield
with a drop in the trans-selectivity (entries 11-12). It has been proposed that the π-acidity of the
Pd(II)-centre could be enhanced by the coordination of benzoquinone (BQ) as a π-accepting ligand.34
BQ was therefore added to the PdCl2(MeCN)2-catalysed reaction (10 mol%) but the depression in
both yield and diastereoselectivity were observed (entry 13). Moreover, no reactions were observed
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with addition of nitrogen-based ligands such as phenanthroline, neocuproine and 2,2'-bipyridine
(bpy), which are known to stabilise the Pd(II)-centre (entries 14-16).35 This is likely due to them
causing a reduction in Lewis acidity of the Pd(II) centre. Subsequently, MeCN was utilised as solvent
but it only lead to significantly reduced conversion and decomposition of 101 (entry 17). In addition,
101 was added to the reaction in 2 portions (each 1.5 eq); however, this did not give improved results
(entry 18).

Table 1: Optimisation of The [3+2] cyclisation of N-tosyl phenylaziridine 26 with 1,3-dimethylindole 101

Entry

Lewis acid

Additive

(mol%)

(mol%)

26:101

Yield

Trans:cis

Solvent

1

2.0:1.0

Cu(OTf)2 (10)

-

50

1.8:1.0

DCE

2

2.0:1.0

Cu(OTf)2 (10)

-

trace

N/A

THF

3

2.0:1.0

Cu(OTf)2 (10)

-

trace

N/A

MeOHa

4

2.0:1.0

Cu(OTf)2 (10)

-

trace

N/A

MeCN

5

2.0:1.0

Cu(OTf)2 (10)

-

41

1.8:1.0

DCM

6

1.0:1.5

Cu(OTf)2 (10)

-

47

3.2:1.0

DCE

7

1.0:3.0

Cu(OTf)2 (10)

-

53

3.7:1.0 d

CHCl3

8

1.0:3.0

Sc(OTf)3 (10)

-

48

2.9:1.0 d

CHCl3

9

1.0:3.0

Ni(acac)2 (10)

-

NR

N/A

CHCl3

10

1.0:3.0

-

82

6.5:1

CHCl3

-

58

5.3:1.0

CHCl3

-

38

6.3:1.0

CHCl3

BQ (30)

65

6.2:1.0

CHCl3

PdCl2(MeCN)2
(10)
PdCl2(MeCN)2
11

1.0:3.0
(5)
PdCl2(MeCN)2

12

1.0:1.5
(10)

13

1.0:3.0

PdCl2(MeCN)2

35

(10)
PdCl2(MeCN)2
14

1.0:3.0

Phen

-

N/A

CHCl3

Neocuproine

-

N/A

CHCl3

Bpy

-

N/A

CHCl3

-

22b

N/A

MeCN

-

53

6.3:1.0

CHCl3

(10)
PdCl2(MeCN)2
15

1.0:3.0
(10)
PdCl2(MeCN)2

16

1.0:3.0
(10)
PdCl2(MeCN)2

17

1.0:3.0
(10)

18

1.0:3.0c

PdCl2(MeCN)2
(10)

a

Methoxylation of 26 observed. b Conversion. c 101 was added in 2 portions d hydrolysis of 26 observed.

Two similar reports concurrently have been published for the pyrroloindoline synthesis using this
approach: Cu(I)/chiral diphosphine catalyst system developed by the Chai group (Scheme 24) and
Pd(PhCN)2Cl2 system used by Zhao and co-workers (Scheme 25). Therefore, instead of pursuing
substrate scope for the reaction uncovered above attention was turned to a new and more versatile
substrate, vinylaziridine 103. The aziridines 103 can be obtained by aziridination of 1,3-butadiene
and this will be discussed in detail in the next section This substrate was subjected to the [3+2]
cycloaddition to give a promising result: the C3-vinyl pyrroloindoline derivative 104 was given in a
moderate purified ratio of trans:cis isomers (4.3:1.0), albeit with a low yield (17%) (Scheme 26). The
formation of 104 was evidenced by a triplet at 2.80 ppm corresponding to the C3-H of trans-104 in
the 1H NMR. In addition, a singlet associated with C8a-H of of trans-104 was found at 5.18 ppm,
further supporting occurrence of the cycloaddition of 103. The conservation of C3-vinyl group in 104
was confirmed by its characteristic signals on the purified 1H NMR of 104, including a mutiplet
(5.54-5.42 ppm) and two doublets (5.04 ppm and 4.90 ppm, respectively). Moreover, the C2 proton
of 101 (6.85 ppm) disappeared in 1H NMR of 104. In addition, 13C NMR of 104 demonstrates seven
aliphatic carbon signals, and this result matches the expected structure of 104. The molecular weight
that was given from High-resolution mass spectrometry is also in line with the structure of 104
(369.1640 g mol-1). In conclusion, the expected cycloadduct 104 has been synthesised in this
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reaction.

Scheme 26: Cycloaddition of vinylaziridine 103 to 1,3-dimethylindole 101

After obtaining initial success in the [3+2] cycloaddition of mono-substituted aziridines to indole
101, attention was switched to the 2,2'-disubstituted aziridine 98 as an electrophile. Thus, the
condition shown in Scheme 26 was applied to 98, however, this only resulted in a complicated
mixture of unidentified products (Scheme 27). The synthesis of 98 will be discussed in the next
section.

Scheme 27: Attempted cycloaddition of aziridine 98

In order for the product to find general utility in synthetic projects, the tosyl unit would have to be
removed. It was therefore found that the diasteromeric mixture of 102 could be readily detosylated
with Mg/NH4Cl under ultrasound conditions to give the pure trans-106, highlighting the utility of the
method developed (Scheme 28). The successful detosylation was evidenced by the absence of tosyl
methyl in the 1H NMR of trans-106, and a broad singlet at 2.44 ppm associated with the N1 amine
proton resulted from the detosylation was also observed. In comparison with 102, only six aliphatic
carbon signals were found in the

13

C NMR of trans-106, suggesting the tosyl group has been

removed in the reaction. The molecular weight of isolated product is 265.1714 g mol-1, which is
approximate to the calculated molecular weight of trans-106 (265.1705 g mol-1). This result further
proved that the tosyl group was successfully removed from 102 in this reaction. The
cis-diastereoisomer 107 could only be isolated with many inseparable impurities.
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Scheme 28: Detosylation of 102

In conclusion, a PdCl2(MeCN)2-catalysed formal [3+2] cycloaddition of phenylaziridine 26 with
1,3-dimethylindole 101 was performed to give a C3-phenyl pyrroloindoline skeleton 102 in an
excellent yield (82%) with a good diastereoselectivity (6.5:1.0). Fortunately, the pure
trans-diastereoisomer of detosylated 102 was isolated in a moderate yield (56%) by column
chromatography. In addition, a C3-vinyl pyrroloindoline skeleton 104 was also synthesised from the
vinylaziridine 103 with a promising diastereoselectivity (4.3:1.0) under the same conditions, albeit
with a low yield (17%). Due to concurrent reports of very similar methods additional substrate was
not investigated and attention turned to the synthesis of tryptamine derivatives.
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Lewis Acid-Catalysed Synthesis of Tryptamines by C3-Unsubstituted Indoles and
Aziridines
A synthetic pathway for β-branched tryptamines has been proposed in Scheme 22a. The Lewis acid
catalyses the generation of 1,3-dipole 13, which is then attacked by the indole 14 to give the iminium
intermediate 15. The β-branched tryptamine 22 therefore can form by rearomatisation of 15 if R1 is a
proton.

Scheme 22a: The proposed synthetic pathway for β-branched tryptamine

The above process could be facilitated with a more reactive 1,3-dipole 99 resulting from Lewis
acid-catalysed ring-opening of the disubstituted aziridine 98 (Scheme 23). Therefore, the
2-methyl-2-phenyl-1-tosylaziridine 98 was first utilised in the project to synthesise the corresponding
β-branched tryptamines containing an all-carbon quaternary centre with a variety of indoles.
It has been reported that aziridine 98 could be readily accessed by the aziridination of
α-methylstyrene 108 using the method developed by the Morgan group (Scheme 29).36 The process
was promoted by a catalytic amount of I2 in the presence of tetrabutylammonium bromide (TBAB) as
a phase transfer catalyst to give the desired aziridine 98 in an excellent yield (89%).
Mechanistically,37 chloramine-T reacts with iodine to give iodo-chloramine-T intermediate 109, and
then an iodonium 110 and anionic intermediate 111 are yielded by the trapping of 109 with
α-methylstyrene 108. The iodoaminated intermediate 112 is subsequently formed by the attack of the
anionic nitrogen atom of 111. Next, iodide attacks the N-Cl group of intermediate 112 to generate the
39

anion 113 and ICl which enables TsNICl to be regenerated to initiate the next catalytic cycle. Finally,
the aziridine 98 is yielded by the expulsion of iodide from the ring-closure of anion 113. The
generation of 98 was evidenced by a pair of symmetric singlets corresponding to the CH 2 (2.99 ppm
and 2.55 ppm, respectively) and one singlet at 2.07 ppm associated with C2 methyl group of 98. In
addition, four aliphatic carbon signals were observed in the 13C NMR of 98, suggesting NTs group
has been coupled with 108. The structure of 98 was confirmed by comparing with the literature.38

Scheme 29: Preparation of aziridine 98

The project commenced with the reaction of aziridine 98 with 1.5 equivalents of N-methylindole
114 to produce a β-branched tryptamine 115 containing an all-carbon quaternary stereogenic centre
(Table 2). The Lewis acids Cu(OTf)2, Sc(OTf)3 and AgSbF6 were quickly identified as effective
catalysts for this reaction (Table 2, entries 1-3), albeit with moderate conversions and yields. The C-C
bond formation in these reactions was exclusively achieved between C3-position of 114 and
C2-position of 98. Evidence for this substitution partially came from the multiplet (4.05-4.03 ppm)
associated with the amine proton of side chain of 115, which is produced by the protonation after the
C-N bond of aziridine 98 is cleaved. Moreover, the disappearance of C3-H of indole 114 (doublet at
6.45 ppm) on the 1H NMR of the crude reaction mixture also indicates the C3-position of 114 has
been substituted. In addition, five signals for aliphatic carbon were observed on the 13C NMR of 115,
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suggesting the coupling reaction of 98 with 114 has been achieved. The molecular weight of the
isolated product (441.1620 g mol-1) is in accordance with the expected structure of 115, further
supporting the occurrence of C3-substitution of 114 with 98. Nevertheless, the impurities 116 and 117,
resulting from aziridine decomposition, were found in all these three crude reaction mixtures
(Scheme 32).
To increase conversion of the reaction, 1.0 equivalent of N-methylindole 114 was then used as the
limiting reagent in the presence of Cu(OTf)2 in the reaction with dropwise addition of 3.0 equivalents
of aziridine 98 at room temperature. This resulted in a complete conversion of 114; however, the
aziridine-derived ring-opened by-products 116 and 117 were still generated (entry 4). The tertiary
alcohol 117 likely resulted from introduction of moisture in the reaction workup (Scheme 23).
However, TLC analysis demonstrated the polarity of 116 is very similar to the targeted compound
115, greatly enhancing the difficulty in purification of 115 using column chromatography. In order to
avoid 116, a reaction using 98 as the sole substrate in the presence of catalyst Cu(OTf)2 in
dichloroethane under the air at room temperature was carried out (Scheme 30a). This test reaction
then gave a mixture of 116 and 117 in 100% conversion with a ratio of 47:53. In addition, 2 portions
of 98 were stored at different temperatures for 3 days. One portion of 98 stored at room temperature
gradually completely converted into 116 and 117 in a ratio of 44:56. However, 98, which was stored
the 0 oC, remained unreacted (Scheme 30b). It was therefore concluded that a low reaction
temperature may deter the generation of 116.
With these results in hand (Scheme 30), a reaction was carried out at 0 oC under the conditions
used in entry 4. To our delight, performing the reaction at low temperature (0 oC) significantly
decreased the quantity of 116, and the desired tryptamine derivative 115 was isolated in an increased
yield of 94% (entry 5); furthermore, the 1H NMR of the isolated 115 showed only a trace amount of
89. It can therefore be seen that the purity of the isolated 115 could be enhanced if the amount of 116
is diminished by carrying out the reaction at low temperature. Nevertheless, it was found that
reducing the temperature to -20oC did not improve the isolated yield (entry 6). In addition, compared
with the yield (94%) in the entry 5, the reduced loading of aziridine 98 (2.0 eq) gave an adverse effect
to the reaction as the yield was diminished to 81%, and the impurity 116 was produced in this
reaction with a largely increased amount and was significantly present in the isolated 115 due to the
aforementioned isolation difficulties (entry 7). Different solvents were then screened in the following
41

three reactions (entries 8-10), but none of them was able to give a satisfactory result. Subsequently,
the catalytic activities of different Lewis acids were also examined under the conditions (entries
11-14). Pleasingly, in contrast to other Lewis acids, the use of PdCl2(MeCN)2 further depressed the
amount of 116 with no significant loss of yield for the desired product 115. Also, the cleanness of the
crude reaction mixture was decreased, and the isolated yield of 115 was therefore reduced to 75%
when 30 mol% benzoquinone (BQ) was present in the reaction despite favourable reduction in
by-products (entry 15). In addition to DCE, one reaction was carried out in CHCl3, however, 116 was
observed in the 1H NMR of the crude reaction mixture in a significantly enhanced amount, and the
isolated yield of 115 was reduced to 71% (entry 16). It was found that reducing catalyst loading (5
mol%) led to less reaction efficiency since the conversion was only 83% in this case (entry 17).
Additionally, 2.0 equivalents of 98 were used in the Pd-catalysed reaction, but the yield was
significantly decreased to 71% with a dramatically enhanced amount of 116 but with a reduced
amount of 117 (entry 18).

Table 2. Optimisation of C3-substitution of N-methylindole 114 with 2-methyl-2-phenyl-1-tosylaziridine 98

Entry

2a:1a

Lewis acid

Solvent

T oC

115:89:90

Conversion (yield%)b

1

1.0:1.5

Cu(OTf)2

DCE

r.t

64:15:21

60(55)

2

1.0:1.5

Sc(OTf)3

DCE

r.t

49:29:22

63(48)

3

1.0:1.5

AgSbF6

DCE

r.t

37:4:59

62(30)

4

3.0:1.0

Cu(OTf)2

DCE

r.t

33:16:51

100(59)

5

3.0:1.0

Cu(OTf)2

DCE

0

31:5:64

100(94)

6

3.0:1.0

Cu(OTf)2

DCE

-20

36:6:58

100(90)

7

2.0:1.0

Cu(OTf)2

DCE

0

53:19:29

100(81)

8

3.0:1.0

Cu(OTf)2

THF

0

0:70:30

100(N/A)

9

3.0:1.0

Cu(OTf)2

Diethyl ether

0

30:20:50

80e

10

3.0:1.0

Cu(OTf)2

CHCl3

0

33:7:60

77e
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a

11

3.0:1.0

AgSbF6

DCE

0

25:5:70

100(30)

12

3.0:1.0

Sc(OTf)3

DCE

0

49:29:22

100(63)

13

3.0:1.0

Ni(ClO4)2.6H2O

DCE

0

20:3:77

73(N/A)

14

3.0:1.0

PdCl2(MeCN)2

DCE

0

62:5:33

100(93)

15

3.0:1.0

PdCl2(MeCN)2c

DCE

0

84:3:13

100(75)

16

3.0:1.0

PdCl2(MeCN)2

CHCl3

0

67:40:0

100(71)

17

3.0:1.0

PdCl2(MeCN)2d

DCE

0

61:6:33

83(69)

18

2.0:1.0

PdCl2(MeCN)2

DCE

0

67:30:2

90(66)

Entries 4-5: dropwise addition of 98 over 4 h. entries 6-13: dropwise addition of 98 over 6 h. b Isolated yield

of 115. c 30 mol% BQ was added. d 5 mol% PdCl2(MeCN)2. e Conversion

Scheme 30: Generation of allylic sulfonamide 116 and hydrolysed aziridine 117 under different conditions

With optimised conditions in hand, the reaction scope and functional-group tolerance were
evaluated with various indoles (Table 3). Products 119 and 120 were successfully synthesised in
good yields from N-benzyl and N-allyl indole respectively because the characteristic signals were
found in the 1H NMR of 119 (doublet for benzyl-CH2 at 5.32 ppm) and 120 (multiplet for allyl’s
olefin-CH at 6.06-6.00 ppm, two doublets for allyl’s olefin-CH2 at 5.25 ppm and 5.14 ppm
respectively). In addition, indoles a bearing halogen atom at C5 position were also subjected to the
reaction conditions, providing the corresponding products in moderate to excellent yields (products
121-123). Also, it needs to be indicated that a relatively low yield of product 122 was obtained
although 100% conversion was found from the clean 1H NMR of the crude reaction mixture,
therefore, it is reasonable to propose the low
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Table 3: Substrate scope for the ring-opening of 2,2'-disubstituted aziridine 98 with indoles

a

Reaction conditions: aziridine 98 (3.0 equiv), N-methylindoles (1.0 equiv), 21 h.

b

8% of an unidentified,

inseparable compound was also produced.

yield of 122 resulted from its instability towards purification on silica gel. Importantly, the molecular
complexity of such halogen-containing products could potentially be further increased using
cross-coupling reactions. Furthermore, a C5 methoxy group was found to be beneficial to the reaction
yield (product 124), and a characteristic singlet at 3.42 ppm corresponding to the methoxy group in
the 1H NMR of 124 suggests the coupling reaction between 98 and indole. The chemoselectivity of
the reaction was then examined with 1H-indole (product 125), and the C3-alkylated product was
observed in a moderate yield of 56% with no N-substitution occurring. This exclusive
chemoselectivity was evidenced by the observation on the broad singlet associated with N1 proton of
indole moiety (8.19 ppm) in the 1H NMR of the product.
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Subsequently, the ring-opening of the less reactive 2-aryl-N-tosylaziridines with various indoles
was explored (Table 4). Initially 1.0 equivalent of N-tosylaziridine 26 was utilised to react with 1.5
equivalents of N-methyl indole 114 in the presence of Cu(OTf)2 and the targeted compound 126 was
obtained in a good yield (73%), but with significant inseparable impurity (Table 4, entry 1). It needs
to be pointed out no aziridine decomposition products were observed for 26 in the presence of Lewis
acids. The ring-opening reaction successfully occurred as the 1H NMR shown a broad triplet (4.38
ppm) for amine proton of side chain. Furthermore, it can be seen from the 1H NMR of 126 that
disappearance of the doublet (6.94 ppm) associated with the C3-H of 114 and presence of the singlet
at 6.78 ppm corresponding to the C2-H of 126 suggest the C3-H of 114 has been substituted. In
addition, further evidence for the C-C bond formation came from the triplet at 4.31 ppm for the side
chain CH of 126, and two symmetric multiplets (3.67-3.63 ppm and 3.57-3.53 ppm respectively)
for the CH2 adjacent to the chiral centre of 126 also suggest 126 contains a side chain resulting from
the ring-opening of 26. Additionally, five signals for aliphatic carbons of 126 were observed in the its
13

C NMR, suggesting 26 has successfully coupled with 126. High-resolution mass spectrometry

found the molecular weight of the isolated compound is 427.1469 g mol-1, matching the expected
structure of 126. This result also support 126 was given via the C3-substitution reaction of 114 with
26.
Other Lewis acids such as Ni(ClO4)2.6H2O and Sc(OTf)3 also behaved in an unsatisfactory manner,
due to the incomplete conversion and the production of an inseparable and unidentified impurity
(entries 2 and 3). Fortunately, a yield of 42% for the production of clean targeted compound was
obtained from the reaction catalysed by PdCl2(MeCN)2, which had been effective for the aziridine 98
(entry 4). Next, to increase the conversion, ligands were then added to stabilise the Pd(II)-centre,
however, 1,10-phenanthroline (phen) largely depressed the conversion to 16% due to the low
solubility of Pd(II)-phen complex that in situ-formed as a yellow precipitate (entry 5). In contrast, the
addition of 1,4-benzoquinone (BQ) increased the conversion to 73%, albeit with a moderate yield
(59%) (entry 6). More BQ, up to 0.3 equivalents, gave an increase in the isolated yield to 61% (entry
7). The solvent effect was also investigated (entries 8-10). However, tetrahydrofuran (THF) and ether
proved less efficient solvents giving a relatively messy 1H NMR of the crude reaction mixture and
low conversion respectively (entries 9 and 10). Finally, chloroform was selected as the optimum
solvent as it gave the highest conversion and yield (entry 8). Interestingly, the dropwise addition of
45

115 over 6 h, which was utilised in the table 2, significantly diminished the yield (entry 11).
According to the promoting effect of BQ in the enantioselective allylic C-H oxidation of 127 found
by the White group (Scheme 31),39 the coordination of Lewis acids such as PdCl2(MeCN)2 to the
carbonyl group of BQ could enhance the π acidity of the Pd(II)-centre,40 thus accelerating the C-C
bond formation when the SN2 nucleophilic attack of indole towards benzylic position of aziridine
possessing enhanced electronegativity.

Table 4. C3-substitution of N-methylindole 114 with 2-phenyl-1-tosylaziridine 26

a

Entry

26:114

Lewis acid

Solvent

Ligand (mol%)

Conv.(Yield)%

1

1.0:1.5

Cu(OTf)2c

DCE

N/A

100(73)

2

1.0:1.5

Ni(ClO4)2.6H2Oc

DCE

N/A

28b

3

1.0:1.5

Sc(OTf)3c

DCE

N/A

100(40)

4

1.0:1.5

PdCl2(MeCN)2

DCE

N/A

63(42)

5

1.0:1.5

PdCl2(MeCN)2

DCE

Phen (12)

16b

6

1.0:1.5

PdCl2(MeCN)2

DCE

BQ (12)

73(59)

7

1.0:1.5

PdCl2(MeCN)2

DCE

BQ (30)

75(61)

8

1.0:1.5

PdCl2(MeCN)2

CHCl3

BQ(30)

99(77)

9

1.0:1.5

PdCl2(MeCN)2

THF

BQ(30)

78b

10

1.0:1.5

PdCl2(MeCN)2

ether

BQ(30)

62b

11a

1.0:1.5

PdCl2(MeCN)2

CHCl3

BQ(30)

90(63)

26 was added dropwise over 6 h. b Conversion. c Inseparable impurities.
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Scheme 31: Effect of benzoquinone (BQ) on Pd(II) catalytic intermediates

Using the optimum conditions, a variety of mono-substituted β-branched tryptamines were
synthesised, demonstrating excellent functional group tolerance of the reaction conditions (method A,
Table 5). All 2-aryl-N-tosylaziridines were synthesised by the method shown in Scheme 29. The
aziridines bearing halogen atom on the ortho, meta and para positions of 2-aryl ring were first
examined under the conditions, affording the corresponding products in moderate to good yields
(product 132-134). Moreover, alkyl and aryl groups such as methyl and naphthalene on the aziridine
were also subjected to the reaction to furnish the corresponding β-branched tryptamines in good
yields (products 131 and 135). Different electron-rich indole derivatives were then examined. Thus,
C-C bond formation was achieved with N-benzyl indole and N-allyl indole, and the corresponding
compounds were synthesised in 60% and 86% yields respectively (products 136 and 137).
C5-substituted indoles, including those bearing a halogen atom or methoxy group at C5 position,
gave the corresponding tryptamines in moderate to good yields under the conditions (products
138-140 and 142). Indoles bearing a substituent at C7 position were also utilised under the conditions.
Gratifyingly, the targeted compound was given in a good yield (76%) when 7-iodo-1-methyl indole
was employed (product 141). However, as a result of the reduced nucleophilicity caused by a C7
electron-withdrawing formyl group, a decreased yield (43%) was obtained for the desired product
(product 143). Furthermore, 1H-indole, which has been previously utilised as N-based nucleophile to
synthesise N-alkylated indole derivatives with complete N1-chemoselectivity, 41 reacted with
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aziridine 26 to give a good yield (76%) of the C3-substituted product 144. Absolute C3-selectivity
was observed since the broad singlet (8.06 ppm) on the 1H NMR of the crude reaction mixture
demonstrates the conservation of N1 proton of 144 in the reaction, moreover, the presence of the
singlet (6.97 ppm) for C2-H of indole moiety of the product 144 provides further evidence for the
exclusive C3-substitution. Nevertheless, a much lower yield (15%) was observed with the expected
C2-selectivity when 1H-pyrrole was used in the reaction as the conversion of phenylaziridine 26 was
only 20%, and the rest of 26 and pyrrole remained unreacted (product 145). 42 Pleasingly,
1H-2-phenylindole then proved to be an effective substrate as the corresponding β-branched
tryptamine 146 was given in a good yield (63%). Furthermore, as expected, exclusive C3-selectivity
was obtained again since the broad singlet (8.31 ppm) associated with N1 proton of indole moiety on
the 1H NMR of the crude reaction mixture was conserved in the reaction (product 146). No reaction
observed with N-methyl-5-nitroindole, likely because its electron-deficiency causes low
nucleophilicity. In addition, a variety of PdCl2(MeCN)2-catalysed reactions to synthesise tryptamines
shown in Table 5 in the absence of BQ (method B) were carried out. In contrast to the BQ-involved
reactions, conversions of almost all arylaziridines were considerably reduced without BQ, except for
tolylaziridine 517. Nevertheless, more significant hydrolysis of tolylaziridine 517 occurred without
BQ, leading to a sharp drop in the yield of product 131. These results highlight the promoting effect
of BQ for this reaction.

Table 5. Substrate scope for the ring-opening of 2-aryl-N-tosylaziridines with indoles
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a

the reaction was carried out in DCM. b 17% inseparable p-benzoquinone accompanied product. c Method A:

PdCl2(MeCN)2 (10 mol%), BQ (30 mol%), CHCl3 (0.1M), 21 h, r.t. Method B: PdCl2(MeCN)2 (10 mol%),
CHCl3 (0.1M), 21 h, r.t. d Method A/B: conversion (isolated yield).

The examples listed in the introduction demonstrate that the aziridine is highly versatile building
block in organic synthesis due to their susceptibility to nucleophilic attack after C-N bond cleavage.
The ring-opening of N-activated aziridines with electron-rich heteroarenes such as indole keeps
drawing attention amongst synthetic chemists, moreover, the corresponding products resulting from
these reactions, such as tryptamine derivatives are synthetically important in pharmacological
chemistry.43 Under this context, it is not surprising to find one paper published for exploring a
general and economic method to regioselectively open the aziridine ring by indole derivatives under
the mild conditions when the manuscript associated with the work in this thesis was under review.
Majee and co-workers developed a metal-free regioselective ring-opening of aziridines 148 with
various indoles 149 in the presence of a non-volatile and generally nonhazardous zwitterionic-type
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salt 150 under the solvent-free conditions. The author considered that the C-N bond of aziridine
moiety is activated through hydrogen bond formed between C2-H of the imidazolium cation and the
nitrogen atom of the aziridine, and all β-substituted typtamines 151 were synthesised in good to
excellent yields with exclusive C3-regioselectivities (Scheme 32).44 However, no reactions were
observed when alkylaziridines involved in the reaction. Mechanistically, the aziridine 26 is activated
by H-bonding between the C2-H of the imidazolium cation and the nitrogen atom of the aziridine,
and indole then acts as a nucleophile to attack the aziridine’s benzylic position with an SN2 manner to
give the ring-opening final compound 144.

Scheme 32: Organocatalysis by an aprotic imidazolium zwitterion: regioselective ring-opening of aziridines 148

With regard to the mechanism of the reaction demonstrated in the table 4, it was proposed that the
aziridine is first activated by coordination of the Lewis acidic Pd(II)-catalyst. The Zhao group
(Scheme 25) provided the results in support of this proposal. 45 The Sc(OTf)3-catalysed [3+2]
cycloaddition of N-benzyl-3-methylindole 152 with the enantioenriched aziridine (S)-26' only
provided a considerably reduced enantiopurity of the product in contrast to a well-retained
enantiopurity of the pyrroloindoline 153 produced with PdCl2(PhCN)2, implying the C-N bond may
be partially cleaved with relatively strong Lewis acid-Sc(OTf)3 to cause the racemisation of (S)-26'
by producing zwitterionic 1,3-dipole, but the C-N bond of (S)-26' can only be polarised with
PdCl2(PhCN)2 as it possesses a lower Lewis acidity (Scheme 32a and b). The resultant polarised C-N
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bond therefore undergoes SN2 nucleophilic attack of indole 92 to the more-substituted position,
ensuring the conservation of enantiopurity of the starting phenylaziridine (S)-26'. To study the
stereochemical course of the reaction developed in this project, enantiopure phenylaziridine (R)-26',
was synthesised from commercially available (R)-2-phenyl glycinol (R, 99% ee).46 This enantiopure
aziridine was treated with indole 114 in the presence of PdCl2(MeCN)2 with and without BQ
respectively. The enantioselective HPLC analysis then indicated both reactions gave the
corresponding products (R)-126' with an excellent retention of enantiopurity (99% and 98% ee
respectively). A standard reaction was then performed with racemic 26. Chiral HPLC analysis
indicated a racemate of 126 was produced in the reaction (Scheme 32e).
Thus, it is reasonable to conclude that while BQ may increase the Lewis-acidity of the
Pd(II)-centre, it is likely that its presence does not change the mechanism to a ring-opening process.
Based on these reports and results, the key intermediates for both reactions were proposed (Scheme
32c and d). In the case of BQ-free reaction, as suggested by the Zhao group (Scheme 25), the NTs
group first coordinates to the Pd(II)-centre, where the resulting intermediate A only has the polarised
C-N bond (Scheme 32c). The enantiopurity is therefore retained as the polarised C-N bond in the
intermediate A induces an SN2-type nucleophilic attack of indole 152 at the more substituted position
of the aziridine. In addition, in the case of the BQ-involved reaction (Scheme 32d), as stated above in
Scheme 47, the coordination of BQ to the Pd(II)-centre weakens the partially cleaved C-N bond of
aziridine (R)-26' by acting as a π-acidic ligand to increase the overall Lewis-acidity of the
Pd(II)-centre, causing enhanced susceptibility of the intermediate B towards the SN2 nucleophilic
attack of indole 98 hence the BQ-involved reaction leads to a higher yield. Furthermore, as the
further weakened C-N bond of aziridine (R)-26' is still not completely broken with the enhanced
Lewis-acidity of the BQ-Pd(II)-catalyst, therefore, the excellent enantiopurity introduced from
(R)-26' is well-retained in the product (R)-126' for the same reason stated in Scheme 32a and b. This
also suggests that BQ could be potentially used as an additive for improving other enantioselective
Lewis acids-catalysed reactions by its coordinating effect. Another possibility to explain the
beneficial effect of the BQ additive is that the Pd(II)-catalyst is undergoing deactivation by reduction
under the reaction conditions to Pd(0) and aggregation to Pd-black, which is observed in reactions
where the BQ is absent. The BQ then may act as a ligand to stabilise Pd(0) so that it can be
reoxidised before forming Pd black.
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Scheme 32: The Zhao group’s enantiopurity study a and b and the corresponding enantiopurity retention study
for our reaction

Next, the detosylation of the products was investigated. The detosylation of 126 under the different
conditions that have been successfully applied to detosylate pyrroloindolines and various tosylamines
was performed (Scheme 33),47 however, only 126 was recovered from all crude reaction mixtures
even if 100 equivalents of Mg was added in the presence of NH4Cl under sonication (Scheme 33c).
Additionally, 126 was also inert to the cleavage conditions using sodium naphthalene anion radical in
THF solution (Scheme 3d).48
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Scheme 33: Attempts to detosylate the 126
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Synthesis of Pyrroloindolines by the Ring-Closure of Tryptamine Derivatives

The ring-closure of β-substituted tryptamines in order to obtain C3-functionalised pyrroloindolines
(Table 6) was the aim in the next stage of research. Inspired by the Reisman group’s work (Scheme
18), Cu(II)-catalyst systems were first used to couple with diaryliodonium salt (entries 2 and 3),
however, no reaction occurred with either Cu(OAc)2.H2O or Cu(OTf)2.

It can be rationalised on the

basis of mechanism proposed by Reisman and co-workers (Figure 3). The expected key intermediate
109 resulting from the nucleophilic attack of indole may not be favoured due to the great steric
hindrance between Cu(III) centre and β-phenyl group.

Table 6: Attempted ring-closure reactions of β-substituted tryptamine 126

Entry

Conditions

Expected product

Yield

Cu(OAc)2.H2O (10
mol%), 4Å MS,
1

N/R
DCM, r.t
[Mes-I-Ph]+BF4Cu(OTf)2 (10 mol%),

2

4Å MS, DCM, r.t

N/R

[Mes-I-Ph]+BF4cyanuric chloride (10
mol%),
3

N/R
benzaldehyde,
DMSO, 100 oC
BF3.OEt2 (3.0 eq),

4

MgSO4,

Trace conversion

benzaldehyde, DCE,
55

60 oC

NaHCO3 (1.5 eq),

43% (trans:cis=

NFSI, MeCN, r.t

2.5:1)

5

Figure 3: Key intermediate 159 of expected Cu(II)-catalysed ring-closure reaction

The formation of 6-membered ring system 157 using the Pictet–Spengler reaction was attempted
(entries 3 and 4). 49 Cyanuric chloride was previously utilised as an acid source,
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so it was

envisioned that this reagent could promote the coupling between 126 and benzaldehyde, however, no
reaction occurred under this condition (entry 3). Subsequently, a stoichiometric amount of Lewis
acid-BF3.OEt2 was added to the reaction but only trace conversion was observed (entry 4).
Subsequently, inspired by the halogenative ring closure reported by Wang and co-workers64
(Scheme 20), N-fluorobenzenesulfonimide (NFSI) was utilised as the fluorinating agent to construct
the pyrroloindoline using β-substituted tryptamine 126 in the presence of NaHCO3. Fortunately,
although the reaction gave a relative messy 1H NMR of the crude reaction mixture, a C3a-fluorinated
pyrroloindoline 160 was isolated in a moderate yield (43%) with a moderate diastereomeric ratio of
2.5:1. The assigned product was evidenced by the absence of singlet (6.76 ppm) corresponding to the
C2 proton of 126 in the 1H NMR of the reaction mixture, moreover, the apparent triplet (4.38 ppm)
associated with the amine proton of 126 cannot be observed, suggesting the occurrence of
ring-closure. Furthermore, the ring-closure reaction of 126 with F+ can also be evidenced by a new
doublet at 5.65 ppm (major isomer) corresponding to the C2a proton of the C3-fluorinated
pyrroloindoline 160. The 13C NMR of 160 shows six aliphatic carbon signals, and this is in line with
the number of aliphatic carbons in the expected structure of 160. Moreover, the signal of C8a proton
was found at 89.1 ppm as a doublet in

13

C NMR due to fluorine-carbon coupling. In addition, the

molecular weight (445.1363 g mol-1) that was given by high-resolution mass spectrometry also
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supports the NMR-determined structure of 160. Subsequently, attempts to optimise the reaction
conditions were carried out (Table 7).

Table 7: Optimisation on synthesis of C3-fluorinated pyrroloindoline 160

Ratio of
Entry

Base

Solvent

Temperature

F+ source

Yield (%)

diastereoisomers
(Major:Minor)

a

1

NaHCO3

MeCN

r.t

NFSI

43

2.5:1.0

2

NaHCO3

MeCNa

r.t

NFSI

45

2.3:1.0

3

NaHCO3

CHCl3

r.t

NFSI

27

2.2:1.0

4

NaHCO3

DCE

r.t

NFSI

37

2.1:1.0

5

NaHCO3

ether

r.t

NFSI

28

2.0:1.0

6

NaHCO3

DCM

r.t

NFSI

27

2.1:1.0

7

NaHCO3

PhCN

r.t

NFSI

34

2.1:1.0

8

K2HPO4

MeCN

r.t

NFSI

36

2.0:1.0

9

NaHCO3

MeCN

-20 oC

NFSI

39

2.5:1.0

10b

NaHCO3

MeCN

r.t

Selectfluor

48

2.1:1.0

Anhydrous MeCN and 3Å MS b The reaction was completed after 3 h.

Performing the reaction in anhydrous MeCN was found to only give slightly increased yield with a
reduced trans-selectivity (entry 2). Other solvents were then screened, however, none of them gave a
significantly improved result (entries 3-7). K2HPO4 was also used as a different base, nevertheless, a
reduced yield plus a diminished selectivity were observed after the reaction was completed (entry 8).
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The next reaction was carried out at −20 oC, but it was found to give a slightly decreased yield
although the ratio of major:minor diastereoisomer remained unchanged (entry 9). In addition, a new
fluorinating agent, selectfluor, was able to give a faster reaction rate as 126 was completely
consumed after the reaction mixture was stirred for only 3 h at ambient temperature, and this reaction
gave a moderate yield (48%) with a ratio of 2.3:1.0 (major: minor isomer) (entry 10).

Scheme 35: C3-fluorination of β-substituted tryptamines

Therefore, the conditions consisting of NaHCO3 (1.5 eq), NFSI (1.2 eq) in MeCN at room
temperature were the best obtained within the time constraints. Two different β-substituted
tryptamines were then subject to the reaction (Scheme 35). N-Benzyl-β-phenyl tryptamine 136 gave a
good selectivity, albeit with a very messy crude reaction mixture and relatively low yield (product
161). The diastereoselectivity of entire reaction was then tentatively assigned as cis (cis:trans=
2.5:1.0, Scheme 35) since both NOESY-1D and NOESY-2D spectra of major isomer of 161 did not
demonstrate the through-space correlation between Ha and Hb (Figure 4 and Appendix). Subsequently,
a good yield (73%) was obtained with N-methyl-β-phenyl tryptamine 121, simultaneously, but a
relatively low ratio of cis:trans isomer was observed (product 162).

Figure 4: NOESY-1D and NOESY-2D results of major isomer of 161

A plausible mechanism was then proposed for the metal-free synthesis of C3a-fluorinated
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pyrroloindoline (Scheme 36a). Initially, the indole moiety acts as the nucleophile to trap electrophilic
F+ from the fluorinating agent (NFSI). The resulting iminium intermediate A undergoes the
ring-closure to give the aminium intermediate B, which is then deprotonated by NaHCO3 to yield the
final product 160.
Finally, the C3a-fluorinated pyrroloindoline 161 was subjected to the conditions that were
successfully applied to detosylate the C3-methyl pyrroloindoline 102 (Scheme 28). Unfortunately,
only decomposition of 161 was observed after the reaction mixture was sonicated for 6 h (Scheme
36b).

Scheme 36: Proposed mechanism for synthesis of C3-fluorinated pyrroloindoline 160 and the detosylation of
161
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Summary
In summary, a PdCl2(MeCN)2-catalysed C3-selective Friedel–Crafts reaction of indole derivatives
with aziridines has been developed. A series of β-substituted tryptamine derivatives were prepared in
moderate to high yields, especially some products containing an all-carbon quaternary centre were
synthesised from the disubstituted aziridine 98. Furthermore, it was found that addition of
1,4-benzoquinone (BQ) is beneficial to the reaction with the less reactive 2-aryl-N-Ts aziridines.
According to BQ chemistry proposed by the White group (Scheme 31), BQ may act as a π-acid,
increasing the Lewis acidity of the Pd(II)-centre to further weaken the C-N bond of 2-aryl-N-Ts
aziridines. Alternatively, it could play a role in preventing catalyst deactivation through the formation
of Pd-black. Importantly, the chiral HPLC analysis indicated the addition of BQ did not significantly
diminish the enantiopurity of the product 126 obtained from the enantiopure phenylaziridine (R)-26',
highlighting the stereospecificity of this reaction. This also suggests that BQ could also be potentially
used as an additive for improving other Lewis acid-catalysed reactions by its coordinating effect,
without degrading the enantiopurity of products (Scheme 32). In addition to the C3-substitution, a
Pd(II)-catalysed formal [3+2] annulations of the N-activated aziridine 26 with 1,3-dimethylindole 101.
The trans domain C3-phenyl pyrroloindoline 102 was synthesised from N-tosyl phenylaziridine 26 in
a good yield with a relatively high diastereoselectivity in the presence of bench stable PdCl2(MeCN)2.
Moreover, a more versatile vinyl moiety was introduced to the resulting pyrroloindoline with
excellent trans-selectivity, albeit with a relatively low yield. Furthermore, the ring-closure of the
corresponding β-substituted tryptamines with N-fluorobenzenesulfonimide (NFSI) to construct a
number of C3a-fluorinated pyrroloindolines under metal-free conditions was also preliminarily
investigated, and three different C3a-fluorinated pyrroloindolines were synthesised in synthetically
acceptable to good yields with moderate trans-selectivities.
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Future Plans

Ir-Catalysed Intramolecular Allylation of Tryptamine Derivatives

As well as further investigating the electrophilic ring-closure of β-branched tryptamines to optimized
yield and diastereoselectivity, other methods to utilised these structures can be envisaged. The natural
products incorporating the spiroindoline or spiroindolenine unit has drawn increasing attention in
pharmacological area. For example, koumine, which was a monomer of gelsemium alkaloids, has
been investigated due to its capacity to relief neuropathic pain (Figure 5).51 Many efficient synthetic
protocols have been developed for the construction of this key structure.

Figure 5: Koumine

A typical example for the Ir-catalysed enantioselective construction of spiroindolenines 165 is
provided by the You group in 2010 (Scheme 37).52 This reaction was carried out in the presence of
2-methyl-1,2,3,4-tetrahydroquinoline-derived phosphoramidite ligand, and the spiroindolenine
derivatives 165 were provided in excellent yields with up to >99/1 d.r and 97% ee via the Ir-catalysed
intramolecular C3 allylic alkylation of tryptamine derivatives 164 using chiral phosphoramidite
ligand.
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Scheme 37: Enantioselective construction of spiroindolenines 165 by Ir-Catalysed allylic alkylation reactions

The analogue synthesis of the spiroindolenine 167 could be developed using the substrate 166 via
an stereospecific dearomatisation/migration process based on Scheme 37. It can be seen from the
expected compound 167 that the complexity of the molecule is ramped up as an extra phenyl group is
introduced at C3a-position (Scheme 37). By utilising the enantiopure starting material 166, an
enantio-enriched compound 167 possessing two stereogenic centres could potentially be synthesised
in a high diastereoselectivity without the need for a chiral ligand (Scheme 38). Moreover, the
expected compound 167 could be divergently manipulated, such as detosylation on N-tosyl group,
reduction of the imine moiety and modifications on the versatile vinyl group, providing multiple
accesses to some potentially bioactive highly functionalised products. A compound 168 possessing a
similar structure of 167 has been identified as a neuropeptide Y receptor (Figure 6).53 Therefore, 167
with substituents at positions 3’ and 5’ would potentially be useful for analogue synthesis of 168.
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Scheme 38: Expected reaction with new substrate 166

Figure 6: Example for potential medicinal application of 167 in Scheme 38

Enantiomerically pure allylic carbonate 166 containing an extra phenyl group at the β position
could be synthesised from the enantiopure N-tosyl phenylaziridine (R)-26' and 171 (Scheme 39).
This is a sequential strategy, including the reduction of ester 169 to alcohol 170 using DIBAL-H,
acetylation of 170 and the SN2 nucleophilic attack of enantioenriched 144 to 171.
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Scheme 39: The designed synthetic route to construct new substrate 166
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The [3+2] Annulations of Vinylaziridines with Electron-Rich Indoles

The Wang group and the Chai group demonstrated the Lewis acid-catalysed [3+2] cycloaddition of
N-activated phenylaziridine (Schemes 24-25). It was found that the reaction scope included in their
works were limited to arylaziridines. The yield was degraded considerably in our reaction when the
more versatile vinylaziridine 103 was utilised in the [3+2] cycloaddition reaction developed in
Scheme 26. Hence, it is beneficial to develop a new route to obtain pyrroloindolines containing a
vinyl group at C3-position in an elevated yield with a high diastereoselectivity.
It was first noticed that the Tamaru group found the Pd-Et3B system works efficiently for the C3
selective allylation of indoles and provides 3-allylindoles in excellent yields. Et3B smoothly promotes
the formation of electrophilic η3 allyl-Pd(II) complex, which then accepts the subsequent nucleophilic
attack from indole 172 to produce 3-butyl-3-methyl-3H-indole 174 in an excellent yield with an
exclusive C3-selectivity (Scheme 40).54

Scheme 40: C3-allylation of indole

In addition, the Trost group indicated that vinylaziridines 175 could be considered as an analogue
of allyl acetate to accept N-nucleophile (Scheme 41). In this reaction, a 5-membered transition state
178 caused by the allyl-Pd(II) complex and electronic abstraction between pyrrole N-H 176 and in
situ-generated amide is proposed as the key intermediate for the synthesis of diamine compounds 177.
This example demonstrates the formation of allyl-Pd(II) complex could be achieved by the oxidative
addition of vinylaziridines 175 to the Pd(0)-catalyst system.
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Scheme 41: N-based allylation with vinyl aziridine and catalysis of Pd(0)

Thus, inspired by these two examples, it was envisioned that [3+2] annulations of vinylaziridine
103 could be realised via an electrophilic allyl-Pd(II) complex. A plausible pathway was proposed for
the designed reaction (Scheme 42). The electrophilic stabilised the allyl-Pd(II) complex initially
formed from vinylaziridine 103 and the Pd(0) systems such as Pd2(dba)3.CHCl3, and then
1,3-dimethylindole 101 could act as a nucleophile to attack the sterically hindered position of the
allyl-Pd(II) complex. The resultant iminium intermediate 180, which has structural similarity with the
product demonstrated in Scheme 40, subsequently undergoes ring-closure to release the
pyrroloindoline 181 and regenerate the Pd(0)-catalyst.

Scheme 42: Designed reaction pathway for [3+2] annulations of vinylaziridine 103
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Chapter 2. Unusual (Z)-Selective Palladium(II)-Catalysed Addition of Aryl
Boronic Acids to Vinylaziridines

Introduction

The reactivity of three-membered strained-ring systems, specifically N-tosyl aziridines, has been
discussed in the chapter 1. As a versatile functional group that can be found in many drug
molecules,55 the vinyl group has exhibited its broad application in the oxidative cleavage,56 olefin
metathesis 57 and addition reactions 58 . Therefore, the palladium-catalysed reactivity of vinyl
aziridines, a particularly interesting sub-class of aziridine, was investigated in this chapter.59
Generally, vinylaziridines can be synthesised by the following methods (Scheme 43),60 including
(1) reaction of a nitrene 182 with a conjugated diene 183 (path a);61 (2) reaction of an allylic carbene
184 with iminiums 185 via aza-Darzens-type reactions (path b); 62 (3) Intramolecular SN2
displacement of vinylated 1,2-amino alcohol derivatives 186 (path c);63 (4) Intramolecular SN2'
reaction of 4-aminobut-2-en-1-ol derivatives 187 (path d) and;64 (5) rearrangement reactions of
pyridinium salts, pyrroles, and pyrrolines (path e).65 The 1,2-addition of a nitrene equivalent to a
conjugated diene was utilised in this research to synthesise the vinylaziridine 103 (details in Results
and Discussion).

Scheme 43: General synthetic routes to vinylaziridines
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Vinylaziridines are bifunctional heterocycles that undergo a range of metal-catalysed synthetic
transformations by releasing its ring strain to achieve a ring-opening reaction, such as ring-opening
additions/cyclisations and rearrangements via the C-N bond breaking with a broad range of substrates
to afford heterocyclic or acyclic compounds (Scheme 44).66 For example, a [3+2] annulation of
vinylaziridine 103 with 1,3-dimethylindole 101 has been successfully demonstrated in chapter 1, and
the ring-opening addition of vinylaziridine 103 was studied in this chapter.

Scheme 44: General reactivities of vinylaziridine 103

The Trost group developed a dynamic kinetic asymmetric cycloaddition of isocyanates 189 to
vinylaziridines 188 (Scheme 45a).67 Also, a diastereoselective palladium-mediated annulation of
vinylaziridines 191 with Michael-acceptors 192 was reported in 2011 by the Aggarwal (Scheme
45b).68

The additive nBu4Cl was required to form an ion pair with the amide anion of allyl-Pd(II)

intermediate 194, enhancing the nucleophilicity of the amide anion of 194 to capture the
Michael-acceptors 192. The Aggarawal group also reported a mild palladium-catalysed regioselective
and diastereoselective ring-opening cyclisation of vinylaziridines 196 under an atmosphere of carbon
dioxide to give a series of 5-vinyloxazolidinones 197. The beneficial effect of TBAB in promoting
the carboxylation was also observed in this reaction (Scheme 45c).69 It is worth noting that all of
these [3+2] cycloaddition reactions proceed via allyl-Pd(II) complexes.70
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Scheme 45: The cycloaddition of N-protected aziridines

Utilising this methodology, vinylaziridines could be directly utilised as the building block in the
preparation of bioactive natural products. For example, the total synthesis of (+)-pseudodistomin D
201 via dynamic kinetic asymmetric transformation (DYKAT) of vinyl aziridines 198 involving
η3-η1-η3 interconversion was developed by Trost and Frandrick (Scheme 46).71 The key intermediate,
DMB-protected vinyl imidazolidinone 200, was obtained in a high yield with an excellent
enantioselectivity in the presence of the chiral ligand via a [3+2] cycloaddition proceeding with a
similar mechanism involving the η3 Pd(II)-allyl complex 202 (Scheme 45b).
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Scheme 46: Total synthesis of (+)-pseudodistomin D

Recently, a single example for the [3 + 2] annulation between para-quinone methide 203 and
vinylaziridine 103 for the synthesis of spiro[4.5]deca-6,9-diene-8-one 205 has been described by
Yuan and co-workers (Scheme 47).72 A high yields and moderate diastereoselectivity were given via
a palladium and phosphine−thiourea cooperative catalysis system 204 involving the η3 allyl-Pd(II)
intermediate.
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Scheme 47: Bifunctional organo/metal cooperatively catalysed [3+2] annulation of 203 with vinylaziridine
103

Rearrangement is also an important reaction of vinylaziridines, and this type of reaction can be
exemplified by a Cu-catalysed ring expansion of N-tosyl vinylaziridine 103 to synthesise 3-pyrrolines
207 (Scheme 48).73 The author proposed that the copper centre chelates to the nearby olefin moiety
of aziridine 103 in the reaction to generate a transition state 206 containing an incompletely cleaved
C-N bond. The rearrangement then occurs to produce the 3-pyrrolines 207, which are common
structural moieties in natural products and pharmaceutical agents. They have also been utilised as
building blocks for other biologically important pyrroles or pyrrolidines.74-75
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Scheme 48: The synthesis of 3-pyrroline 207 via intramolecular rearrangement of vinyl aziridine 103

Generally, by controlling the conditions such as different nucleophiles and catalysts (Scheme
49),76-77 C2, C3 or the terminus of the vinyl group could be potential sites for nucleophilic attack via
different mechanisms. The cleavage of the aziridine C-N bond could be controlled under two
different conditions. Firstly, with the additional reactivity introduced by vinyl group in the presence
of metal-catalysts such as Pd(0), the key allyl-metal intermediate enables a nucleophile to attack
either the terminal or the C3-position of vinylaziridine 103. Therefore, the linear adduct 211 or the
branched adduct 212 containing a stereogenic centre could be yielded, respectively (Scheme 49a).
Alternatively, as demonstrated in the chapter 1, the C-N bond could also be cleaved by Lewis acid
activation. In this case, the generation of a resonance-stabilised dipole 210 (or activated
aziridine-Lewis acid complex) is also able to give the same linear or branched products (Scheme 49b).
In addition, a direct SN2/SN2' nucleophilic attack may occurs with organometallic reagents such as
cuprate to give 211, 212 or the C3 opening product 212’, respectively (Scheme 49c).
The presence of the double bond in the allylic amine products, resulting from reactions of vinyl
aziridines, provides a versatile point for further synthetic manipulations, making them powerful
organic building blocks.78 Specific examples of these different nucleophilic ring-opening modes of
vinylaziridines are now given in the next section.
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Scheme 49: Different ring-opening pathways of vinylaziridine 103

Transition Metal-Catalysed Ring-Opening Addition of Vinylaziridines with Various
Nucleophiles

Several examples of the [3+2] cycloadditions intermediated by allyl-Pd(II) complexes generated
from vinylaziridines were shown in Scheme 45. In addition, the use of allyl-Pd(II) complexes to give
branched ring-opened adducts has been shown by the Trost group. They have developed a
Pd-catalysed allylation reaction of pyrroles using vinylaziridines (Scheme 50).79 The synthetic value
of this reaction was demonstrated by applying this method to the preparation of several bioactive
compounds. For example, cyclooroidine 218, an antibiotic and cytotoxic agent, can be synthesised
from 217, which was previously prepared via hydroboration of 216 – this synthesis demonstrates
utility of double bond.
The achiral and linear product is typically obtained in the Pd-catalysed allylic alkylation of
monosubstituted π-allyl-Pd intermediates. However, in Trost’s reaction, a branched product forms
due to a favourable 5-membered transition state that forms after ring-opening of vinylaziridine 214.
In this transition state, the N-based pyrrole nucleophile 215 is directed by the amide anion of the
vinylaziridine 214 by a hydrogen bond with the pyrrole N-H. The final ring closure occurs to release
216 by loss of CF3 group.
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Scheme 50: The palladium catalysed asymmetric alkylation of vinylaziridines 214 with nitrogen heterocycles
215

It can be seen from the mechanism above that vinylaziridine 214 has been successfully utilised as a
nitrogen analogue of traditional allylating agents such as allylic ester derivatives in the
palladium-catalysed ring-opening addition reaction to give chiral 1,2-diamines 216 with a versatile
double bond. It is worth drawing attention to the fact that the chiral 1,2-diamine moiety is frequently
found in natural products. Also, Trost’s group employed 5-bromopyrrole-2-carboxylate esters 219
and vinylaziridine 214 to synthesise additional chiral 1,2-diamines 220 via the palladium-catalysed
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ring-opening addition reaction of vinylaziridine 214. The chiral 1,2-diamines 220 synthesised in this
reaction can be further modified to the natural product (–)-longamide B 221 (Scheme 51). 80
Longamide B 221, which had only be previously isolated from agelasdispar as a racemate in small
quantities, has proved to be an antibiotic agent against several strains of Gram-positive bacteria.
Therefore, three reactions shown in Schemes 46, 50 and 51 developed by the Trost group
demonstrate the synthetic importance of vinylaziridines in natural products synthesis area. Moreover,
they were performed with Pd(0) catalysts to construct bioactive molecules, highlighting the utility of
the vinylaziridine-derived η3 allyl-Pd(II) complexes in synthesis.

Scheme 51: Concise enantioselective syntheses of pyrrole alkaloid natural products

Alternatively, some research with respect to the ring-opening addition of vinylaziridines with
heteroatoms has involved other transition metal catalysts. For example, a Ni(0)-BINAP-catalysed
ring-opening addition reaction of the bicyclic vinylaziridine 221 with B2(Pin)2 was explored. An
electrophilic π-allyl-nickel complex was proposed as the key intermediate to give a functionalised
allylic boron derivative 222 via transmetallation. 81 After the ring-opening reaction occurred, a
1,3-amino alcohol 223 was synthesised by employing 168 to react with an aldehyde (Scheme 52).82
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Scheme 52: The Ni-catalysed ring-opening reactions of vinylaziridine 221

Very recently, in working towards the utility of nucleophilic allyl-metal complexes, the Krische
group reported a Csp3-Csp3 coupling reaction of N-nosyl vinylaziridine 232 with benzyl alcohol 225
to afford an enantiopure branched adduct 226 with a moderate diastereoselectivity in the presence of
cyclometalated π-allyliridium ortho-C,O-benzoate complex (Scheme 53). 83 Mechanistically, this
redox process initiates with dissociation of the propene from the original Ir catalyst. The catalytically
active species 225 was generated by the coordination of deprotonated benzyl alcohol 224.
Subsequently, β-hydride elimination occurs to form hydride complex 226 coordinated to
benzaldehyde. The following step allows the dissociation of benzaldehyde from the complex 226, to
give the H-Ir(III) complex 227, which is then deprotonated by the base to produce the anionic
complex 228. The oxidative addition of 228 to aziridine 232 and the protonation by H-base lead to
the formation of the allylic Ir(III) complex 229. The complex η3 229, equilibrates with η1 complex
230, allowing sequential Ir-C cleavage and Csp3-Csp3 bond formation with previously released
benzaldehyde to give complex 231. Finally, one molecule of benzyl alcohol 224 enters into the
catalytic cycle to cause the release of the desired product 226 and regenerate complex 225.
Importantly, vinylaziridine 232 is converted into a nucleophilic organometallic intermediate in the
reaction, and this is reverse from above examples (Schemes 50-52), where vinylaziridines were
converted to electrophilic species, making this a particular important contribution to the field.

76

Scheme 53: Redox-triggered C−C coupling of vinylaziridine 232 with benzyl alcohol 224

The Lewis acid-catalysed ring-opening addition reaction of vinylaziridines has also been explored
(Scheme 49b), and various nucleophiles such as nitrogen, oxygen, sulfur and boron were selected to
open the aziridine ring. For example, the Kang group developed a nucleophilic ring-opening reaction
of cis-3-substituted-2-vinylaziridine 233 by various heteroatom nucleophiles in the presence of
BF3.OEt2 (Scheme 54a).84 The reaction occurs exclusively to give the branched products 234 as a
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result of the favourable nucleophilic attack at the C2-position for stereoelectronic reasons.85 In
addition, lithium triethylborohydride has been show to act as a hydride source to open the ring of
vinylaziridine 235. Baron and co-workers utilised this reaction to prepare the aminocyclopentene 237
as a precursor for synthesis of agelastatin A 238, a novel inhibitor of osteopontin (OPN)-mediated
neoplastic transformation and metastasis.86 In this reaction, the cyclopentadiene monoaziridine 235
was treated with lithium tetraethylborohydride to give aminocyclopentene 237 in a relatively high
yield (79%) at 0 oC in THF (Scheme 54b).87 A reduction of cyclopentadiene monoaziridine 235
through the action of LiEt3BH, either via a SN2' nucleophilic or a radical reaction, was proposed.88

Scheme 54: The ring-opening reactions of vinylaziridines with heteroatoms and hydride

To achieve C-C bond formation in the ring-opening of vinylaziridine, stoichiometric
organometallics such as Grignard reagents, cuprates and organozinc reagents have all been utilised.
For instance, the Pineschi group successfully developed an addition of dimethylzinc to the
vinylaziridine 239 in the presence of Cu(OTf)2 and a chiral phosphoramidite ligand. The
corresponding ring-opening product 240 was given in a moderate yield with high enantioselectivity
(Scheme 55). An increased anti-stereoselectivity was observed with the addition of dimethylzinc due
to the presence of in situ-generated copper complexes and phosphoramidites. Furthermore, the major
product, cyclic primary allylic amine, is a valuable building block in organic synthesis. 89
Nevertheless, the substrate scope of the reaction is limited to the cyclic vinylaziridine and alkylzinc
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reagents. Thus, the relatively less investigated acyclic vinylaziridine and sp2 carbon-based
nucleophiles such as arylboronic acids are chosen as the coupling partners in the proposed project.

Scheme 55: The Cu(II)-catalysed addition of alkylzinc reagent to cyclovinylaziridine 239

A di-substituted vinylaziridine 241, which is given in moderate yield with good
diastereoselectivity from the reaction of α-lithio allyl bromide 242 with an N-Dpp imine, undergoes a
ring-opening reaction with a Grignard reagent to afford the major linear allylic amine 244 in a
moderate yield. However, 10 % of a branched isomer 245 was observed as a by-product (Scheme
56a).90 The authors also provided the first method to prepare absolute linear 1,3-disubstituted allylic
amine with use of lower-order organocuprate in favour of an SN2' pathway. In this reaction, N-Dpp
vinylaziridine 241 reacted with lithium dimethylcuprate to give 1,3-disubstituted N-Dpp allylic amine
243 in a good yield with absolute regioselectivity and a trans-selectivity (Scheme 56b).89

Scheme 56: Ring-opening of N-Dpp vinylaziridine 241 by Grignard reagent
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The Comasseto group found that the Lipshutz lithium cuprate, generated from a stoichiometric
amount of organolithium reagent and a Cu(I) species, is able to promote the ring-opening reaction of
the vinylaziridine 246. The reaction proceeded preferentially via an SN2' pathway, giving trans
3,6-disubstituted cyclohexenes 247a as the major product in moderate to excellent yields with good
regioselectivities. Nevertheless, by-products 247b from the SN2 route were also produced in the
reactions (Scheme 57a).91 Also, an acyclic vinylaziridine 103 was subjected to the conditions and
gave the linear product 248a resulting from an SN2' pathway in a good yield with an excellent
regioselectivity and a trans-selectivity (Scheme 57b), and this emphasises the utility of acyclic
vinylaziridine 103 in the ring-opening reaction to regioselectively yield the trans-linear product
(Scheme 49a).

Scheme 57: The ring opening reaction of 2-vinylaziridines by carbon nucleophiles from lithium cuprates

It can be seen that C-C bond formation in the ring-opening reaction of vinylaziridines under
catalytic conditions is significantly less investigated. Although above methods allow C-C bond
formation via the ring-opening addition of aziridine, the reactions must be carried out under the
air-free and anhydrous conditions, and expensive and less functional-group-tolerant stoichiometric
organometallic reagents are generally required (Schemes 57-58). The use of excess stoichiometric
organometallic reagents usually leads to the formation of significant organometallic side-products,
which is not environmentally friendly. Therefore, the development of a safe and economic method to
fulfill C-C bond formation via the catalytic ring-opening addition reaction of vinylaziridine is a
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serious need in organic synthesis. Furthermore, the C-C coupling reactions listed above mainly use
heteronucleophiles, and a limited number of carbonucleophiles to attack vinylaziridine. In this project,
it was planned to achieve a new Csp3-Csp2 bond formation from the Pd(II)-catalysed ring-opening
reaction of vinylaziridine and various air-stable and non-toxic arylboronic acids via a redox neutral
cycle thereby avoiding air-sensitivity.

Research Plan Based on the Reactivity of Vinylaziridine

As stated above, vinylaziridines have structural similarities to allyl acetates, therefore, a
Pd(II)-catalysed γ-selective and stereospecific allyl-aryl coupling between acyclic allylic esters 250
and arylboronic acids 249 developed by the Sawamura group helped guide the design of the reaction
investigatde here. The corresponding coupling compound 251 was produced in a good yield with an
exclusive γ-selectivity in the reaction (Scheme 58).92

Scheme 58: Addition of phenylboronic acid to the allylic acetate

Stoichiometric reactions of intermediary palladium complexes that were potentially relevant to the
catalysis of Sawamura’s reaction were performed to understand the mechanism (Scheme 60). The
cationic mono(acetoxo)palladium(II) complex 253 was prepared in an excellent yield from the
reaction of phenanthroline-ligated Pd(OAc)2 complex 252 with AgSbF6 and pyridine-d5 in DCE.
Complex 253 was then treated with phenylboronic acid at an elevated temperature to give a cationic
(σ-phenyl)palladium(II) complex 254 in a moderate yield. Both of 253 and 254 (10 mol%) were
added to the coupling reaction with 250, and the coupling product 251 was smoothly synthesised in
good yields in the two reactions with almost exclusive γ-selectivities (Scheme 59a). Moreover, the
π-complex 256 was yielded as the intermediate when the [PdI(σ-Ph)(phen)] 255 reacted with 20
equivalents of allylic acetate in the presence of AgSbF6. Subsequently, the complex 256 was
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completely consumed after it was heated at 40 oC in DCE for 4 h to give the carbopalladation product
257. Slight β-hydride elimination of the complex 257 was observed as trace E-cinnamyl acetate 258
was found after the reaction was completed, however, the allylbenzene 259 resulting from the
β-acetoxy elimination of 257 was not observed due to its relatively lower stability compared with that
of 258 (Scheme 59b).

Scheme 59: Mechanistic studies for addition of phenylboronic acid to the allylic acetate 250

Based on the results obtained in the studies of the stoichiometric reactions (Scheme 59), the
authors proposed a mechanism for this oxidative Heck reaction (Scheme 60). Firstly, the catalytically
active species, cationic palladium complex A, is generated by the reaction of 1,10-phenanthroline,
Pd(OAc)2 and AgSbF6. Transmetallation then occurs so a phenyl ring is transferred from the boronic
acid to the Pd(II)-centre to form an aryl palladium(II) complex B. A π-complex C is then formed by
the coordination of allylic acetate 250 to the cationic Pd(II)-centre. Subsequently, the regioselective
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migratory insertion of the C-C double bond then gives a Pd(II) complex D, and following β-acetate
elimination allows the generation of the final product 251 and the recovery of initial Pd(II)-catalyst. It
is worth noting that the palladium catalyst remains the +2 oxidation state during the catalytic process,
meaning the reaction is not sensitive to oxygen.

Scheme 60: Allyl-aryl coupling between acyclic allylic esters 250 and arylboronic acids

Excellent γ-regioselectivity was obtained in the allylic substitution reaction shown in Scheme 60.
Generally, the model demonstrated in Scheme 61 could briefly explain the control of regioselectivity
of the metal-mediated allylic substitution reaction. Firstly, an SN2' process occurs with an
organometallic species, such as phenylboronic acid, giving a (π-allyl)metal species I (oxidative
addition). Subsequently, reductive elimination allows a new C-C bond to form in the γ-position,
generating an allylic compound 261 to predominantly create a new stereogenic centre at the
γ-position by shifting the double bond.93 Nevertheless, a significant side-reaction, α-substitution,
may occur to give by-product 262 (Scheme 61a). In the case shown in Scheme 60, the control of
γ-regioselectivity is realised by the coordination of acetate group to the cationic Pd(II)-centre in the
key intermediate D.94 The β-acetate elimination therefore occurs to release the coupling product 251
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with excellent γ-selectivity (Scheme 61b).

Scheme 61: Allylic substitution with hard nucleophile via a π-allyl metal intermediate

It has been mentioned that the Pd(II)-catalysed process (Scheme 60) is redox neutral as the
palladium catalyst is maintained in the +2 oxidation state for the entire catalytic cycle. This is
because of the dissociation of the acetate group to regenerate A rather than a β-hydride elimination
that would subsequently be followed by reductive elimination to give Pd(0). On the basis of this and
the structural similarity of vinylaziridine 103 to allylic acetates, it was

envisioned that

vinylaziridine 103 could be used in a similar redox neutral process to obtain γ-regioselectivity and
maintain the Pd(II)-catalyst with breaking of the C-NTs bond driven by the release of ring strain. This
would also keep the “leaving group” (NTs) in the product, giving a functionalised sulfonamide
product. Such a process would be highly atom economical as all atoms from starting aziridine ends
up in product (Scheme 62). In this proposed process, firstly, the key intermediate 264 would be
generated by the regioselective migratory insertion of vinylaziridine 103. The ring strain could then
promote the formation of allylic amine 265 via the ring-opening β-nitrogen elimination.
Styrenylaziridine 266 resulting from the β-hydride elimination of 264 may also be yielded as a
by-product, but this should be disfavoured as it is not accompanied by the release of ring strain
(Scheme 62).
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Scheme 62: Proposed key intermediate directing the γ-regioselectivity

For the generation of trans linear allylic amine 265 (Scheme 62), the Szabo group reported a
palladium pincer complex 268-catalysed the cross coupling of N-tosyl-2,3-disubstituted
vinylaziridine 267 with organoboronic acids (Scheme 63).95

Scheme 63: (E)-allylic amine generated from Pd(II)-pincer complex-catalysed ring-opening of vinylaziridine
267 with phenylboronic acid

The proposed mechanism illustrates that transmetallation of organoboronic acids first occurred,
followed by a SN2'-type ring-opening of N-tosyl 2,3-disubstituted vinylaziridine (rather than by
migratory insertion) 267 to release a thermodynamically favourable linear trans allylic amine 269 as
the major product in an excellent yield with a high E/Z-selectivity, and the results of DFT modeling
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study suggested that the transmetallation probably determines the reaction rate.96 Furthermore, the
oxidation state of the palladium centre is maintained at +2 throughout the entire catalytic process.
Therefore, this reaction successfully avoids oxidative side reactions that may occur in the
Pd(0)-catalysed reaction (Scheme 63). However, this method requires a non-commercially available
Pd-pincer catalyst 268 and a stoichiometric amount of base, limiting the application of the reaction.
Moreover, only one vacant site on the Pd(II)-centre is available for external coordination as a result
of the terdentate pincer ligand structure and the strong ligand-metal interaction.97 Therefore, this
Pd(II)-pincer catalyst system 268 cannot undergo the acetate or NTs-assisted stereocontrol (Schemes
60 and 62), which could potentially lead to alternate stereochemical outcomes with respect to the
double bond.
Therefore, inspired by Pd(II)-catalysed reactions of allyl acetates with boronic acids (Scheme 60),
it was aimed to develop an Pd(II)-catalysed addition of arylboronic acids to vinylaziridines (Scheme
62). The reaction is driven predominantly by the β-heteroatom elimination based on the propensity of
3-membered strained-ring systems to undergo ring-opening.

86

Results and Discussion

It has been demonstrated in Scheme 63 that Pd(II)-pincer complex 268-catalysed ring-opening of
N-tosyl 2,3-disubstituted vinylaziridine 267 with phenylboronic acid to give the coupling product in a
good yield with an excellent trans-selectivity. Nevertheless, the single coordination site on the
palladium pincer complex 268 compromises the coordination of vinylaziridine 103 to the
transmetallated palladium complex. Therefore, a simple Pd(OAc)2/phenanthroline/AgSbF6 system
was utilised to generate a cationic catalyst that could catalyse the reaction of vinylaziridine 103 with
boronic acids and control the stereochemical outcome by the coordination of N-sulfonyl group of the
aziridine 103.
The aziridine 103 could be readily synthesised by aziridination of 1,3-butadiene 272 using
catalytic phenyltrimethylammonium tribromide (PTAB) (Scheme 65).98 A number of signals for
vinyl group of 103 were found at 5.58-5.48 ppm (multiplet), 5.44 ppm (doublet) and 5.25 ppm
(doublet) in the 1H NMR 103. In addition, two distinctive doublets associated with CH2 next to the
stereogenic centre of 103 (2.79 ppm and 2.21 ppm) also evidenced the successful aziridination.

Scheme 65: Synthesis of vinylaziridine 103

The PTAB is a source of electrophilic bromine, which functions as the catalyst to initiate the
reaction. It also probably behaves as a solid-liquid phase transfer agent to assist the dissolution of
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chloramine-T 273 in acetonitrile.121 The bromonium ion A initially is formed from the addition of
Br-Cl to the olefin, followed by the formation of β-bromo-N-chloro-N-toluenesulfonamide B by the
nucleophilic attack of TsNCl. Subsequently, attack of Br- (or TsNCl-) on the N-Cl group of B releases
the anion C and regenerated electrophilic bromine D as Br-Cl. The desired aziridine 103 is then given
by expulsion of Br- from the anion C.
Brief preliminary research, at the end of the proceeding Masters degree project, was carried out
under the conditions similar to that reported by Sawamura and co-workers (Scheme 66).99 The
product 274 was synthesised in a moderate yield with an unusual Z-selectivity (4.6:1 mixture of Z:E
isomers), and trace styrenylaziridine was observed as the by-product in the 1H NMR of the crude
reaction mixture (Scheme 62).

Scheme 66: Preliminary result for addition of phenylboronic acid to vinylaziridine 103

Complete optimisation of the process and substrate scope were performed during the PhD and is
summarised in the table 1. Firstly, with other conditions kept the same as in Scheme 66, a reaction
was carried out with 2,2'-bipyridine, which is a different N-based ligand (entry 1, Table 1). This only
resulted in a reduced yield of 42% with a 3.5:1 ratio of Z/E isomers. The evidence for generation of
the linear product 274 came from two mutiplets (5.80-5.65 ppm and 5.48-5.35 ppm, respectively)
associated with two olefinic protons of 274. A broad singlet at 4.48 ppm associated with the amine
proton was found in the 1H NMR of 274, suggesting the ring-opening of 103. The presence of this
amine proton in the structure of 274 was further evidenced by a broad frequency at 3274 cm-1 in IR
spectrum of 274, and this amine proton resulted from the C-N bond cleavage of 103. Two aliphatic
CH2 of 274 were found as a triplet at 3.70 ppm and a doublet at 3.28 ppm respectively in the 1H NMR
of 274. In addition, the 13C NMR demonstrates correct number of aliphatic carbons in the expected
structure of cis-274. Two olefinic carbon signals of cis-274 were also observed at 132.8 ppm and
126.3 ppm. Moreover, high-resolution mass spectrometry also gave a molecular weight (302.1203 g
mol-1) that highly match the calculated molecular weight of 274. In conclusion, 274 has been
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successfully synthesised via the ring-opening of 103 with phenylboronic acid. Many by-products also
appeared on the 1H NMR of the crude reaction mixture. Perhaps as a result of the rotation of the
C2-C2' bond, the 2,2'-bipyridine was apparently not able to coordinate to the Pd centre as rigidly as
the 1,10-phenanthroline has in the previous reactions (Scheme 67).100-101

Scheme 67: The coordination of 1,10-phenanthroline and 2,2’-bipyridine to the Pd(II)-centre

Table 1: Further optimisation for the reaction in Scheme 66

Entry

Conditions

Yield (%)

Ratio (Z/E)

42

3.5:1

64

1.6:1

79

4.2:1

Pd(OAc)2 (10 mol%)
2,2'-bipyridine (15 mol%)
1
AgSbF6 (10 mol%)
KOAc (1.0 eq)
Pd(OAc)2 (10 mol%)
Phen (15 mol%) AgSbF6
2
(10 mol%)
n-Bu4NBr (15 mol%)
Pd(OAc)2 (10 mol%)
3
Phen (15 mol%)
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AgSbF6 (10 mol%)
Pd(OAc)2 (10 mol%)
4

27a

1.7:1.0

Phen (15 mol%)
a

Conversion.

The addition of a catalytic amount of n-Bu4NBr was expected to enhance the reaction in the
ways shown in Scheme 68. In the pathway a, bromide may occupy the vacant site potentially
available for the β-H elimination, preventing the formation of by-product styrenylaziridine 279
(Pathway a, Scheme 68). In addition, the nucleophilic attack of bromide at the Pd(II)-centre may
facilitate the strain-relieving ring-opening process (pathway b, Scheme 68). However, the addition of
n-Bu4NBr only led to a sharp drop in the Z/E ratio with no significant change in the yield, and the
trace styrenylaziridine was still present in the crude reaction mixture (entry 2, Table 1).

Scheme 68: Expected function of n-Bu4NBr

The next reaction was performed with no base or additive. Surprisingly, this simplification of the
conditions resulted in a very clean 1H NMR of the crude reaction mixture. The product 274 was
isolated in a high yield (79%) with a 4.2:1 mixture of Z:E isomers (entry 3). These results suggest
that the ring-opening occurred to generate the internal alkene with no significant styrene formation
due to the absence of signals range from 6.00 ppm to 7.00 ppm in 1H NMR of the crude reaction
mixture. To examine the effect of AgSbF6 in the reaction, it was removed from the reaction mixture.
As a result, the conversion was dramatically reduced to 27% with a sharp drop in the ratio of Z:E
isomers (entry 4). This suggests the Ag maintains the Pd catalyst in a cationic state, facilitating
transmetallation and coordination between Pd and NTs.
Subsequently, the reaction scope was examined with a variety of arylboronic acids (Table 2). The
reactions utilising substituted arylboronic acids were found to require the addition of 0.5 equivalents
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of potassium acetate (entries 2-9, Table 2). For example, the electron-rich tolylboronic acid gave the
corresponding allylic sulfonamide in a 40% yield with a good Z/E ratio (3.5:1) in the presence of 0.5
equivalents of potassium acetate (KOAc) (entry 2). However, the reaction efficiency was
considerably diminished either with no KOAc or with no AgSbF6 (17% conversion). Furthermore,
the Z/E ratio was significantly reduced if the silver salt was omitted but KOAc was present (entry 2).
It was found that highly electron-deficient arylboronic acids were the optimum substrates for this
reaction (Table 1, entries 3-6). For instance, the addition of (4-(ethoxycarbonyl)phenyl)boronic acid
resulted in an excellent yield (94%) with a moderate Z/E ratio (2.7:1.0) in the presence of KOAc, but
a slight decomposition occurred with no KOAc since an unclean 1H NMR of the crude reaction
mixture was observed (entry 3).

An excellent yield (90%) was observed again with use of

(4-nitrophenyl)boronic acid (entry 5), albeit with a moderate Z/E ratio (2.2:1.0). NOESY-1D was
applied to determine the Z/E configuration for the product 284 as it has well-separated signals for the
two aliphatic CH2 (see Appendix). The triplet corresponding to the a' protons (CH2 at 3.58 ppm,
minor isomer) next to the NHTs was first selected as the reference for the NOSEY-1D, and it was
found that two olefinic protons (H1 at 5.47-5.45 ppm, H2 at 5.73-5.71 ppm) and an amine proton (HN
at 4.67 ppm) correlated to a'. The other doublet corresponding to the b' next to the aromatic ring
(CH2 at 3.42 ppm) was absent on the NOSEY-1D spectrum (Figure 10). This result suggests a' has
proximity in space to only H1, H2 and HN. The minor isomer was therefore assigned as trans-olefin.
In contrast, a NOSEY-1D spectrum of the major isomer shows the triplet a (CH2 next to the NHTs at
3.73 ppm) correlates to only one olefinic proton H1 (multiplet, 5.55-5.53 ppm), amine proton HN (app.
triplet, 4.73 ppm) and the doublet b (CH2 next to the aromatic ring at 3.44 ppm), but the NOSEY-1D
does not demonstrate the correlation between a and H2, suggesting the major isomer is a cis-olefin
(Figure 7). Therefore, the reaction exhibited an unusual Z-selectivity that was in stark contrast to that
observed by Szabo’s Pd-pincer complexes (Scheme 63).

Figure 7: NOESY-1D results of 284
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Halogen-substituted arylboronic acids were investigated in the reaction scope for the potential
application of the corresponding ring-opened products in coupling reactions. As expected, the more
electron-deficient 4-fluorophenylboronic acid released the allylic sulfonamide in a good yield (75%)
with a moderate Z-selectivity (entry 6). However, 4-chlorophenylboronic acid, which is less
electron-deficient than 4-fluorophenylboronic acid, was able to give the targeted product in moderate
yield (57%), but with a slightly increased Z/E ratio (2.8:1.0) compared with the result in entry 6
(entry 4). A yield (38%) and a low Z/E ratio (1.8:1.0) were observed with indolylboronic acid (entry
7). A moderate yield (42%) was obtained with relatively high Z/E ratio (4.5:1.0) when
3-methoxyphenylboronic acid participated into the reaction (entry 8). The more electron-rich
(3,4-dimethoxyphenyl)boronic acid was utilised, lowering the yield to 25% with a 3.1:1.0 mixture of
Z/E isomers (entry 9). Thus, electron-rich arylboronic acids only resulted in moderate to relatively
low yields. It is worth noting that these reactions were very clean, and the low yields predominantly
resulted from incomplete conversion of the starting vinylaziridine 103 (entries 2, 7 to 9). It can be
tentatively proposed that the decrease in the conversion is caused by the more efficient reduction of
Pd(II) catalytically active species to Pd(0) with electron-rich boronic acids (Scheme 69).102-103 Firstly,
an acid-base reaction occurs between Pd(OAc)2 and arylboronic acid to afford the intermediate 289.
The complex 290 is then generated with the transmetallation of the aryl group to the cationic
palladium centre, and this Wagner Meerwein rearrangement-type process should be favoured by the
electron-rich aryl group. The AcO-B(OH)2 was released by the reductive elimination of 290, and the
resulting complex 291 repeats the process consisting of acid-base reaction, transmetallation and
reductive elimination in sequence. Overall, the Pd(OAc)2 was reduced to the Pd(0) species, and two
molecules of AcO-B(OH)2 and 1,1'-biaryl resulting from the homocoupling were yielded in the
reaction.104 This proposed mechanism was evidenced by the palladium black deposited on the
bottom of the reaction flask after the reaction was completed, and trace 1,1'-biaryl was observed on
the 1H NMRs of the crude reaction mixtures. Furthermore, in accordance with the expectation, more
significant 1,1'-biaryl was found in the crude 1H NMR of the electron-rich compounds.
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Scheme 69: Self-coupling of arylboronic acids induced by Pd(OAc)2

When 2-methoxyphenylboronic acid was used as a reactant no coupling reaction was observed
(entry 10). Instead, undesired products were generated as a result of hydrolysis of the aziridine and
ring-opening by acetate with 2-chlorophenylboronic acid (entry 11), again suggesting the reaction
was sensitive to steric hindrance.
The boronic acid may be a proton source following elimination since the boronic esters exhibited
a lack of reactivity in the reaction (entry 12, Table 2). Furthermore, the results in Table 2
demonstrates utilisation of electron-deficient boronic acids resulted in more efficient coupling
reactions. Therefore, the reaction rate of this reaction may not be determined by the transmetallation
step, because less nucleophilic electron-poor arylboronic acids generally slows transmetallation in
contrast to electron-neutral arylboronic acids.105-106
In all cases shown in the table 2, trace amounts of the inseparable styrenyl system were found, as
evidenced by the presence of distinctive down-field olefinic signals at the 1H NMR of the crude
reaction mixture. For example, it was found in the crude 1H NMR for the product 282 that olefinic
signals of the styrenyl by-product were present at 6.25-6.45 ppm. As proposed in Scheme 62,
competing β-H elimination may cause the generation of styrenyl compounds 266 in the reactions.
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Table 2: Reaction scope and optimization for the Pd(II)-catalysed addition of arylboronic acids to the
vinylaziridine 103

Entry

Ar

Product

Yield (%)b

Z:E ratio

1

C6H5

274

79c

4.2 : 1

17% conversion (no KOAc)e
4-MeC6H4

2

40% (0.5 eq KOAc)

3.5 : 1

17% conversion (0.5 eq KOAc

1.6:1

281
no AgSbF6)
Partial decomposition e

4-EtO2C-C6H4

3

94% (0.5 eq. KOAc)

2.7 : 1

4

4-ClC6H4

283

57

2.8 : 1

5

3-NO2C6H4

284

90

2.2 : 1

6

4-FC6H4

285

75

2.5 : 1

286

38

1.8 : 1

7

a

(no KOAc)

282

8

3-OMe-C6H4

287

42

4.5 : 1

9

3,4-OMe-C6H4

288

25

3.1:1

10

2-OMe-C6H4

-

N.R.

N/A

11

2-ClC6H4

-

Aziridine hydrolysisd

N/A

12

Phenylboronic ester

-

N.R.

N/A

Conditions: vinylaziridine (1.0 eq.), boronic acids (1.5 eq.), Pd(OAc) 2 (10 mol%), Phen (15 mol%), AgSbF6

(10 mol%), KOAc (0.5 eq.), 70 °C, 22 h.

b

attack of acetate on aziridine also observed.

Isolated yields.
e

c

No addition of KOAc.

d

Product derived from

Messy NMR of crude reaction mixture so Z/E ratio cannot be

measured.

The mechanism for the reaction is tentatively proposed on the partial basis of the coupling
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reaction between allylic esters and arylboronic acids reported by Sawamura and co-workers and the
experimental results uncovered (Scheme 70).117

Scheme 70: Proposed model for the Z-stereoselectivity of the arylboronic acid addition to the vinylaziridine
103

Firstly, a catalytically active Pd(II) species, originally generated from the reaction of the
1,10-phenanthroline, Pd(OAc)2 and AgSbF6, undergoes transmetallation with the boronic acid to
release the complex B. According to the proposal demonstrated by the Njardarson group, the NTs
group of vinylaziridine 103 has capacity of coordinating to a cationic Cu(II) centre, and this initiates
a ring-opening rearrangement reaction (Scheme 71a).107 Therefore, the N-tosyl-vinylaziridine 103
likely coordinates to the cationic Pd-aryl complex B (Scheme 70) through the N-protecting group
(Scheme 71b).108
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Scheme 71: coordination of the vinylaziridine 103 to the cationic Pd(II)-centre

Conformation C is proposed since it minimises the 1,3-allylic strain (Scheme 70). In support of
this, the reaction of vinylepoxides with cuprates through a confirmation 289 in which the double
bond and the epoxide ring were restricted to occupy approximately perpendicular planes is
demonstrated in Scheme 72a.109 As a result of the significant 1,3-allylic strain between Ca and Cb, the
other possible confirmation 290 is not favoured in the reaction. Similarly, the double bond and the
aziridine ring of 103 need to be positioned on roughly perpendicular planes in confirmation C to
minimise the 1,3-allylic strain (Scheme 72b).110 In addition, relatively high yields were observed
with electron-deficient arylboronic acids, suggesting the coordination of NTs to the cationic Pd(II)
complex B might be the rate-determining step. This is because the electron-deficient aryl group in B
leads to low electron density of the Pd(II)-centre, enhancing the subsequent coordination between the
cationic Pd(II)-centre and NTs to form C.
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Scheme 72: Formation of the confirmation C in Scheme 70

The following migratory insertion to the lower face of conformation C is regioselectively
directed by the ancillary coordination through the N-tosyl group (Scheme 70), and complex D is
therefore given in this process and favours an anti-periplanar conformation E for subsequent
elimination to give the cis-allylic sulfonamide as major product. A less favoured and highly strained
bicyclic intermediate F, would experience hampered coordination between the N-tosyl group of the
vinylaziridine 103 and the cationic Pd(II)-centre. This less favoured intermediate causes a
syn-elimination to yield the trans-allylic sulfonamide as minor side-product. In addition, in
comparison with the acetate introduced by the substrate in Sawamura’s work (Scheme 61), it can be
proposed that the additional acetate (KOAc) may take up a vacant site on the Pd(II) centre to aid
catalyst regeneration and generate AcO-B(OH)2 through the transmetallation step.
To see if selectivity would be higher, a more coordinating electron-rich N-phthalimide aziridine
292 was prepared in an excellent yield (80%) using the method demonstrated in Scheme 73a.111 The
synthesis begins with oxidation of N-aminophthalimide 293 by PIDA to produce intermediate 294
(Scheme 73b), followed by dissociation of phenyliodide from 294 with the formation of the acetoxy
nitrenium ion (N-acetoxyaminophthalimide 295). N-acetoxyaminophthalimide 295 is the reactive
intermediate that aziridinates the olefin to form the desired aziridine 292. Simultaneously, acetic acid
and iodobenzene are given as by-products. The structure of 292 contains one vinyl group because
characteristic signals of vinyl group, including a mutiplet (CH, 5.80-5.73 ppm) and two doublets
(5.55 ppm and 5.37 ppm, repectively), were observed in 1H NMR of 292. Aliphatic CH2 of 292 was
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evidenced by two doublets of doublet at 2.72 ppm and 2.52 ppm. In addition, a quartet at 3.08 ppm
corresponding to aliphatic CH of 292 was also observed. Two aliphatic carbon signals associated
with aliphatic CH2 and CH were observed at 38.9 ppm and 44.2 ppm repectively in the 13C NMR of
292, supporting the generation of 292 in this reaction.
The relatively electron-rich N-phthalimide group is expected to give a more efficient reaction
since its potential better coordination ability with the cationic Pd(II)-centre could favour confirmation
C (Scheme 70). Additionally, the formation of unfavoured configuration F (Scheme 70) from 292
could be facilitated due to the improved coordination between the electron-rich N-phthalimide group
and the cationic Pd(II)-centre. Therefore, increased E-selectivity was expected in the reaction.
In consideration of the reduced ring-opening capacity of 292 caused by electron-rich
N-phthalimide group, KOAc (0.5 eq) was added to the reaction to facilitate the C-N bond cleavage.
292 was completely consumed to afford the corresponding product 296 in a good yield (70%) at
ambient temperature with a 4.1:1.0 Z/E ratio (Scheme 90b). The Z-selectivity was not significantly
different from that of 274 (4.2:1). This may because increased steric hindrance between the large
N-phthalimide group and the Pd(II)-centre disfavours configuration F despite potentially enhanced
coordination (Scheme 70). However, the yield was reduced in the absence of KOAc.
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Scheme 73: Ring-opening of N-phthalimide vinylaziridine 292
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Hydrolysis of Vinylaziridine 103

Subsequently, inspired by the Pd(II)-catalysed acetoxylation of olefin 297 developed by the White
group (Scheme 74a),112 a C-H oxidation of vinylaziridine 103 was attempted for synthesis of 299 as
a new allylic acetate that could be utilised in the future Pd(0)-catalysed coupling reaction. However,
the reaction only produced a relatively messy crude reaction mixture. Column chromatography was
performed to isolate the linear acetate-substituted sulfonamide 300 in a 45% yield with many
inseparable impurities. Additionally, a branched hydrolysed vinylaziridine 301 was also isolated in
significant quantity (Scheme 74b). The branched-selectivity was evidenced by conservation of vinyl
group in the 301, and this regioselectivity leads to some characteristic signals in 1H NMR of 301,
including a mutiplet at 5.79-5.72 ppm (olefinic CH) and two doublets associated with terminal CH2
of 301 (5.29 ppm and 5.17, respectively); furthermore, the aliphatic CH adjacent to OH was found at
4.22 ppm as an apparent singlet. Additionally, the 13C NMR shows nine carbon signals in total, which
is in agreement with the number of carbons in the symmetric structure of 301. The structure of 301
was then confirmed by compared with literature.113

Scheme 74: The acetoxylation of 103

The branched selectivity of 301 drew our attention since vicinal amino alcohols are important
structural motifs of bioactive molecules.114 It should be noted that the hydrolysis of vinylaziridines
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only has very limited examples. For instance, Somfai and co-workers found the complete branched
selectivity of enantioenriched vic-amino alcohols 303 were obtained from enantiomerically pure N-H
vinylaziridine 302 in the presence of HClO4 (1.0 eq) in a co-solvent system (THF/H2O) (Scheme
75).115

Scheme 75: example for the hydrolysis of vinylaziridines 302

However, there is no example for the transition-metal-catalysed hydrolysis of vinylaziridines.
Fortunately, this chance result provided a starting point for this topic (Scheme 74). Therefore, a
palladium-catalysed hydrolysis of vinylaziridine 103 was studied as a side-project.
The first reaction was carried out in the presence of Pd(OAc)2 (10 mol%), BQ (2.0 eq) in the
co-solvent mixture (DMSO/H2O) without acetic acid. As a result, 301 was isolated in a moderate
yield (65%) at ambient temperature with no need of an inert atmosphere. However, a number of
observable signals including a broad triplet (NH, 4.80 ppm), an apparent singlet (OHCHCOCH3, 4.21
ppm), a pair of symmetric triplets (CH2, 3.34-3.32 ppm and 3.30-3.26 ppm) and a singlet (Tosyl
methyl, 2.36 ppm) in the 1H NMR of crude reaction mixture suggest the generation of by-product 304
by the Wacker oxidation of 301. The by-product 304 cannot be isolated without significant impurities,
and it largely increased the difficulty of purifying 301 (Scheme 76).

Scheme 76: Generation of branched allylic alcohol 301
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To increase the yield of 301, a series of reactions were performed under different conditions (Table
3). First of all, 2.0 equivalents of BQ were removed to prevent the Wacker process. Nevertheless, this
only slightly increased the cleanness of the crude reaction mixture but reduced the isolated yield of
301 (56%) (entry 1, Table 3). Moreover, the observable by-product 304 was still present in the 1H
NMR of the crude reaction mixture presumably due to air oxidation. Next, it was found that the
by-product 304 was largely removed when 15 mol% of phen was added as the ligand (entry 2). This
may be because the bidentate 1,10-phenanthroline is a strong chelating ligand for the Pd(II) centre.116
The resulting complex 305 therefore has a rigid structure to inhibit the generation of the complex 306,
which

is

catalytically active

for

the

Wacker process

(Scheme

77).

117

Additionally,

phenanthroline-metal complexes have become attractive catalysts that can serve as a Lewis acid.118

.
Scheme 77: The complex formed from phen and Pd(OAc)2

Surprisingly, the yield was considerably improved to 89% when 2.0 equivalents of BQ was added
to increase the acidity of Pd(II) centre in the presence of phen ligand.119 However, observable 304
was still present in the 1H NMR of crude reaction mixture (entry 3). To minimise the amount of 304,
the loading of BQ decreased to 15 mol%, however, the yield was then considerably reduced to 58%
(entry 4). Subsequently, PdCl2 was used to replace Pd(OAc)2, however, a relatively messy 1H NMR
of the crude reaction mixture was obtained if the phen was absent, and 304 was isolated in a 29%
yield with some inseparable impurities but the desired product 301 was only isolated in a 15% yield
(entry 5). BQ was considered as the major oxidant that participated in the Wacker process to produce
304, therefore, BQ was removed in the next reaction. This resulted in a high yield (80%) for the
desired product 301, although the O2-involved Wacker process still occurred to a slight extent (entry
6). Phen (15 mol%) was therefore added to inhibit the Wacker process, and the cleanness of the 1H
NMR of the crude reaction mixture was significantly improved; furthermore, 301 was isolated in an
excellent yield (89%) (entry 7). The yield was only slightly increased when 15 mol% of BQ was
added as an additive, but the cleanness of the crude reaction mixture decreased (entry 8). The
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conditions shown in the entry 7 were considered to be promising, therefore, two reactions were
performed with reduced catalyst and ligand loading based on the conditions in entry 7 (entries 9 and
10), and good yields of 301 were obtained in both reactions. Subsequently, the reaction proceeded
smoothly without compromising in the cleanness of the crude reaction mixture even if the catalyst
loading was reduced to 1 mol% (entry 11). A control reaction was also performed in the neat water,
but only a low conversion (8%) was obtained (entry 12). The co-solvent mixture gave an increased
conversion but with a 1:1 ratio of linear:branched products in the absence of the catalyst-system
(entry 13). In conclusion, the catalyst loading could be reduced to 1 mol% without significant
reduction in yield.

Table 3: Optimisation on hydrolysis of 103 to give branched allylic alcohol 301

Entry

Conditionsc

Yield (%)

Pd(OAc)2 (10 mol%),
56

1
DMSO/H2O (1:1, v/v)
Pd(OAc)2 (10 mol%),
2

Phen (15 mol%)

62

DMSO/H2O (1:1, v/v)
Pd(OAc)2 (10 mol%),
3

Phen (15 mol%), BQ (2.0 eq)

89

DMSO/H2O (1:1, v/v)
Pd(OAc)2 (10 mol%),
Phen (15 mol%),
58

4
BQ (15 mol%),
DMSO/H2O (1:1, v/v)
PdCl2 (10 mol%),
5

BQ (2.0 eq),

15d

DMSO/H2O (1:1, v/v)
6

PdCl2 (10 mol%),

80
103

DMSO/H2O (1:1, v/v)
PdCl2 (10 mol%),
7

Phen (15 mol%)

89

DMSO/H2O (1:1, v/v)
PdCl2 (10 mol%),
Phen (15 mol%),
93

8
BQ (15 mol%),
DMSO/H2O (1:1, v/v)
PdCl2 (5 mol%),
9

Phen (7.5 mol%)

77

DMSO/H2O (1:1, v/v)
PdCl2 (2.5 mol%),
Phen (4 mol%)

10

79

DMSO/H2O (1:1, v/v)
PdCl2 (1 mol%),
11

Phen (2 mol%)

88

DMSO/H2O (1:1, v/v)

a

Conversion.

b

12

H2O

8a

13b

DMSO/H2O (1:1, v/v)

80a

1:1 ratio of linear: branched products in crude reaction mixture.

c

Reactions were carried out

under the air. d 304 was isolated in a 29% yield.

According to the experimental results (Table 3), a plausible key intermediate 307 was proposed to
elucidate the branched selectivity in the hydrolysis of vinylaziridine 103. Firstly, DMSO stabilises
the cationic Pd(II)-centre by interacting with positive charges through the oxygen atom in DMSO.120
The complex 309 is therefore formed in the presence of DMSO, phen and Pd(OAc)2. The complex
309 then behaves as a Lewis acid and coordinates to the NTs group, polarising the C2-N bond of
vinylaziridine 103 to create a partial positive charge at the C2-position. The ring-opening is then
achieved with direct SN2 nucleophilic attack of water molecule to give the complex 308,121 followed
by hydrolysis and dissociation of the desired product 301 with acetate to regenerate the
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phenanthroline-Pd complex 309 (Scheme 78).

Scheme 78: The mechanism for Pd(II)-catalysed generation of 301

Additionally, phenol 310 and ethanol 312 were also used as the nucleophile. Unfortunately, no
reactions occurred under the conditions in either case (Scheme 79).

Scheme 79: Ring-opening of vinylaziridine 103 with phenol 310 and ethanol 312

Subsequently, aniline was utilised as an alternative N-based nucleophile to replace water in the
reaction. The 1H NMR of the product demonstrated a complete conversion of 103 to the branched
product 314, and the formation of 314 was evidenced by a mutiplet (5.72-5.67 ppm) and two
doublets (5.26 ppm and 5.19 ppm, respectively) associated with the vinyl group of 314. In addition,
a number of signals in the 1H NMR of crude reaction mixture, including a doublet corresponding to
the NH of aniline moiety in 314 (3.64 ppm), an apparent quartet associated with the aliphatic CH
of 314 (3.91 ppm), a broad triplet corresponding to tosyl NH of 314 (3.55 ppm) and a pair of
symmetric multiplets corresponding to the aliphatic CH2 of 314 (3.20-3.13 ppm and 3.04-2.98 ppm,
respectively), also suggest the formation of 314 in the reaction. However, 314 was isolated through
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the column chromatography in only a moderate yield with significant inseparable impurities due to
decomposition in the column (Scheme 80). The reaction scope was not investigated in this
side-project due to time constraint although a promising result was obtained.

Scheme 80: Ring-opening of vinylaziridine 103 by aniline

106

Summary
In summary, the Pd(II)-catalysed addition of arylboronic acids to N-tosyl-2-vinylaziridine 103 to
yield a series of unusual cis-allylic sulfonamides as major products has been demonstrated, and the
resultant allylic sulfonamides are potentially synthetically useful precursors for the synthesis of
nitrogen-containing bioactive molecules. 122 Moreover, the unusual Z-selectivity highlights the
reaction to be an intriguing complementary strategy to the related reactions catalysed by Pd-pincer
complexes (Scheme 64). Notably, the procedure does not require rigorous inert atmosphere and
utilises a commercially available Pd(OAc)2 catalyst in combination with an air stable
nitrogen-containing ligand (phen), which largely increases the practicality of this reaction. In addition,
a branched allylic alcohol 301 was given in an excellent yield by the hydrolysis of vinylaziridine 103
in the presence of a simple Pd(II)-catalyst system with very low loading (1 mol%). Although the
aniline effectively gave a 100% conversion of 103 to the corresponding product 314 under the same
conditions, 314 was isolated in only a moderate yield with significant inseparable impurities as 314
was decomposed in the column. This final result suggests the scope of ring-opening may be limited,
but in future work the hydrolysis of other aziridines should be investigated.
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Future Plans

The Pd(0)/Pd(II)-catalysed ring-opening of 2-ethynyl-1-tosylaziridine

The Pd(II)-catalysed addition of boronic acids to vinylaziridines has been developed in this chapter.
In the next stage, 2-ethynyl-1-tosylaziridine 318, which has not been previously investigated for its
reactivity in such ring-opening reactions, could be utilised in the future in order to obtain allenic
products. Firstly, a route to synthesise this less developed substrate was proposed (Scheme 81).

Scheme 81: Proposed synthetic route for 2-ethynyl-1-tosylaziridine 318

According to the synthesis developed by the Padron group, amino alcohol 316 could be prepared
via a 2-step method utilising trimethylsilanyl-propynal 315.123 It was envisioned that the subsequent
ring-closure may be realised in the presence of TsCl and KOH, which has been reported by the Craig
group and the Ghorai group to make enantiopure aziridines.124

Scheme 82: Possible reactions based on 2-ethynyl-1-tosylaziridine 319

Two reaction pathways for the reactivity of 319 can be envisioned. Firstly, the ring-opening
reaction of 319 will be performed with phenylboronic acid in the presence of the Pd(II)-system that
was developed in this chapter. A sulfonamide 320 containing allene motiety is expected to be
generated via the pathway shown in Scheme 82. In addition, Michael and co-workers developed the
Pd(0)-catalysed cross-coupling of N-sulfonylaziridines 324 with boronic acids, and the
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azametallacycle 325 was proposed as the key intermediate resulting from the oxidative addition of
aziridine 324 to Pd(0) (Scheme 83a). After protonolysis of 325 with m-chlorophenol additive,
transmetallation of the boronic acid and reductive elimination of 327 generate the product 325. The
presence of m-chlorophenol additive is crucial as it may minimise the lifetime of two intermediates to
prevent β-H elimination by controlling the protonlytic equilibrium and the rate of transmetallation.
Thus, it is possible that the same type of intermediate 321 could be generated by oxidative addition
of 319, and 321 is able to undergo protonolysis and transmetallation, followed by the reductive
elimination to release the final compound 322 in the presence of m-chlorophenol additive (Scheme
83b). This intriguing issue of regioselectivity would be an interesting topic of investigation that has
not yet been explored in methods that involve direct oxidative addition to aziridines by low-valent
transition metals and could lead to either alkyne 322a or allene 322b.

Scheme 83: Pd(0)-catalysed cross-coupling of N-sulfonylaziridines with boronic acids
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Chapter 3. Ring-Opening of Vinylcyclopropane-1,1-dicarboxylates by
Boronic Acids under Ligandless Palladium Catalysis in Neat Water

Introduction

In this chapter, research focused on strained donor-acceptor vinylcyclopropane-1,1-dicarboxylates
328, which are carbon analogues of vinylaziridine 103

investigated in chapter 2. The vicinally

positioned donor vinyl group and acceptor dual CO2Et groups are installed at the C1 and C2-positions
of the 3-membered ring 328. It has been previously mentioned in chapter 2 that C-N bond breaking of
103 could be achieved in the presence of transition metal-catalysts, and this process is facilitated by
the electron-withdrawing N-activating groups such as tosyl (Scheme 88a). The C1-C2 bond breaking
of 328 can be cleaved similarly with the facilitation of donor (vinyl) and acceptor groups (CO2Et)
(Scheme 84b).

Scheme 84: C-N bond cleavage of 103 and similar C-C bond cleavage of 328

Generally, there are four pathways to achieve ring-opening of the donor-acceptor
vinylcyclopropane 328 with activating agents (Scheme 85).125-126 They are: a) Lewis acid-catalysed
C-C bond cleavage of 328; b) radical chain pathway initiated by organotransition metal reagents such
as Bu2SnIH; c) ring-opening via rhodacycle 331 resulting from a high-valent Rh(III) catalyst; d) and
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formation of the η3 allyl-metal complex 332 as a result of low-valent transition metal catalysts. This
last process is of primary interest in this chapter. Linear or branched adducts are generated via these
pathways with various nucleophiles (Scheme 85). Each mode of activation will now be discussed in
detail.

Scheme 85: C-C bond activation of vinylcyclopropane 328 in the presence of activating agents

Lewis Acid-Catalysed C-C Bond Breaking of Vinylcyclopropanes

Firstly, in the Lewis acid-catalysed reactions a, vinylcyclopropane-1,1-dicarboxylates 328 could be
activated by the Lewis acid, undergoing favourable two-point coordination to the germinal diester
(Scheme 86). This activating process leads to polarisation in the vicinal C1(sp3)-C2(sp3) bond of
328,127 alternatively, heterolytic ring-opening of the cyclopropane ring occurs to give a reactive
1,3-dipole 333. Subsequently, linear 335 or branched adduct 334 can therefore be produced with a
nucleophile in the presence of 333, (Scheme 86a), or a cyclic structure 336 can be generated through
a formal [3+2] cycloaddition of dipolarophiles such as alkenes or alkynes (Scheme 86b).128

111

Scheme 86: Lewis acid-catalysed C-C bond breaking of vinylcyclopropanes 328

An early example of Lewis acid-promoted ring-opening of vinylcyclopropanes 339 comes from
Sartori and co-workers in 1983 who carried out a Friedel–Crafts reaction in the presence of a
stoichiometric amount of SnCl4 (Scheme 87). Potassium phenoxides were treated with
vinylcyclopropanes 339 in toluene at 80oC for 10 h, yielding a series of trans-ethyl
6-(2-hydroxyphenyl)-2-carbethoxy-4-hexenoates 340 as major products in low to moderate yields.129
The hexacoordinate adduct 341 resulting from coordination of the acid metal ion to oxygen atoms of
both reactants directs the less-hindered terminus of the vinyl group to attack at the ortho-position
during the C1sp3-C2sp3 bond breaking of vinylcyclopropane 339. This regioselectivity is because the
terminal position of the vinyl moiety favours the attack, being held in close proximity to the
ortho-position of phenoxide 338.
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Scheme 87: SnCl4-catalysed reaction of potassium phenoxides with vinylcyclopropanes 339

A major drawback of this reaction is the stoichiometric use of SnCl4, which is required to achieve
only a relatively low yield of the products. In 2008, the Johnson group utilised catalytic amount of
SnCl4 to carry out a [3+2] cycloaddition of aldehydes/ketones 345 and donor-acceptor
vinylcyclopropanes 344 (Scheme 88), affording a variety of biologically important substituted
tetrahydrofurans 346.130 The achiral zwitterionic 1,3-dipole 347 is generated from the oxygen atoms
of acceptor groups to the acidic tin centre, and the vinyl moiety serves as a donor group to stabilise
the partially positive charge on the 1,3-dipole (Scheme 86).

Scheme 88: Lewis acid-catalysed cycloadditions of D-A cyclopropanes 344 with aldehydes and ketones 345
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Moreover, the Johnson group provided some examples for the Lewis acid-catalysed dynamic
kinetic asymmetric [3+2] cycloaddition of susbtituted vinylcyclopropanes 348 with aldimines 349
(Scheme 89). 131 In this reaction, 2,5-cis-disubstituted pyrrolidines 350 were enantioselectively
prepared in the presence of catalytic MgI2 and a pybox ligand in good yields from racemic substituted
vinylcyclopropanes. The least sterically hindered diaxial transition state 351 resulting from
E-aldimine dipolarophiles was proposed to account for the cis-selectivity of the reaction, and an fast
and competitive substrate racemisation relative to annulation was found to lead to the high
enantioenrichment of the product 350.

Scheme 89: Asymmetric [3+2] cycloaddition of susbtituted vinylcyclopropane 348 with aldimines 349

C-C Bond Breaking of Vinylcyclopropanes via the Radical Chain Pathway

A radical chain pathway b has been established with radical initiators, such as Bu2SnIH to open
vinylcyclopropanes (Scheme 89b). Recently, the Shibata group reported a coupling reaction of
donor-acceptor vinylcyclopropanes 352 with aldehydes catalysed by tin hydride-Bu2SnIH (Scheme
94).132 The reaction shows that Bu2SnIH is able to effectively promote the hydrostannation of
vinylcyclopropanes 352, and the resulting allylic tin compound 353 smoothly reacts with aldehydes
to give a series of homoallyl alcohols 354 in excellent diastereoselectivities. The presence of radical
initiator V-70L in the reaction was essential to maintain the high yields of the products, and no
reaction was observed without the tin catalyst.
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Scheme 90: Coupling reaction of vinylcyclopropanes 352 with aldehydes catalysed by tin hydride

A plausible catalytic cycle for the reaction was proposed (Scheme 90). Initially, the
di-n-butyliodotin radical (Bu2ISn.) generated in situ adds to the terminus of vinylcyclopropanes 352,
yielding the cyclopropylmethylene radical 355. Next, the subsequent regioselective ring cleavage
occurs from a hindered position to give a homoallyl radical 356 possessing a stable
trans-configuration, which reacts with Bu2SnIH to the trans-allylic tin 357 and regenerate the
di-n-butyliodotin radical. The resultant trans-allylic tin radical 357 subsequently reacts with
benzaldehyde via transition state 358 to afford the thero-homoallyl tin alkoxide 359, followed by the
rate-determining protonation with MeOH to release the product 354 and the tin methoxide. Finally,
the Ph2SiH2 reacts with the tin methoxide to regenerate Bu2SnIH.
Although the excellent diastereoselectivity was obtained (Scheme 90), enantiospecific coupling
reactions occurring via a radical chain pathway still lack investigation. To address this, the Maruoka
group has shown for the first time that the organic thiyl radical catalyst can promote the asymmetric
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radical ring-opening process of vinylcyclopropanes 360 (Scheme 91). 133 A series of highly
enantioenriched 5-membered ring systems 362 were synthesised in the reaction in good to excellent
yields with high diastereoselectivities. This C–C bond-forming radical cyclisation was successfully
developed with a chiral thiol precatalyst possessing a chiral pocket, which has a unique functionality
that is capable of directly giving a radical in a vinylcyclopropane to promote the radical C-C bond
formation (Scheme 85b).
Mechanistically, it was proposed that the radical C–C bond formation initiates with photolytic
generation of the thiyl radical from the corresponding sulfide. The subsequent radical transfer is
believed to follow the Beckwith–Houk model134-135 and occurs to preferably release the favoured
trans-isomer 362 in the presence of benzoyl peroxide (BPO) as an oxidant (Scheme 91b).
Furthermore, the excellent diastereoselectivity was not diminished by a thiyl radical-mediated
hydrogen abstraction after this radical cyclisation.

Scheme 91: An organic thiyl radical catalyst for enantioselective cyclisation
116

Ring-Opening of Vinylcyclopropanes via Rhodacycles

High-valent transition metals have demonstrated excellent capacity for activating C-H bond for the
construction of C-C and C-heteroatom bonds.136 This aspect has been harnessed for ring-opening of
vinylcyclopropanes with C-H aryl systems. Among a variety of transition metals, a Rh(III) catalyst
was selected to achieve a rhodacycle 331 due to its advantage of high catalytic efficiency, mild
reaction conditions and a broad substrate scope in C-H activation of arenes (Scheme 85c). 137
Ring-opening of vinylcyclopropanes via rhodacycles has great potential for exploration as it is under
investigated. Wang and co-workers demonstrated a sole example for the catalytic activity of RhIII in a
sequential C-H activation and the C-C activation reaction. Aryl systems 364 bearing a directing group,
such as amide, pyrimidine and oxime reacted with various vinylcyclopropanes 365 to give a variety
of

trans-ring-opening

products

366

in

moderate

to

excellent

yields

with

excellent

diastereoselectivities. Mechanistically, after the formation of the rhodacycle 370 via C-H activation,
the β-carbon elimination may occur to relieve the ring strain. The resulting allylated arenes 366 could
be used to synthesise some valuable building blocks.138 The alkene insertion step, followed by the
β-carbon elimination, has been identified as the rate-determining step (Scheme 92).

Scheme 92: Rhodium(III)-catalysed C–H/C–C activation sequence
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Ring-Opening of Vinylcyclopropanes via η3-Allyl Transition Metal Complexes

Low-valent transition metals (TM) can activate vinylcyclopropanes via the oxidative addition to
form the electrophilic η3-allyl transition metal complexes 332 (Scheme 85d). This process is
energetically favorable due to the formation of an allyl-metal bond in the zwitterionic π-allyl metal
intermediate, and the relief of ring-strain is a partial driving force of the ring-opening process (ca. 28
kcal.mol-1).139 Therefore, vinylcyclopropanes have been utilised in the low-valent TM-catalysed
cycloaddition reactions and allylic substitution with various nucleophiles (Scheme 93).

Scheme 93: Two pathways for ring-opening of vinylcyclopropane via the π-allyl-metal complex 332

In the cycloaddition reaction (Scheme 93a), the key zwitterionic π-allyl metal intermediate 332
results in a 5-membered ring structure 373 via formal [3+2] cycloaddition (Scheme 93a)140 In
addition, a linear 374 or branched adduct 375 could be generated via the SN2 or SN2' nucleophilic
attack on vinylcyclopropanes in the presence of low-valent transition metals. This reaction is
generally limited to moisture sensitive organometallics and soft nucleophiles such as malonates
(Scheme 93b).
The first reported nucleophilic ring-opening reaction of activated vinylcyclopropanes 376 was
developed by Burgess in 1985 (Scheme 94). The zwitterionic π-allyl metal intermediate 332 was
initially generated from the ring-opening of a donor-acceptor vinylcyclopropane 376 in the presence
of catalytic Pd(PPh3)4, followed by nucleophile trapping with various active methylenes 377 such as
malonates, 1,3-diketones and bis(phenylsufonyl) methane to give a series of adducts 378. However,
in some cases, further deprotonation of the mono-alkylated product occurred to furnish the
di-alkylated product 379 via the nucleophilic attack towards the vinylcyclopropane 376.141
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Scheme 94: Conjugate nucleophilic ring-opening of activated vinylcyclopropanes 376

An

increasing

number

of

nucleophiles

were

utilised

for

ring-opening

addition

of

vinylcyclopropanes. For example, Moreau and co-workers reported a regio- and stereoselective
Pd(0)-catalysed ring-opening reaction of readily available tetraethyl 2-vinyl-1,1-cyclopropane
bisphosphonate 380 with secondary amines 381 to synthesise a series of allylic amines 383 in
excellent yields with complete stereoselectivities (Scheme 95).142 The reaction likely proceeds with
the initial generation of an η3 π-allyl-Pd(II) complex 382 and subsequent nucleophilic attack from a
secondary amine 381 to the less sterically hindered position of the intermediate. The resulting
geminal bisphosphonates 383 and their derivatives display some interesting pharmacologically
activitie,s such as binding to bone minerals and inhibiting the resorption of living bone.143

Scheme 95: Pd(0)-catalysed synthesis of amino alkenyl geminal bisphosphonates 383

Very recently, the scope of nitrogen-based nucleophiles in the ring-opening of donor-acceptor
vinylcyclopropanes was extended to N-heterocycles such as purines by the Guo group.144 Dual
nucleophilic sites of purines (N9 and N7) allowed a diversity-oriented synthesis of acyclic
nucleosides, which have attracted considerable interest as a variety of acyclic nucleosides such as
acyclovir 384, ganciclovir 385, penciclovir 386 and famcidovir 387 have been identified as anti-HIV
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agents (Figure 8).145
Firstly, a series of vinylcyclopropanes 389 with different ester groups were subjected to the
SN2'-type ring-opening reaction (1,5-ring-opening) with purines 388 in the presence of catalytic
Pd2(dba)3.CHCl3 and DIOP ligand, affording N9 adducts 390 as the major products in moderate to
excellent yields with exclusive trans-selectivity. As indicated in Scheme 85d, the electrophilic
allyl-Pd(II) intermediate C4 generated from the oxidative addition of vinylcyclopropanes 389 to
Pd2(dba)3.CHCl3 was proposed (Scheme 96a). A relatively rare 1,3-ring-opening reaction of
vinylcyclopropanes 389 proceeding via an SN2 pathway was observed if a stoichiometric amount of
the Lewis acid (AlCl3, 1.0 eq) was utilised. Therefore, a number of branched N9 adducts 391 were
synthesised in low to good yields (Scheme 96b). The same 1,3-ring-opening was achieved with a
catalytic amount of MgI2, however, N7 rather than N9 substitution regioselectively occurred in this
case (Scheme 96c). It should be realised that reaction b and c are mechanistically different from
reaction a. As a result of coordination of the bidentate vinylcyclopropane 389 and N3 in the
6-chloropurine to aluminium centre, reaction b proceeds with 1,3-ring-opening since the N9 position
is close to the C3-position in vinylcyclopropane 389 (Scheme 96). Similarly, the coordination of the
bidentate vinylcyclopropane 389 and bidentate N3, N9 in 6-chloropurine to Mg gives a complex with
octahedral geometry, causing attack from the uncoordinated N7 position to C3 in the
vinylcyclopropane to give the N7-adduct 392 (Scheme 96c). Both key intermediates 393 and 394
indicate that the two reactions involving AlCl3 and MgI2 respectively are catalysed by Lewis acids,
and they are complementary examples that enrich the Lewis acid-catalysed ring-opening reactions of
donor-acceptor vinylcyclopropanes (Scheme 85a).

Figure 8: Representative acyclic nucleosides approved by FDA as anti-HIV agents
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Scheme 96: Diversity-oriented synthesis of acyclic nucleosides via ring-opening of vinyl cyclopropanes with
purines

All Pd-catalysed examples above produced the linear structures as the major product (Schemes
94-96), however, Szabo and co-workers synthesised branched products 398 via a 2-step strategy
involving a Pd(II)-pincer complex 268 and a Pd(0) catalyst (Scheme 97).146 The trans-allylic boronic
acids 396 were first generated and then subjected to the conditions of the Suzuki-Miyaura coupling.
This coupling reaction is initiated by oxidative addition of 397 to the Pd(0)-catalyst, followed by a
highly regioselective carbopalladation process with 396 to give intermediate 399. Subsequent
elimination of the palladium boronate occurs to give a branched product 398 in an excellent yield
with an almost absolute regioselectivity. It is of note that this sequence does not proceed via an
(η3-allyl)palladium intermediate.
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Scheme 97: Palladium-catalysed coupling of allylboronic acids 396 with iodobenzene 397

The utility of the palladium(0)-catalysts was then further demonstrated by the synthesis of sulfur
compounds 404 via the carbonylative ring-opening addition of vinylcyclopropanes 400 (Scheme 98).
Alper and Xiao developed a thiocarbonylative ring-opening of donor-acceptor vinylcyclopropanes
400 with thiols 403 and carbon monoxide in the presence of Pd(OAc)2 and PPh3 (Scheme 98).147 The
catalytically active Pd(0) species is generated in-situ in the reaction.

Scheme 98: Pd-catalysed thiocarbonylative ring-opening of vinylcyclopropanes 400 with thiols 403

Mechanistically, the oxidative addition of the vinylcyclopropane to the in situ-generated Pd(0)
species gives an η3 π-allyl-Pd(II) complex 401, followed by CO insertion to give an acylpalladium
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complex 402. It should be noted that CO insertion is faster than subsequent reductive elimination.
Reductive elimination then occurs to form the thioester and regenerate the Pd(0)-catalyst. The
reaction has shown broad functional group tolerance as a range of aryl, heteroaryl, as well as alkyl
thiols were involved into the reaction scope. However, it should be noted that isomerisation of the
thiocarbonylation to the conjugated thioesters was observed

to some extent in most cases.

A dual catalyst system was utilised by the Werz group for developing a Pd(0)-catalysed
three-component coupling involving in situ-generated arynes 410, terminal alkynes 406, and
vinylcyclopropanes 407 (Scheme 99).148 The reaction starts with generation of the copper acetylide
412, resulting from the deprotonation of a terminal alkyne 406 using a stoichiometric amount of KF
and CuI. The in situ-generated benzyne 410149 then reacts with the nucleophilic copper acetylide 412
to afford the reactive nucleophilic aryl copper intermediate 411. Simultaneously, the Pd(0)-catalyst
participates in the reaction to activate the vinylcyclopropane 407 to form the electrophilic η3
π-allyl-palladium complex 408. The transmetallation subsequently occurs between the nucleophilic
copper intermediate 411 and this π-allyl-palladium complex 408, followed by reductive elimination
to give the π-complex 409. Therefore, the desired coupling product 408 is dissociated from the
palladium centre to regenerate the active palladium catalyst.
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Scheme 99: Pd-Catalysed three-component coupling of terminal alkynes, arynes, and vinylcyclopropanes

As an alternative to Pd(0)-catalysed process, Pd(II)-species have been found to be effective in the
ring-opening addition of vinylcyclopropanes (see also Scheme 97). For example, the palladium
pincer complex 268 was again utilised by the Szabo group in a Pd(II)-catalysed ring-opening reaction
to synthesise

allylic

boronic

acid

derivatives

416

from vinylcyclopropanes

414

and

tetrahydroxydiboron (Scheme 100).150 Transmetallation allows a B(OH)2 group to transfer on the
Pd(II)-centre, followed by a SN2' nucleophilic attack on the vinylcyclopropanes 414 to yield the
allylic boronic acids 415. The allylic boronic acids 415 were then treated with aqueous KHF2 to
afford the more stable potassium trifluoro-(allyl)borate derivatives 416 in high yields. It is worth
mentioning that allylic boronic acid derivatives are valuable precursors for synthesis of
allylborane-based building blocks, such as chiral tartrate-based reagents.151-152
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Scheme 100: Pincer complex-catalysed synthesis of allylborates 416

Apart from palladium-catalysed process, Yorimisu and Oshima further extended the catalyst scope
to Ni(0) species for the borylative ring-opening reaction of donor-acceptor vinylcyclopropanes 417
(Scheme 101a).153 Allylboronic acids, synthesised by the Szabo group (Scheme 100), can have
limited application due to their instability, so they were treated with aqueous KHF2 solution to give
the stable potassium trifluoro(allyl)borates. The one-pot strategy developed by the Yorimisu group
allows the direct formation of the relatively stable functionalised allylic boronates 422 in the presence
of catalytic Ni(0), providing a complementary method to afford such synthetically useful substrates.
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Scheme 101: Ni(0)-catalysed ring-opening of vinylcyclopropanes with [Bpin 2] 2

The oxidative addition of vinylcyclopropanes 417 to the Ni(0) species is likely the first step of the
catalytic process, affording π-allyl(oxa-π-allyl)nickel species 418, with bidentate coordination of the
oxophilic Ni centre to the carbonyl and vinyl groups. Transmetallation then occurs to generate a
π-allyl nickel complex 419. The subsequent reductive elimination allows the generation of the boron
enolate 420 and recovery of the initial Ni(0)-catalyst. Finally, protonolysis gives allylic boronates 422
in moderate to excellent yields with high E-selectivity. In addition, the first oxidative addition was
found to be promoted by the bidentate coordinate of the Ni centre to the carbonyl and vinyl group as
a reduced yield of 44% was observed for the parent trans-vinylcyclopropane 429 (E1= H, E2=
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CO2t-Bu), and this slow process may compete with side-reactions. In contrast, the reaction of a
cis-vinylcyclopropane 423 (E1= CO2t-Bu, E2= H) proceeded efficiently (Scheme 101b).
Iron catalysts have recently emerged in the activation of vinylcyclopropanes due to the economic
and environmental advantages of this abundant metal.154 For example,

rstner has shown a highly

regioselective iron-catalysed addition of alkyl Grignard reagents to activated vinylcyclopropanes 430
(Scheme 102a),155 which is the example of the use of a hard organometallic nucleophile in catalytic
ring-opening additions of vinylcyclopropanes. The reaction could either proceed via a direct SN2'
addition mechanism or an allyl-iron based process. The latter mechanism is possible as low-valent
ferrates can be generated in-situ by treating Fe(acac)3 with alkyl Grignard reagents. A number of
linear ring-opened products 431 were prepared with moderate to good selectivities (Scheme 102b). In
pathway I, an iron-ate type intermediate is proposed for this nucleophilic displacement. Additionally,
the possibility of generating an iron-allyl complex 433 followed by the reductive elimination cannot
be excluded (pathway II, Scheme 102).

Scheme 102: Iron-catalysed addition of Grignard reagents to activated vinylcyclopropanes 430

The C-C bond activation of donor-acceptor vinylcyclopropanes with iron catalysts was further
investigated by Plietker and co-workers. They reported the allyl-iron intermediate could be efficiently
generated from the nucleophilic ferrate Bu4N[Fe(CO)3(NO)] (TBAFe) to activate donor-acceptor
vinylcyclopropanes 435 towards the attack of soft-nucleophiles (Scheme 103).156 In this reaction,
after generating the allyl-iron complex 436, pronucleophiles such as malodinitrile, a cyanophenyl
ester, cyanocyclopentanone and a phenylazlactone were deprotonated by the carbanion of the
allyl-iron complex 436, giving, after nucleophilic attack, a series of functionalised acyclic products
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437 in good to excellent yields with high stereo- and regioselectivies (Scheme 107a). Interestingly,
with the addition of mesityl substituted NHC-ligands, the [3+2] cycloadducts 438 were synthesised in
good yields (Scheme 103b). The reactions demonstrate the synthetic versatility of the allyl-iron
complex 436, nevertheless, only relatively low to moderate diastereoselectivities were obtained
(Scheme 103b).

Scheme 103: The allylic C−C-bond activation in the presence of the low-valent iron (II) complex TBAFe

All the aforementioned examples involving donor-acceptor cyclopropanes allow the nucleophilic
trapping at the donor site and electrophilic trapping at the acceptor site. In contrast, a rare reaction
reported by Johnson and Krische demonstrated the polarity inversion of donor-acceptor
cyclopropanes 439 to give the nucleophilic allyl complexes 442 with Ir(III) catalysts (Scheme
104).157 In this reaction, the key nucleophilic allyl-Ir species 442 reacts with primary alcohols or
aldehydes 440 to afford enantiopure allylic alcohols 441 in high yields and with good
diastereoselectivies. This special strategy could be a complementary method to the related Lewis
acid-catalysed pathway (Scheme 85a) and the electrophilic allyl-metal complex pathway (Scheme
85d). The reaction proceeds in a similar manner to that discussed in Chapter 2 for the vinylaziridine
system also reported by Krische and co-workers (Scheme 53).
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Scheme 104: Polarity Inversion of donor-acceptor cyclopropanes 439 with Ir-catalysis
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Research Plan
Although the transition metal-catalysed ring-opening of vinylcyclopropanes with sp3 carbon-based
nucleophiles has been established with alkyl Grignard reagents and malonates, the substrate scope is
limited due to the relatively poor functional tolerance and the high sensitivity to protic solvents of the
former (Scheme 102). Therefore, the synthetic versatility of vinylcyclopropanes’ nucleophilic
ring-opening would be significantly increased if the scope of nucleophiles could be extended to the
non-stabilised, bench-stable and economic sp2 carbon nucleophiles such as arylboronic acids.
Furthermore,

the

regioselective

synthesis

of

the

branched

allylic

product

from

the

vinylcyclopropane-1,1-dicarboxylate 328 and boronic acids in one-pot was also important to the
project. This strategy would avoid using aryl iodides, which were previously utilised by the Szabo
group for synthesising the branched allylic product via a 2-step method (Scheme 97).
A designed catalytic cycle is illustrated in Scheme 105 to briefly describe the project. Firstly, a
Pd(0)-catalyst system was chosen to form the expected η3-allyl Pd(II) complex 445 stabilised by the
internal carboxylate oxygen atom. According to the Ikariya group’s proposal, transmetallation then
could occur to deliver a phenyl group on the Pd(II)-centre of 445.158 Reductive elimination from the
resulting intermediate 446 is very interesting as two possible products may be finally released. This is
because the reductive elimination can be governed by both sterics and electronics depending upon the
nature of the R group,159 in other words, there are thermodynamic and kinetic aspects to the control.

Scheme 105: Designed reaction pathway to regioselectively synthesise linear/branched products

Overall, a Pd(0)-system to achieve the coupling reaction of vinylcyclopropanes via the
π-allyl-Pd(II) complex to regioselectively synthesise linear or branched product is the major aim of
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this chapter. The project combines the synthetic versatility of vinylcyclopropanes and the high
catalytic efficiency of the Pd(0)-catalyst system, furthermore, arylboronic acids will be used as a
stable and hypotoxic C-based nucleophile. If successful, the reaction would extend the substrate
scope for ring-opening of vinylcyclopropanes and is complementary to Plietker and urstner’s work
(Schemes 102-103).
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Results and Discussion

To realise the proposal in Scheme 105, studies commenced with the synthesis of
2-vinylcyclopropane-1,1-dicarboxylate

328.

This

substrate

was

easily

synthesised

from

(E)-1,4-dibromobut-2-ene 363 and diethyl malonate 362 in the presence of Cs2CO3 in an excellent
yield (Scheme 106).160 Generation of 328 was evidenced by a number of signals in 1H NMR of the
crude reaction mixture, including a mutiplet (5.46-5.39 ppm) corresponding to the olefinic CH and
two doublets (5.28 ppm and 5.12 ppm, respectively) associated with the olefinic CH2. In addition, a
quartet (2.56 ppm) corresponding to the aliphatic CH and two symmetric doublets of doublet (1.67
ppm and 1.53 ppm) associated with the aliphatic CH2 were also observed in 1H NMR of the crude
reaction mixture, suggesting the cyclopropane ring has been formed in the reaction. The formation of
328 was further evidenced by eleven carbon signals shown in the 13C NMR because the structure of
328 demonstrates eleven carbons in total. In addition, it should be noted that two ester carbon signals
were observed at 169.5 ppm and 167.3 ppm respectively, suggesting two ester groups that originated
from 448 was incorporated into 328.

Scheme 106: Preparation of vinylcyclopropane 328

This synthesis starts with deprotonation of diethyl malonate by a stoichiometric amount of Cs2CO3.
The resulting anion 449 acts as nucleophile to attack 1,4-dibromobutene 452 via an SN2 pathway,
producing the allyl adduct 450, which is then deprotonated by Cs2CO3. Finally, the intramolecular
SN2' reaction of the resultant anion 451 releases the vinylcyclopropane 328 (Scheme 105).
By employing the same conditions as the chapter 2 for the oxidative Heck reaction of
vinylaziridines, the ring-opening of the vinylcyclopropane 328 was achieved (Table 1, entry 1),
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though the conversion was only 48%. Unfortunately, the E:Z-selectivity (67:33) was very low,
furthermore, a significant amount of an inseparable impurity was observed whenever the reaction was
attempted.161 The coordination of carbonyls of 328 to the Pd(II)-centre leads to the remote distance
between vinyl group and the Pd(II)-centre, potentially causing the low efficiency of the reaction in
comparison to the aziridine 103 (Confirmation II, Scheme 70) (entry 1).

Table 1. Optimisation conditions for the ring-opening of 328

Selectivity
Entry

Conditions

Yield (%)
(Linear:Branched)

Pd(OAc)2 (10 mol%)
Phen (15 mol%),
1

48%b

AgSbF6 (10 mol%),

only linear
(E/Z= 67:33)

DCE
Pd(OAc)2 (2 mol%)
8.7: 1
2

PPh3 (4 mol%),

51%
(E/Z= 95: 5)

THF/H2O
Pd(OAc)2 (1 mol%),
3

84%

11.5:1 (E/Z= 98: 2)

H 2O

4

No catalyst, H2O

29%c

1.2: 1
(only E observed)

a

5

Pd(OAc)2, THF/H2Oe

26%c

only linear

6

Pd(OAc)2, THF

trace

only linear

7

Pd(PPh3)4, H2Oe

N.R

N/A

Ratios measured from the 1H NMR of the crude reaction mixture.

b

Inseparable impurity also formed.

c

Conversion, product not isolated.d 5.0 equivalents of distilled water used. e The reaction was carried out under
nitrogen.
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A Pd(0)-catalyst system (entry 2) that has been shown to successfully catalyse the Suzuki-Miyaura
coupling of allylic carbonates with arylboronic acids was then utilised in the reaction. 162 The
Pd(0)-catalyst system generated the Pd(0) species in situ by stirring Pd(OAc)2 with PPh3; this
catalytic system delivered the desired product in moderate conversion and yields but with good
linear:branched as well as trans:cis ratios.
Thus, it was essential to identify an efficient Pd(0)-catalyst to further enhance the credentials of
reactions involving vinylcyclopropanes 328 with boronic acids. In this regard, three reports then drew
our attention. Firstly, the use of an amphiphilic Pd(II)-pincer complex 456 in water has been reported
to form vesicles that catalyse the addition of boronic acids to vinylepoxide 453, but the reaction
displayed poor regioselectivity and utilised a complex catalyst consisting of both a hydrophilic group
and a hydrophobic group (Scheme 107).163

Scheme 107: Palladium-catalysed oxirane ring opening with PhB(OH)2 in water

On the other hand, Pd nanoparticles (Pd NPS) have exhibited excellent catalytic activity in
aryl-aryl coupling reactions in neat water under the ligand-free conditions. For example, a Pd
nanoparticle solution was made by dispersing an acylmetal salt [(CO)5W]C(Me)ONEt4] into distilled
water and then adding the resulting mixture into a well-mixed aqueous solution of K2PdCl4 and
polyethylene glycol.164 Sakar and co-workers successfully utilised the catalyst solution to perform a
series of Heck/Suzuki/Sonogashira-type coupling using aryl halides 457 and arylboronic acids,
showing the excellent versatility of Pd nanoparticles (Pd NPS) in the catalysis of coupling reactions
(Scheme 108), while the presence of the stabiliser polyethylene glycol (PEG) and a stoichiometric
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amount of K2CO3 were required.165

Scheme 108: Pd nanoparticles-catalysed coupling reaction

The Zhang group subsequently demonstrated that Pd NPS can form in neat water from Pd(OAc)2
and arylboronic acids without ligands and additional stabilisers (Scheme 109).166 Furthermore, the in
situ-generated Pd NPS allows the addition of arylboronic acids to enantiopure (S) secondary allylic
carbonates 463, producing the allyl–aryl coupling products 464 in high yields with excellent chemo-,
regio- and E/Z-selectivities. TEM analysis showed that Pd NPS could be generated with an average
size of 2.6 nm by simply stirring the mixture of Pd(OAc)2 and phenylboronic acid in water for 5 mins.
Therefore, a mechanism was proposed on the basis of TEM analysis and the experimental results
(Scheme 109). The electrophilic π-allyl-Pd(II) complex 465 is formed by stereospecific oxidative
addition of in situ-generated Pd NPS to the chiral allylic carbonate from the back side.
Transmetallation then occurs with the active π-allyl-Pd(II) intermediate 465 and phenylboronic acid,
followed by the reductive elimination, which occurs at the less sterically hindered terminus of the
π-allyl-Pd(II) intermediate 466 to furnish the inversed (R)-allyl-aryl coupling products 464 with
complete regioselectivity and retained enantiopurity. Finally, the released Pd(0) species is
reaggregated to recover Pd NPS. The coupling reaction may occur at the interface of the organic
substrate and water, and the stabilisation of Pd-NPS is likely achieved with the released boronic acid
monobutoxide dissolved in water.
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Scheme 109: Stereospecific coupling of allylic carbonates 463 with arylboronic acids catalysed by in situ
generated Pd NPs

All these examples above show that Pd nanoparticle catalysis has demonstrated its merit in
catalytic activity for organic synthesis under environmentally benign conditions that could be applied
to green chemistry, as nanoparticle catalysis occurs on the broad surface of the metal. Therefore, in an
attempt to identify an efficient Pd(0)-catalyst system, we turned our attention to the use of Pd(OAc)2
and boronic acids in water (Scheme 109), a simple system which has been previously reported to
produce Pd(0) nanoparticles via the pathway shown in Scheme 69. When these conditions were
deployed, it was pleasing to find that the internal alkene 452 was smoothly produced in a high yield
(84%) with excellent E/Z-selectivity (11.5:1) (entry 3, Table 1). The key diagnostic evidence for the
formation of this product came from the 1H NMR signals associated with ring-opening of 328. These
included two identical multiplets corresponding to two alkene protons, which were observed
downfield at 5.72-5.66 ppm and 5.51-5.45 ppm respectively, suggesting the generation of an internal
alkene via the nucleophilic attack accompanied by the shifting of the terminal double bond from the
C2 carbon of the cyclopropane ring. The cleavage of the C1-C2 cyclopropane bond was evidenced by
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the chemical shift of the triplet (3.40 ppm) associated with the methine proton of the malonate moiety.
Further evidence of generation of 452 came from a doublet (3.31 ppm) corresponding to the CH2
between the phenyl group and the olefinic CH, and a triplet (2.62 ppm) associated with the CH2
between the methine and the olefinic CH also support the formation of 452 in the reaction. 13C NMR
of the purified product demonstrates five aliphatic carbon signals, which are in line with numbers of
aliphatic carbons in the symmetric structure of 452. The molecular weight (313.1428 g mol-1) of
purified product that was given by high-resolution mass spectrometry matches the NMR-determined
structure of 452. In addition, the stereochemistry of the product 452 was determined by NOESY-1D
(See Appendix). It was observed that the triplet a corresponding to the CH2 (2.62 ppm) has proximity
in space to two olefinic protons (H1: 5.72-5.66 ppm and H2: 5.51-5.45 ppm) and triplet c associated
with the methine proton (3.40 ppm). However, the doublet b corresponding to the CH2 adjacent to the
phenyl ring does not have the NOESY-1D signal to a. In conclusion, the E-isomer is likely the major
product of this reaction (Figure 9).

Figure 9: NOESY-1D results of the product 452

Importantly, these conditions do not require the addition of ligand, stabiliser or organic solvent,
rendering the reaction synthetically practical and economical. The reaction does not require strict
exclusion of air, making it operationally simple. As a control, the reaction was then carried out in the
absence of catalyst, and roughly equal amount of branched:linear product in low conversion observed
highlighted the importance of the catalyst (entry 4). Low conversion (26%) and dominant
E-selectivity were given when only Pd(OAc)2 was stirred in a mixture of THF and 5.0 equivalents of
distilled water (entry 5), while only trace product was observed with the use of anhydrous THF (entry
6). Other Pd(0) species such as Pd(PPh3)4 were also utilised in water, however, no reaction was
observed (entry 7).
With these optimised conditions in hand, the vinylcyclopropane was treated with a variety of
boronic acids to give the corresponding alkenes in generally high yields and linear trans-selectivities
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(Table 2). It was evident that electron-deficient arylboronic acids generally gave the desired product
in excellent yields (products 467 to 470). Moreover, ortho-substitution was tolerated and gave a good
yield (product 476), while the yield was reduced for more electron-rich systems and naphthyl-derived
boronic acids (product 471, 473, 478 and 474). Additionally, it needs to be noted that the relatively
low yields, such as observed for products 476, 478 and 467, were a result of the incomplete
conversion of 328 rather than production of side-products. The unreacted 328 could be therefore
recovered with the column chromatography in these cases.
In addition, a cyano group could be tolerated as the electron-withdrawing donor group on the
vinylcyclopropane (product 477). The corresponding 1,1'-dicyano-2- vinylcyclopropane 530 was
prepared in a moderate yield (43%) from malononitrile and (E)-1,4-dibromobut-2-ene 363 by the
method shown in Scheme 106. An alkenyl boronic acid was an effective substrate to couple with
phenylboronic acid, and the corresponding linear adduct was given in a moderate yield and with a
complete

linear

selectivity

(product

475).

Unfortunately,

alkylboronic

acids

such

as

cyclohexylboronic acid gave no reaction under the conditions.

Table 2. Reaction scope for linear products with respect to boronic acids
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a

ratios measured from the crude 1H NMR b no branched isomer observed.

In order to see if branched ring-opened products could be obtained, attention was turned to
vinylcyclopropanes substituted with an aryl group on the olefin unit (Table 3). The
styrenylcyclopropane 498 was synthesised from cinnamaldehyde 531 via a 2-step strategy (Scheme
110a). 167 The presence of styrenyl group in 498 was evidenced by two characteristic signals,
including a doublet at 6.64 ppm and a doublet of doublet at 5.83 ppm. Further evidence for formation
of 498 came from a quartet associated with aliphatic CH (2.74 ppm) and two doublets of doublet at
1.82 ppm and 1.66 ppm, respectively (aliphatic CH2). In addition, the

13

C NMR demonstrates all

fifteen carbons in the symmetric structure of 498, supporting the synthesis of 498 was achieved in
this reaction. Other trans β-styrenylcyclopropanes could be easily prepared by cross-metathesis using
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the unsubstituted vinylcyclopropane 328 and the corresponding commercially available styrenes 480
in the presence of the Grubbs second generation catalyst (Scheme 110b).

Scheme 110: The synthesis of β-styrenylcyclopropanes with Grubbs Catalyst, 2nd Generation

Pleasingly, using the optimised conditions (entry 1, Table 1) with substituted vinylcyclopropane
498, the branched product 485 was generated as the major product with complete E-selectivity in an
excellent yield (Table 3). Evidence for generation of the branched isomer came from the doublet and
the doublet of doublet (6.44 and 6.29 ppm, respectively) associated with the styrenyl motif of 485 in
the 1H NMR. Furthermore, the triplet corresponding to the CH between two carboxylates group was
also observed at 3.36 ppm, suggesting the ring-opening reaction has occurred (see Appendix).

13

C

NMR demonstrates six signals for aliphatic carbons, which is in accordance with the number of
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aliphatic carbons in symmetric structure of 485. It needs to be noted that two ester carbons of 485 that
originated from 498 were observed at 169.5 ppm and 169.4 ppm, respectively. High-resolution mass
spectrometry gave a molecular weight of 389.1745 g mol-1 for the isolated product, which is in line
with the calculated molecular weight of 498. In conclusion, formation of the branched product 498
was achieved under the conditions used in Table 2.
The scope of this ring-opening was then investigated with a range of arylboronic acids, and it
proved to have high functional group tolerance, providing high to exclusive branched selectivity in
each case. A series of functional groups, including halides (products 486, 488 and 489), ester (product
490) and ketones (product 487), were tolerated under the conditions. It was also found that both
electron-rich (product 492) and highly electron-deficient boronic acids (product 491) could be
effective coupling partners to give corresponding products in moderate to high yields, respectively.
Moreover, ortho-substituted boronic acids could also be used, albeit a drop in yield was observed
(product 489), however, pent-1-en-1-ylboronic acid, which previously gave a moderate yield in Table
2, now gave a complex mixture of products when reacted with the vinylcyclopropane 498. This might
result from the steric hindrance
proposed

intermediate

446

between pent-1-en-1-yl group and ester group of 498 in the
after

transmetallation

(Scheme

105).

Subsequently,

the

vinylcyclopropanes with the substituted electron-rich aromatic ring on the terminus of alkene moiety
were also studied, and the corresponding products were obtained in good yields and excellent
branched-selectivities (product 494 and 497). Highly sterically hindered vinylcyclopropane 499
bearing an ortho-chloro group was subject to the conditions, and product 495 was then isolated in a
relatively high yield with an excellent selectivity. Additionally, Suzuki coupling did not occur with
p-bromophenyl-substituted vinylcyclopropane 500, which produced the sole branched isomer 496 in
a synthetically acceptable yield. Again, it needs to be highlighted that the moderate yields in the table
3 for some products such as 489, 491 and 495 were a result of low conversions of the corresponding
vinylcyclopropanes after the reaction completed, and the unreacted vinylcyclopropanes were
recovered by the column chromatography.
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Table 3. Reaction scope with respect to boronic acid for branched systems
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a

ratios measured from the 1H NMR of the crude reaction mixture, only the E isomer of the major product was

observed b no linear isomer observed.

To show that these products can be manipulated in a facile manner, the product 452 was subjected
to the Krapcho decarboxylation reaction to give the ester 500 in a good yield (Scheme 111). The 1H
NMR of the pure product 500 showed a mutiplet with an integration of four (2.40-2.36 ppm) for two
adjacent methylenes between the olefin moiety and the single carboxylate group. Further evidence
for formation of 500 came from two signals in 1H NMR, including two mutiplets associated with two
olefinic protons of 500 (5.66-5.57 ppm and 5.55-5.46 ppm, respectively) and a doublet at 3.33 ppm
corresponding to the CH2 next to the phenyl group of 500. Importantly, it was found that integrations
for two characteristic signals of carboxylate such as a quartet at 4.12 ppm (OCH2CH3) and a triplet at
1.24 ppm (OCH2CH3) demonstrate 500 has only one carboxylate group. In addition, high-resolution
mass spectrometry (241.1208 g mol-1) also confirmed the removal of one carboxylate from 452.

Scheme 111: Decarboxylation reaction of 452

According to the designed reaction pathway (Scheme 105),168 a catalytic cycle was proposed to
explain the experimental results (Scheme 112). Firstly, Pd(0) nanoparticles can be generated via
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double processes of transmetallation plus reductive elimination (Scheme 69), and Zhang and
co-workers136 have proved the reduction of Pd(II) to Pd(0) by the reaction of palladium acetate and
two molar equivalents of arylboronic acid in water. The presence of trace biphenyl signals were also
observed in the 1H NMR of the crude reaction mixture, providing some evidence for this mode of
activation to give Pd(0) nanoparticles. ollowing catalyst activation, the η3 π-Pd-allyl complex A is
formed via oxidative addition to the vinylcyclopropane 328. Next, transmetallation may be assisted
by water or internally by the ester enolate as shown in the ester enolate B.169 In support of this, it has
been postulated that transmetallation in the coupling of 1,1-diboron compounds is facilitated by the
intramolecular coordination between the boron atom and an ester group.170 Finally, the resultant
complex C undergoes reductive elimination to afford the ring-opened product, and it is proposed that
this is the key step that determines the regiochemical outcome of the reaction. Linear products could
be furnished via reductive elimination at the least hindered carbon when R = H. Alternatively, when
R = Ar′ the reductive elimination occurs to release the branched products. The former result could be
explained by the generation of thermodynamically stable internal alkene by reductive elimination to
install an Ar group on the terminus of the vinyl moiety. Reductive elimination occurring on the
terminal carbon also minimises the steric repulsion between the Pd-Ar complex and the
vinylcyclopropane substrate. In contrast, the formation of the branched product can be explained as
reductive elimination allows generation of the more stable conjugated system over the internal alkene.
Additionally, the steric impulsion between two terminal aryl groups in the internal alkene may also
play a role in determining the selectivity. It was therefore proposed that the transition state for the
formation of the conjugated branched product is also likely to be lower in energy than that for the
formation of linear product.
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Scheme 112: Proposed mechanism for palladium-catalysed coupling of vinylcyclopropanes with boronic acids

As an analogue of vinylcyclopropane 328, vinylaziridine 103 was also subjected to the
Pd(OAc)₂/H2O/PhB(OH)2 conditions (Scheme 113). However, an inseparable mixture of three
isomers: cis, trans and branched products were obtained in a ratio of 1.0:7.7:5.7. The formation of the
branched product 502 was an interesting divergence from the vinylcyclopropane system.

Scheme 113: Palladium-catalysed coupling of vinylaziridine 103 with phenylboronic acid

In addition to the Pd NPS-catalysed addition of boronic acids to vinylcyclopropanes, it was
envisioned that benzaldehyde 504 could act as a dipolarophile to cyclise with the Pd-stabilised
zwitterionic dipolar intermediate 503 resulting from the oxidative addition of Pd NPS to 328,
affording a 5-membered ring system 505, however, no reaction occurred even at an elevated
temperature (50 oC) (Scheme 114).
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Scheme 114: Unsuccessful cyclisation of vinylcyclopropane 328 with benzaldehyde 504 in neat water
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Summary
In conclusion, in situ generated Pd nanoparticles have been identified as a highly efficient catalyst
for the ring-opening of donor-acceptor vinylcyclopropanes with boronic acids in neat water. The
excellent regioselectivity is driven by the reductive elimination step of the catalytic cycle, with
branched ring-opened products being synthesised for trans β-styrenylcyclopropanes and
thermodynamically stable internal alkenes being obtained for cyclopropanes with a vinyl tether.
Moreover, the reaction requires only low loading of commercially available Pd(OAc)2 as a
precatalyst with no ancillary ligands and additives, rendering it practical and economical.
Unfortunately, the expected [3+2] annulations of vinylcyclopropane 328 did not occur with
benzaldehyde in the presence of Pd(OAc)2 and a catalytic amount of phenylboronic acid in water
even at the elevated temperature (50 oC).
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Future Plans

Enantioselective

variant

for

Pd

NPS-Catalysed

Ring-Opening

Reaction

of

Vinylcyclopropanes with Arylboronic acids in Neat Water

According to the Helmchen group, enantioenriched (R)-vinylcyclopropane 507 could be
synthesised from the carbonate 506 in the presence of [Ir(COD)Cl]2 and phosphorus amidite (Scheme
115).171

Scheme 115: Ir-catalysed cyclisations of carbonates 506

(R)-vinylcyclopropanes 510 that are substituted with an aryl group on the olefin unit will be
synthesised via the method shown in Scheme 110 (Scheme 116).

Scheme 116: Synthesis of enantioenriched substituted vinylcyclopropanes 510

These (R)-vinylcyclopropanes 510 could then be utilised in Pd NPS-catalysed ring-opening
reaction of vinylcyclopropanes with arylboronic acids in Neat Water. According to the Zhao group’s
work (Scheme 109), an enantioenriched branched product 511 may be given with complete
enantiospecificity with inversion of the absolute configuration (Scheme 117).
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Scheme 117: Enantioselective variant for Pd NPS-catalysed ring-opening reaction of vinylcyclopropanes with
arylboronic acids in Neat Water

In addition to 3-membered ring systems, 4-membered ring system is also an interesting and
suitable substrates for investigation in future work. For example, Helmchen and co-workers also
synthesised an enantiopure dimethyl 2-vinylcyclobutane-1,1-dicarboxylate 513 under the conditions
in Scheme 115 (Scheme 118).

Scheme 118: Synthesis of entioenriched 4-membered ring system 513

Two reaction pathways were proposed for Pd NPS-catalysed ring-opening of enantiopure 513 in
neat water. Firstly, a linear product 514 is expected to be generated (Scheme 119a). Alternatively, a
substituted vinylcyclobutane 515 will be prepared via alkene metathesis using Grubbs catalyst
(Scheme 116). Subsequently, this substrate will be subjected to the conditions in Scheme 117.
Similarly, this reaction may afford an enantioenriched branched product 516 with complete
enantiospecificity with inversion of the absolute configuration (Scheme 119b).
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Scheme 119: Designed reaction pathways for 4-membered ring system 513
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EXPERIMENTAL SECTION

General Information

All reactions were performed under atmosphere of nitrogen in oven-dried glassware. Anhydrous
solvents were purified by passage through a solvent purification system (purification over activated
alumina, copper catalyst, and/or molecular sieves). Flash grade silica gel was used for column
chromatography, and thin layer chromatography was performed on silica gel (32-36 μm) 60 254
aluminium backed sheets, visualized with a 254 nm UV lamp and stained with either ceric(IV) dip
containing phosphomolybdic acid (37.5 g), ceric sulphate (7.5 g), sulphuric acid (37.5 ml) and water
(750 mL) or potassium permanganate dip containing potassium permanganate (1.5 g), potassium
carbonate (10 g) and sodium hydroxide solution (10%, 1.25 mL) and water (200 mL). 1H NMR and
13

C NMR were recorded in deuterated chloroform (CDCl3) and coupling constants are recorded in Hz

and chemical shifts are recorded as δ values in ppm, referenced against residual solvent peaks ( 1H
NMR) or to the

13

C NMR resonances of the solvent. The following abbreviations are used in the

assignments of 1H NMR signals; s = singlet; d =doublet; td= doublet of triplet; tdd = triplet of doublet
of doublet; m= multiplet. Other reagents and starting materials were commercially available and used
without further purification. High-performance liquid chromatography (HPLC) was performed with a
Waters 1525 binary pump and a WatersTM 486 tunnable absorbance detector, using Chiralpak AD (25
cm x 0.46 cm) and Chiralpak OD-H (25 cm x 0.46 cm) columns. Optical rotation was measured by
JASCO P-2000 polarimeter, using a 10 mL cell with a 1 dm path length and are reported as [α]19D (c
in g per 100 ml CHCl3) at 19 ºC.
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Synthesis and Characterisation of Substrates

General Procedure 1 for Synthesis of Aziridines1

To a 0.5M solution of 0.5M solution of the corresponding styrene (1.0 eq) and chloramine-T
trihydrate (1.2 eq) in 1:3 dicloromethane:distilled water was added iodine (10 mol%) and
tetrabutylammonium bromide (0.1 eq) at room temperature under the nitrogen gas. The resulting
mixture was stirred for overnight and subsequently passed through a pad of silica gel (1.5 cm),
evaporated and first purified by the flash column chromatography with 20% ethyl acetate in hexane
to afford yellow solids.

1-Tosyl-2-phenyl aziridine 26

Following the general procedure 1, using 1.00 mL, 8.73 mmol of styrene. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 20:80 (v/v), white solid product (2.00
g, 83% yield) was obtained. 1H NMR (500 MHz, CDCl3) δ 7.87 (d, J = 8.5 Hz, 2H, tosyl CHAr), 7.33
(d, J = 8.0 Hz, 2H, tosyl CHAr), 7.31-7.26 (m, 3H, CHAr), 7.22-7.20 (m, 2H, CHAr), 3.77 (dd, J = 7.0,
4.5 Hz, 1H, PhCHNTs), 2.98 (d, J = 7.0 Hz, 1H, CHCH2NTs), 2.43 (s, 3H, Tosyl), 2.38 (d, J = 4.5 Hz,
1H, CHCH2NTs).

C NMR (125 MHz, CDCl3) δ 144.7, 135.1, 135.0, 129.8, 128.6, 128.3, 128.0,

13

126.6, 41.1, 36.0, 21.7. Note Data matched that reported previous.1, 25
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2-(p-Tolyl)-1-tosylaziridine 517

Following the general procedure 1, using 1.00 mL, 7.59 mmol of 4-methylstyene. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 20:80 (v/v), white solid product (1.81
g, 83% yield) was obtained. 1H NMR (300 MHz, CDCl3): δ 7.86 (d, J = 8.1 Hz, 2H, tosyl CHAr), 7.32
(d, J = 8.1 Hz, 2H, tosyl CHAr), 7.10 (s, 4H, CHAr), 3.77 (dd, J = 7.0, 4.5 Hz, 1H, ArCHNTs), 2.97 (d,
J = 6.9 Hz, 2H, CHCH2NTs), 2.43 (s, 3H, tosyl), 2.38 (d, J = 4.8 Hz, 2H, CHCH2NTs), 2.31 (s, 3H,
tolyl). 13C NMR (125 MHz, CDCl3) δ 138.1, 132.0, 129.8, 129.3, 128.0, 127.1, 126.5, 125.8, 41.1,
35.8, 21.7, 21.2. Note Data matched that reported previous.13, 14

2-(4-Bromophenyl)-1-tosylaziridine 518

Following the general procedure 1, using 0.20 mL, 1.53 mmol of 4-bromostyene. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 20:80 (v/v), white solid (286 mg,
53% yield) product was obtained. 1H NMR (500 MHz, CDCl3): δ 7.86 (d, J = 8.0 Hz, 2H, tosyl CHAr),
7.42 (d, J = 9.0 Hz, 2H, CHAr), 7.34 (d, J = 8.0 Hz, 2H, tosyl CHAr), 7.09 (d, J = 9.0 Hz, 2H, CHAr),
3.72 (dd, J = 7.0, 4.0 Hz, 1H, ArCHNTs), 2.99 (d, J = 7.0 Hz, 1H, CHCH2NTs), 2.44 (s, 3H, tosyl),
2.34 (d, J = 4.5 Hz, 1H, CHCH2NTs). 13C NMR (125 MHz, CDCl3) δ 144.9, 134.8, 134.2, 131.8,
129.9, 128.2, 128.0, 122.3, 40.4, 36.0, 21.7. Note Data matched that reported previous.15

2-(2-Chlorophenyl)-1-tosylaziridine 519

Following the general procedure 1, using 0.20 mL, 1.56 mmol of 2-chlorostyene. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 20:80 (v/v), white solid product (235
mg, 49% yield) was obtained. 1H NMR (500 MHz, CDCl3): δ 7.90 (d, J = 8.0 Hz, 2H, tosyl CHAr),
7.36 (d, J = 8.0 Hz, 2H, tosyl CHAr), 7.33 (d, J = 8.0 Hz, 1H, CHAr), 7.20-7.17 (m, 3H, CHAr), 4.04
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(dd, J = 7.5, 4.5 Hz, 1H, ArCHNTs), 3.04 (d. J = 7.5 Hz, 2H, CHCH2NTs), 2.45 (s, 3H, tosyl), 2.29 (d,
J = 4.5 Hz, 2H, CHCH2NTs). 13C NMR (125 MHz, CDCl3) δ 144.9, 134.7, 133.8, 133.1, 129.9, 129.3,
129.2, 128.1, 127.5, 127.1, 39.0, 35.7, 21.7. Note Data matched that reported previous.16

2-(4-Iodophenyl)-1-tosylaziridine 520

Following the general procedure 1, using 121 mg, 0.525 mmol of 4-iodostyene. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 20:80 (v/v), white solid product (140
mg, 67% yield) was obtained. 1H NMR (300 MHz, CDCl3): δ 7.85 (d, J = 8.1 Hz, 2H, tosyl CHAr),
7.61 (d, J = 8.1 Hz, 2H, CHAr), 7.33 (d, J = 8.1 Hz, 2H, tosyl CHAr), 6.95 (d, J = 8.4 Hz, 2H, CHAr),
3.70 (dd, J = 4.2, 7.2 Hz, 1H, ArCHNTs), 2.97 (d, J = 6.9 Hz, 1H, CHCH2NTs), 2.43 (s, 3H, tosyl),
2.33 (d, J = 4.2 Hz, 1H, CHCH2NTs). 13C NMR (125 MHz, CDCl3) δ 144.9, 137.7, 134.9, 134.9,
129.9, 128.4, 128.0, 93.9, 40.5, 36.0, 21.7. Note This compound has been made according to the
procedure reported by Morgan.1

2-(Naphthalen-2-yl)-1-tosylaziridine 521

Following the general procedure 1, using 475 mg, 3.08 mmol of 4-iodostyene. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 20:80 (v/v), white solid product (229
mg, 23% yield) was obtained. 1H NMR (300 MHz, CDCl3): δ 7.90 (d, J = 8.1 Hz, 2H, tosyl CHAr),
7.81-7.23 (m, 4H, CHAr), 7.48-7.45 (m, 2H, CHAr), 7.33 (d, J = 8.1 Hz, 2H, tosyl CHAr), 7.28-7.26 (m,
1H, CHAr), 3.93 (dd, J = 4.5, 7.2 Hz, 1H, ArCHNTs), 3.07 (d, J = 6.9 Hz, 1H, CHCH2NTs), 2.50 (d, J
= 4.2 Hz, 1H, CHCH2NTs), 2.42 (s, 3H, tosyl). 13C NMR (125 MHz, CDCl3) δ 144.7, 135.0, 133.2,
133.1, 132.5, 129.8, 128.5, 128.0, 127.8, 127.8, 126.5, 126.3, 126.2, 123.7, 41.4, 36.0, 21.7. Note
Data matched that reported previous.17
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1-Tosyl-2-methyl-2-phenyl aziridine 98

Following the general procedure 1, using 1.00 mL, 7.70 mmol of α-methylstyene. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 20:80 (v/v), white solid product (1.97
g, 89% yield) was obtained. 1H NMR (500 MHz, CDCl3): δ 7.87 (d, J = 8.3 Hz, 2H, tosyl CHAr), 7.40
– 7.36 (m, 2H, CHAr), 7.35 – 7.29 (m, 4H, tosyl CHAr & CHAr overlap), 7.29 – 7.26 (m, 1H, CHAr),
2.96 (s, 1H, CCH2NTs), 2.52 (s, 1H, CCH2NTs), 2.43 (s, 3H, tosyl), 2.05 (s, 3H, CH3CPhNTs). 13C
NMR (CDCl3, 75 Hz) δ 143.9, 140.9, 137.6, 129.5, 128.3, 127.7, 127.4, 126.4, 51.7, 41.8, 21.5, 20.8.
Note Data matched that reported previous.18

Synthesis and Characterisation of Vinylaziridine 1032

Chloramine-T trihydrate (2.57 g, 11.3 mmol) and phenyltrimethylammonium tribromide (10 mol%)
were dissolved in MeCN (42 mL). With vigorous stirring, the solvent was then purged with
1,4-butadiene 272 for 30 mins and then sealed. After 24 h, the reaction mixture was passed through a
pad of silica gel (5 cm), evaporated and purified by flash column chromatography (30% ethyl acetate/
hexane) to give the desired product as white crystals (813 mg, 60%). 1H NMR (300 MHz, CDCl3) δ
7.81(d, J = 3.6 Hz, 2H, tosyl CHAr), 7.32 (d, J = 3.6 Hz, 2H, tosyl CHAr), 5.58-5.48 (m, 1H, CH=CH2),
5.44 (d, J = 17.0 Hz, 1H, CH=CH2), 5.25 (d, J = 10.0 Hz, 1H, CH=CH2), 3.26 (m, 1H,
NTsCHCH=CH2), 2.79 (d, J = 7.1 Hz, 1H, CHCH2NTs), 2.47 (s, 3H, tosyl), 2.21 (d, J = 7.1 Hz, 1H,
CHCH2NTs). 13C NMR (CDCl3, 125 Hz) δ 144.6, 135.2, 133.0, 129.8, 127.9, 120.4, 41.0, 34.2, 21.7.
Note Data matched that reported previous.25
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Synthesis and Characterisation of (R)-Phenylaziridine (R)-26'3

To a solution of (R)-2-phenyl glycinol (1.00g, 7.29 mmol, 1.0 eq, 99% ee) in anhydrous CH2Cl2 (100
ml), was added triethylamine (2.54 ml, 18.2 mmol, 2.5 equiv) followed by aryl sulfonyl chloride
(1.53 g, 8.02 mmol, 1.1 equiv) in one portion. The reaction was allowed to stir at room temperature
for 8 h. The reaction was quenched with water, extracted with CH2Cl2 and dried over anhydrous
sodium sulfate. Solvent was then removed under reduced pressure to give the crude product (2.22g)
for next step without purification. The crude product was then refluxed with KOH (1.28 g, 22.9 mmol,
3.0 eq) and TsCl (1.60 g, 8.38 mmol, 1.1 eq) in THF (38 mL) at 65 oC for 3 h to afford pure (R)-2phenyl-N-sulfonylaziridine 26' (1.91 g, 96%). The 1H NMR of (R)-26' is in agreement with 26.

Synthesis and Characterisation of 2-(2-Vinylaziridin-1-yl)isoindoline-1,3-Dione 2924

Phthalimide (1.50 g, 10.2 mmol, 1.0 eq) was dissolved in 96% ethanol (10 mL). Hydrazine (0.45 ml,
11.2 mmol, 1.1 eq, 80% water solution of N2H4.H2O) was subsequently added drop-wise with stirring.
The resulting solution was stirred at 0 oC for overnight, then diluted with dichloromethane (20 mL),
quenched with distilled water (3×20 mL), dried over MgSO4 and concentrated by evaporation. The
crude product was recrystalised in 96% ethanol to afford white solids 206 (893 mg, 54%). 1H NMR
(500Mz, CDCl3) δ 7.89-7.85 (m, 2H, CHAr), 7.77-7.73 (m, 2H, CHAr), 4.14 (s, 2H, NH2).
N-amino-phthalimide 206 (893 mg, 5.51 mmol, 1.0 eq) and PhI(OAc)2 (1.33 g, 4.13 mmol, 0.75 eq)
were dissolved in anhydrous dichloromethane (27.6 mL). The solution was bubbled with
1,3-butadiene (1 atm) at room temperature for 30 mins with stirring, then diluted with
dichloromethane (30 mL), quenched with distilled water (3×30 mL), dried over MgSO4 and
concentrated by evaporation. The crude product was finally purified with 35% ethyl acetate in
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n-pentane to give yellow solids (984 mg, 83%). 1H NMR (500MHz, CDCl3 data for major rotamer) δ
7.78-7.77 (m, 2H, CHAr), 7.69 (m, 2H, CHAr), 5.80-5.73 (m, 1H, CHCH=CH2), 5.55 (d, J = 17.0 Hz,
1H, CHCH=CH2), 5.37 (d, J = 10.0 Hz, 1H, CHCH=CH2), 3.08 (q, J = 7.0 Hz, 1H, CHCH=CH2),
2.72 (dd, J = 2.0, 8.0 Hz, 1H, CH2CHCH=CH2), 2.52 (dd, J = 4.0, 5.5 Hz, 1H, CH2CHCH=CH2). 13C
NMR (125 MHz, CDCl3 data for major rotamer) δ 165.3, 134.4, 134.3, 130.6, 123.2, 119.9, 119.8,
44.2, 38.9. IR ν(cm-1): 2364, 1715, 1464, 1378, 1184, 1064, 1053, 937, 887, 813, 706. HRMS (ES):
m/z 215.0821 [C12H10N2O2+H]+, calcd. 215.0815.

General Procedure 2 for Synthesis of Indoles5

DMSO (0.2 M) was mixed with potassium hydroxide (4.0 eq) by stirring for 30 mins. The
corresponding indole (1.0 eq) was then added, and the resulting solution was stirred at room
temperature for 1 hr. Iodomethane (2.0 eq) was subsequently added dropwise to the reaction, stirred
for 24hrs. The reaction mixture was diluted with ether (50 mL) and washed with water (3×50 mL).
The organic phase dried over anhydrous MgSO4 and concentrated. Purification by the flash column
chromatography with 30% ethyl acetate in hexane gave the targeted compounds.

1-Methyl indole 114

Following the general procedure 2, using 5.00 g, 38.1 mmol of 1H-indole. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 30:70 (v/v), brown liquid product
(4.75 g, 95% yield) was obtained. 1H NMR (500 MHz, CDCl3): δ 7.60 (d, J = 7.5 Hz, 1H, CHAr),
7.25 (d, J = 8.0 Hz, 1H, CHAr), 7.19 (t, J = 7.0 Hz, 1H, CHAr), 7.08 (t, J = 7.0 Hz, 1H, CHAr), 6.94 (d,
J = 3.0 Hz, 1H, NCH=CH), 6.45 (d, J = 3.0 Hz, 1H, NCH=CH), 3.64 (s, 1H, NCH3).

13

C NMR

(CDCl3, 75 Hz) δ 136.7, 128.8, 128.5, 121.5, 120.9, 119.3, 109.2, 100.9, 32.8. Note Data matched
that reported previous.5
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5-Bromo-1-methylindole 522

Following the general procedure 2, using 300 mg, 1.53 mmol of 5-bromoindole. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 30:70 (v/v), yellow solid product
(286 mg, 89% yield) was obtained. 1H NMR (500 MHz, CDCl3): δ 7.74 (s, 1H, CHAr), 7.30-7.28 (m,
1H, CHAr), 7.19 (d, J = 8.0 Hz, 1H, CHAr), 7.05 (d, J = 3.0 Hz, 1H, NCH=CH), 6.42 (d, J = 3.0 Hz,
1H, NCH=CH), 3.77 (s, 3H, NCH3). 13C NMR (CDCl3, 75 Hz) δ 135.2, 130.0, 129.9, 124.2, 123.2,
112.6, 110.6, 100.4, 32.9. Note Data matched that reported previous.19

5-Iodo-1-methylindole 523

Following the general procedure 2, using 500 mg, 2.06 mmol of 5-iodoindole. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 30:70 (v/v), brown solid product (508
mg, 96% yield) was obtained. 1H NMR (500 MHz, CDCl3): δ 7.95 (s, 1H, CHAr), 7.46 (d, J = 9.0 Hz,
1H, CHAr), 7.10 (d, J = 8.0 Hz, 1H, CHAr), 7.00 (d, J = 3.5 Hz, 1H, NCH=CH), 6.40 (d, J = 2.0 Hz,
1H, NCH=CH), 3.77 (s, 3H, NCH3). 13C NMR (CDCl3, 75 Hz) δ 135.7, 130.9, 129.6, 129.6, 129.5,
111.3, 100.2, 82.9, 32.9. Note Data matched that reported previous.20

5-Methoxy-1-methylindole 524

Following the general procedure 2, using 500 mg, 3.40 mmol of 5-methoxylindole. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 30:70 (v/v), brown solid product (510
mg, 93% yield) was obtained. 1H NMR (500 MHz, CDCl3): δ 7.21 (d, J = 9.0 Hz, 1H, CHAr), 7.09 (d,
J = 2.0 Hz, 1H, CHAr), 7.02 (d, J = 2.5 Hz, 1H, NCH=CH), 6.89 (dd, J = 8.5, 2 Hz, 1H, CHAr), 6.40
(d, J = 3.0 Hz, 1H, NCH=CH), 3.85 (s, 3H, NCH3), 3.77 (s, 3H, OCH3). 13C NMR (CDCl3, 75 Hz) δ
153.9, 132.0, 129.2, 128.7, 111.8, 109.8, 102.4, 100.3, 55.8, 32.8. Note Data matched that reported
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previous.21

7-Iodo-1-methylindole 525

Following the general procedure 2, using 300 mg, 1.24 mmol of 7-iodoindole. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 30:70 (v/v), brown solid product (312
mg, 98% yield) was obtained. 1H NMR (500 MHz, CDCl3): δ 7.66 (d, J = 7.5 Hz, 1H, CHAr), 7.56 (d,
J = 7.5 Hz, 1H, CHAr), 7.00 (d, J = 3.0 Hz, 1H, NCH=CH), 7.76 (t, J = 8.0 Hz, 1H, CHAr), 6.40 (d, J
= 3.0 Hz, 1H, NCH=CH), 4.17 (s, 3H, NCH3). 13C NMR (CDCl3, 75 Hz) δ 135.4, 133.8, 131.9, 130.8,
121.1, 120.9, 100.7, 72.8, 36.8. Note Data matched that reported previous.22

7-Fluoro-1-methylindole 526

Following the general procedure 2, using 300 mg, 2.22 mmol of 5-fluoroindole. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 30:70 (v/v), red solid product (252
mg, 76% yield) was obtained. 1H NMR (300 MHz, CDCl3): δ 7.28-7.19 (m, 2H, CHAr), 7.07 (d, J =
3.0 Hz, 1H, NCH=CH), 6.99-6.93 (m, 1H, CHAr), 6.43 (d, J = 2.4 Hz, 1H, NCH=CH), 3.78 (s, 3H,
NCH3). 13C NMR (CDCl3, 75 Hz) δ 157.8 (J = 231 Hz), 133.3, 130.3, 128.5, 109.9 (J = 11 Hz), 109.6
(J = 6 Hz), 105.4 (J = 23 Hz), 100.7 (J = 6 Hz), 33.0. Note Data matched that reported previous.23

1-Methyl-1H-indole-7-carbaldehyde 527

Following the general procedure 2, using 300 mg, 2.07 mmol of 1H-indole-7-carbaldehyde. Purified
by chromatography on silica gel, eluting with ethyl acetate/hexane 30:70 (v/v), yellow solid product
(158 mg, 48% yield) was obtained. 1H NMR (500 MHz, CDCl3): δ 10.22 (s, 1H, O=CH), 7.88 (d, J =
8.0 Hz, 1H, CHAr), 7.70 (d, J = 7.5 Hz, 1H, CHAr), 7.23 (t, J = 8.0 Hz, 1H, CHAr), 7.08 (d, J = 3.0 Hz,
1H, NCH=CH), 6.59 (d, J = 3.0 Hz, 1H, NCH=CH), 4.15 (s, 3H, NCH3). 13C NMR (CDCl3, 75 Hz) δ
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191.0, 133.6, 132.3, 131.5, 130.2, 128.0, 122.8, 118.7, 102.2, 38.9. Note Data matched that reported
previous.24

1,3-Dimethyl indole 101

Following the general procedure 2, using 1.00 g, 7.62 mmol of 3-methylindole. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 30:70 (v/v), yellow liquid product
was obtained in quantitative yield. 1H NMR (500 MHz, CDCl3): δ 7.57 (d, J = 8.0 Hz, 1H, CHAr),
7.27(t, J = 8.5 Hz, 1H, CHAr), 7.22 (t, J = 7.0 Hz, 1H, CHAr), 7.11 (t, J = 7.0 Hz, 1H, CHAr), 6.82 (s,
1H, CH3C=CHN), 3.73 (s, 3H, NCH3), 2.33 (s, 3H, NCH=CCH3). 13C NMR (CDCl3, 125 Hz) δ 137.1,
128.7, 126.6, 121.5, 119.0, 118.5, 110.1, 109.1, 32.5, 9.6. Note Data matched that reported
previous.19

Synthesis and Characterisation of N-Benzyl Indole 5285

To a solution of 1H-indole (600mg, 5.12mmol, 1.0eq) and potassium hydroxide (0.431 mg,
7.68mmol, 1.5eq) in DMF (11 mL) added benzyl bromide (0.913ml, 1.31g, 7.68mmol, 1.5eq). The
resultant mixture was stirred for overnight, diluted with ethyl acetate (20 mL), washed with distilled
water (3×20 mL), dried over MgSO4 and concentrated. Purification by the flash column
chromatography with 30% ethyl acetate in hexane gave white solid (871g, 82%). 1H NMR (500 MHz,
CDCl3): δ 7.65 (d, J = 8.0 Hz, 1H, Indole CHAr), 7.31-7.25 (m, 4H, Indole CHAr , CHAr &
CH=CHNBn overlap), 7.17 (t, J = 7.5 Hz, 1H, Indole CHAr), 7.13-7.09 (m, 4H, Indole CHAr & CHAr
overlap), 6.55 (s, 1H, BnNCH=CH), 5.33 (s, 2H, NCH2Ph). 13C NMR (CDCl3, 75 Hz) δ 137.5, 136.2,
128.7, 128.6, 128.2, 127.5, 126.7, 121.6, 120.9, 119.4, 109.6, 101.6, 50.0. Note Data matched that
reported previous.5
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Synthesis and Characterisation of N-Allyl Indole 5296

To a solution of 1H-indole (500mg, 4.27mmol, 1.0eq) and sodium hydroxide (0.342mg, 8.54mmol,
2.0eq) in DMSO (11 mL) added allyl bromide (0.410mL, 0.573g, 4.70mmol, 1.1eq). The resultant
mixture was stirred for overnight, diluted with ethyl acetate (20 mL), washed with distilled water
(3×20 mL), dried over MgSO4 and concentrated. Purification by the flash column chromatography
with 20% ethyl acetate in hexane gave white solids (457mg, 68%). 1H NMR (500 MHz, CDCl3): δ
7.64 (t, J = 7.0 Hz, 1H, CHAr), 7.33 (t, J = 7.0 Hz, 1H, CHAr), 7.25-7.18 (m, 1H, CHAr), 7.13-7.19 (m,
2H, CHAr & CH=CHN overlap), 6.52 (d, J = 4.0 Hz, 1H, CH=CHN), 6.04-5.97 (m, 1H,
NCH2CH=CH2), 5.21 (dd, J = 4.5, 6 Hz, 1H, NCH2CH=CH2), 5.10 (d, J = 17.0 Hz, 1H,
NCH2CH=CH2), 4.74 (d, J = 1.5 Hz, 2H, NCH2CH=CH2). 13C NMR (CDCl3, 75 Hz) δ 136.1, 133.5,
128.7, 127.8, 121.5, 120.9, 119.4, 117.2, 109.6, 101.4, 48.8. Note Data matched that reported
previous.6

General Procedure 3 for Synthesis of Diethyl 2-Vinylcyclopropane-1, 1-Dicarboxylate
3287

To a solution of (E)-1,4-dibromobut-2-ene (3.0 g, 14.0 mmol, 1.0 eq) in anhydrous tetrahydrofuran
(70 mL) was added diethyl malonate (2.14 mL, 14.0 mmol, 1.0 eq) and caesium carbonate (11.4 g,
35.1 mmol, 2.5 eq). The mixture was refluxed at 60 oC. After the reaction proceeds for 16 h, the
mixture was extracted with ethyl acetate (3×50 mL) and the combined organic layer was washed with
distilled water and dried over MgSO4. After filtration, the solvent was removed in vacuo. The residue
was purified by flash column chromatography (Ethyl acetate: Hexane, 10:90) to furnish a clear oily
liquid in the yield of 87%. 1H NMR (500 MHz, CDCl3) δ 5.46-5.39 (m, 1H, CH=CH2), 5.28 (d, J =
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17.0 Hz, 1H, CH=CH2), 5.12 (d, J = 11.5 Hz, 1H, CH=CH2), 4.24-4.13 (m, 4H, OCH2CH3), 2.56 (q,
J = 8.0 Hz, 1H, CH2CHCH=CH2), 1.67 (dd, J = 8.0, 5.0 Hz, 1H, CH2CHCH=CH2), 1.53 (dd, J = 9.5,
5.0 Hz, 1H, CH2CHCH=CH2), 1.52-1.24 (m, 6H, OCH2CH3).

C NMR (CDCl3, 75 Hz) δ 169.5,
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167.3, 133.0, 118.3, 61.5, 61.3, 35.8, 30.9, 20.2, 14.0, 13.9. Note Data matched that reported
previous.7

2-Vinylcyclopropane-1,1-dicarbonitrile 5307

This compound was synthesised in 43% yield according to the general procedure 3 using
1,4-dibromobutene (1.0 g, 4.67 mmol, 1.0 eq), malononitrile (339.7 mg, 5.14 mmol, 1.1 eq), caesium
carbonate (3.81 g, 11.2 mmol, 2.5 eq) and anhydrous tetrahydrofuran (23.4 mL). Ethyl acetate cannot
be completely removed due to volatility of this compound. 1H NMR (500 MHz, CDCl3) δ 5.65-5.59
(m, 1H, CH=CH2), 5.54 (d, J = 16.0 Hz, 1H, CH=CH2), 5.51 (d, J = 9.5 Hz, 1H, CH=CH2), 2.69 (q, J
= 8.0 Hz, 1H, CHCH=CH2), 2.07 (dd, J = 8.5, 6.5 Hz, 1H, CH2CHCH=CH2), 1.83 (dd, J = 6.5, 8.5
Hz, 1H, CH2CHCH=CH2). 13C NMR (75 Hz, CDCl3) δ 129.6, 123.0, 114.8, 113.2, 33.1, 23.2, 5.6.
Note Data matched that reported previous, solvent signals present in the 1H and 13C NMR.7, 26

General

Procedure

4

for

Synthesis

of

(E)-Diethyl

2-Styrylcyclopropane-1,

1-Dicarboxylate 4988, 9

To a solution of cinnamaldehyde (3.3 g, 25.0 mmol, 1.0 eq) in anhydrous dichloromethane (40 mL),
which was cooled with -5 oC ice/salt water was added diethyl malonate (6.4 g, 39.9 mmol, 1.6 eq)
dropwise over 10 mins. A few drops of piperidine and sodium sulphate (10 g) were then added at
room temperature. The reaction mixture was stirred for 24 hrs, diluted with ethyl acetate (50 mL),
washed with distilled water (3×50 mL), and organic layer was dried over MgSO4 and evaporated
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under reduced pressure. The resulting crude product was purified with Kugelrohr distillation to give
the intermediate as a dark oil. 1H NMR (CDCl3, 500 MHz) δ 7.52 (d, J = 11.0 Hz, 1H,
C=CHCH=CHPh), 7.49 (d, J = 14.0 Hz, 2H, C=CHCH=CHPh), 7.40-7.32 (m, 3H, CHAr), 7.26 (app t,
J = 14.0 Hz, 1H, CHAr), 7.04 (d, J = 14.0 Hz, 1H, C=CHCH=CHPh), 4.37 (q, J = 7.0 Hz, 2H,
OCH2CH3), 4.28 (q, J = 7.0 Hz, 2H, OCH2CH3), 1.38 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.32 (t, J = 7.0
Hz, 2H, OCH2CH3). Note Data matched that reported previous.8, 9 To a mixture of sodium hydride
(0.535 g, 22.3 mmol, 1.1 eq, 60 % dispersion in mineral oil) and trimethylsulfonium iodide (4.90 g,
22.3 mmol, 1.1 eq) in anhydrous dimethylformamide (28.5 mL), which has been stirred at room
temperature for 30 mins, was added a solution of the intermediate in anhydrous dimethylformamide
(12.1 ml). The reaction mixture was stirred for overnight, diluted with ethyl acetate (50 mL), washed
with distilled water (3×50 mL), dried over MgSO4, evaporated under reduced pressure and purified
with 15% ethyl acetate in hexane to give yellow oil (1.00 g) as product in 14% overall yield. 1H NMR
(CDCl3, 500 MHz) δ 7.30-7.26 (m, 4H, CHAr), 7.23-7.20 (m, 1H, CHAr), 6.64 (d, J = 15.5 Hz, 1H,
CH=CHPh), 5.83 (dd, J = 15.5, 8.5 Hz, 1H, CH=CHPh), 4.27-4.16 (m, 4H, OCH2CH3), 2.74 (q, J =
8.0 Hz, 1H, CHCH=CHPh), 1.82 (dd, J = 7.5, 5.0 Hz, 1H, CH2CHCH=CHPh), 1.66 (dd, J = 7.5, 5.0
Hz, 1H, CH2CHCH=CHPh), 1.27 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.23 (t, J = 7.0 Hz, 3H, OCH2CH3).
C NMR (CDCl3, 125 Hz) δ 169.6, 167.6, 136.8, 133.6, 128.6, 127.6, 126.1, 124.8, 61.7, 61.5, 36.3,
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31.2, 21.0, 14.2, 14.1. Note Data matched that reported previous.8, 9

General Procedure 5 for Synthesis of Substituted Styrenyl Cyclopropanes10

(E)-Diethyl 2-(4-methylstyryl)cyclopropane-1,1-dicarboxylate 481

An oven-dried 10 mL flask was charged with Grubbs catalyst, 2nd generation (34.5 mg, 0.041 mmol,
5 mol%) under nitrogen atmosphere at room temperature. A solution of 328 (300 mg, 1.41 mmol, 1.0
eq) and 4-methylstyrene (0.21 mL, 1.63 mmol, 2.0 eq) in anhydrous dichloromethane (3.2 mL) was
added to the flask. Ethyl acetate (50 mL) was added after which the reaction mixture was refluxed at
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65 oC overnight, then it was washed with brine (3×30 mL) and the organic phase was dried over
MgSO4. After filtration, the solvent was removed in vacuo. The resulting crude product was then
purified with flash column chromatography (20% ethyl acetate in hexane). The product was isolated
as light green oil (134.1 mg) in 55% yield. 1H NMR (CDCl3, 300MHz) δ 7.19 (d, J = 8.1 Hz, 2H,
CHAr), 7.09 (d, J = 7.8 Hz, 2H, CHAr), 6.60 (d, J = 15.6 Hz, 1H, CHCH=CHPh), 5.76 (dd, J = 15.9,
8.7 Hz, 1H, CHCH=CHPh), 4.27-4.14 (m, 4H, OCH2CH3), 2.72 (q, J = 8.7 Hz, 1H,
CH2CHCH=CHPh), 2.31 (s, 3H, tolyl), 1.81 (dd, J = 7.2, 5.1 Hz, 1H, CH2CHCH=CHPh), 1.64 (dd, J
= 7.2, 5.1 Hz, 1H, CH2CHCH=CHPh), 1.28 (t, J = 7.2 Hz, 3H, OCH2CH3), 1.24 (t, J = 7.2 Hz, 3H,
OCH2CH3). 13C NMR (75Mz, CDCl3) δ 169.9, 167.9, 137.7, 134.2, 133.8, 129.5, 126.3, 123.9, 61.9,
61.8, 36.6, 31.6, 21.5, 21.3, 14.5, 14.4. IR ν(cm-1): 2926, 2360, 2333, 1734, 1718, 1559, 1502, 1457,
1374, 1319, 1280, 1250, 1201, 1135, 1026, 964. HRMS (ESI-TOF): m/z 325.1403 [C18H22O4 + Na]+,
calcd. 325.1416.

(E)-Diethyl 2-(2-chlorostyryl)cyclopropane-1,1-dicarboxylate 482

This compound was synthesised in 96% yield according to the general procedure 5 using 328

(150

mg, 0.707 mmol, 1.0 eq), 2-chlorostyrene (0.18 mL, 1.41 mmol, 2.0 eq) and Grubbs catalyst 2nd
generation (30.0 mg, 0.0350 mmol, 5 mol%) in anhydrous dichloromethane (2.7 mL). 1H NMR
(CDCl3, 300 MHz) δ 7.41-7.38 (m, 1H, CHAr), 7.34-7.31(m, 1H, CHAr), 7.20-7.12 (m, 2H, CHAr),
7.03 (d, J = 15.6 Hz, 1H, CHCH=CHAr), 5.82 (dd, J = 15.6, 9.0 Hz, 1H, CHCH=CHAr), 4.29-4.16
(m, 4H, OCH2CH3), 2.79 (q, J = 7.5 Hz, 1H, CH2CHCH=CHAr), 1.83 (dd, J = 7.2, 4.8 Hz, 1H,
CH2CHCH=CHAr), 1.69 (dd, J = 7.2, 4.8 Hz, 1H, CH2CHCH=CHAr), 1.29 (t, J = 7.2 Hz, 3H,
OCH2CH3), 1.24 (t, J = 7.2 Hz, 3H, OCH2CH3).

C NMR (75Mz, CDCl3) δ 169.4, 167.5, 134.8,
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132.7, 129.7, 129.7, 128.5, 127.8, 126.8, 126.5, 61.7, 61.6, 36.4, 31.1, 21.1, 14.2, 14.1. IR ν(cm-1):
1730, 1718, 1653, 1559, 1317, 1274, 1199, 1126, 963, 749. HRMS (ESI-TOF): m/z 345.0886
[C17H19ClO4 + Na]+, calcd. 345.0870.
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(E)-Diethyl 2-(4-methoxystyryl)cyclopropane-1,1-dicarboxylate 483

This compound was synthesised in 66% yield according to the general procedure 5 using 328 (120
mg, 0.565 mmol, 1.0 eq), 4-methoxystyrene (0.15 mL, 1.13 mmol, 2.0 eq) and Grubbs catalyst 2nd
generation (24.0 mg, 0.028 mmol, 5 mol%) in anhydrous dichloromethane (2.1 mL). Note compound
contained 10% of homo-coupled styrene which could not be completely removed following multiple
attempts at chromatography. 1H NMR (CDCl3, 500 MHz) δ 7.23 (d, J = 8.5 Hz, 2H, CHAr), 6.89 (d, J
= 9.0 Hz, 2H, CHAr), 6.58 (d, J = 15.5 Hz, 1H, CHCH=CHAr), 5.68 (dd, J = 16.0, 8.5 Hz, 1H,
CHCH=CHAr), 4.26-4.15 (m, 4H, OCH2CH3), 3.79 (s, 3H, OCH3), 2.71 (q, J = 8.0 Hz, 1H,
CH2CHCH=CHAr), 1.80 (dd, J = 7.5, 4.5 Hz, 1H, CH2CHCH=CHAr), 1.64 (dd, J = 7.5, 4.5 Hz, 1H,
CH2CHCH=CHAr), 1.28 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.22 (t, J = 7.0 Hz, 3H, OCH2CH3).

13

C

NMR (125 MHz, CDCl3) δ 169.7, 167.6, 159.2, 133.1, 129.6, 127.3, 122.4, 114.0, 61.6, 61.5, 55.3,
36.3, 31.4, 21.0, 14.3, 14.1. IR ν(cm-1): 2166, 2022, 1734, 1719, 1654, 1636, 1578, 1512, 1254, 1201,
1176, 1132, 1032, 964. HRMS (ESI-TOF): m/z 341.1378 [C18H22O5 + Na]+, calcd. 341.1365.

(E)-Diethyl 2-(4-bromostyryl)cyclopropane-1,1-dicarboxylate 484

This compound was synthesised in 13% yield according to the general procedure 5 using 328 (111.5
mg, 0.5250 mmol, 1.0 eq), 4-bromostyrene (0.14 mL, 1.1 mmol, 2.0 eq) and Grubbs catalyst 2nd
generation (22.3 mg, 0.0260 mmol, 5 mol%) in anhydrous dichloromethane (2.1 mL). 1H NMR
(CDCl3, 500 MHz) δ 7.40 (d, J = 8.5 Hz, 2H, CHAr), 7.15 (d, J = 8.5 Hz, 2H, CHAr), 6.57 (d, J = 15.5
Hz, 1H, CHCH=CHAr), 5.82 (dd, J = 16.0, 9.0 Hz, 1H, CHCH=CHAr), 4.26-4.15 (m, 4H,
OCH2CH3), 2.71 (q, J = 8.5 Hz, 1H, CH2CHCH=CHAr), 1.81 (dd, J = 6.5, 4.5 Hz, 1H,
CH2CHCH=CHAr), 1.66 (dd, J = 6.5, 4.5 Hz, 1H, CH2CHCH=CHAr), 1.29 (t, J = 7.5 Hz, 3H,
OCH2CH3), 1.22 (t, J = 7.0 Hz, 3H, OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 169.5, 167.5, 135.7,
132.4, 131.7, 127.6, 125.8, 121.3, 61.7, 61.6, 36.3, 31.0, 21.0, 14.2, 14.1. IR ν(cm-1): 2983, 1721,
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1489, 1370, 1318, 1274, 1200, 1131, 1073, 1024, 1009, 964, 813. HRMS (ESI-TOF): m/z 389.0381
[C17H19BrO4 + Na]+, calcd. 389.0364.

Synthesis and Characterisation of Products

General Procedure 6 for the Ring-Opening of 2,2'-Disubstituted Aziridine 98 with
N-Methylindoles

A solution of 2-methyl-2-phenyl-1-tosyl aziridine 98 (3.0 eq) in anhydrous DCE (30 mL) was added
dropwise over 6 h to a solution of N-methylindoles (1.0 eq) in anhydrous DCE (10 mL) in the
presence of PdCl2(MeCN)2 (10 mol%) at 0 oC under a N2 atmosphere. The resultant solution was then
stirred at 0 oC for overnight, diluted with ethyl acetate (20 mL), washed with distilled water (3×20
mL), and organic layer was dried over MgSO4 and evaporated under reduced pressure. The crude
product was then purified with column chromatography (ethyl acetate: hexane=40:60) to give the
product as a clear oil.

4-Methyl-N-(2-(1-methyl-1H-indol-3-yl)-2-phenylpropyl)benzenesulfonamide 118

Following the general procedure 6, using 100 mg, 0.348 mmol of aziridine 98 and 15.4 mg, 0.116
mmol of 114. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v),
clear oil product (45.2 mg, 93% yield) was obtained. IR (KBr): ν = 3337, 2978, 2922, 1647, 1560,
1540, 1473, 1452, 1374, 1317, 1155, 1085, 1045, 879, 663. 1H NMR (500 MHz, CDCl3): δ 7.49 (d, J
= 8.5 Hz, 2H, CHAr), 7.28 (d, J = 8.5 Hz, 1H, CHAr), 7.25-7.14 (m, 8H, CHAr), 7.01 (s, 1H,
C=CHNCH3), 6.76-6.72 (m, 2H, CHAr), 4.03 (m, 1H, CH2NHTs), 3.79 (s, 3H, NCH3), 3.65 (dd. J =
9.0, 11.5 Hz, 1H, CH2NHTs), 3.53 (dd, J = 4.5, 11.5 Hz, 1H, CH2NHTs), 2.39 (s, 3H, tosyl), 1.73 (s,
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3H, PhC(CH3)CH2). 13C NMR (75 MHz, CDCl3): δ 145.7, 143.2, 137.7, 136.1, 129.6, 128.4, 127.8,
126.9, 126.6, 126.5, 125.6, 121.7, 120.7, 118.9, 117.8, 109.4, 51.5, 43.0, 32.9, 27.3, 21.5. HRMS: m/z;
calcd for C25H26N2O2SNa: 441.1613 [M+ Na]+; found: 441.1620.

N-(2-(1-Benzyl-1H-indol-3-yl)-2-phenylpropyl)-4-methylbenzenesulfonamide 119

Following the general procedure 6, using 90.4 mg, 0.315 mmol of aziridine 98 and 22.0 mg, 0.105
mmol of 528. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v),
clear oil product (73.5 mg, 81% yield) was obtained. 8% inseparable compound was also produced.
IR (KBr): ν = 3287, 3061, 2923, 1598, 1543, 1496, 1453, 1402, 1327, 1184, 1160, 1092, 1062, 1029,
965, 909, 814, 729, 699, 665. 1H NMR (500 MHz, CDCl3): δ 7.48 (d, J = 8.5 Hz, 2H, CHAr),
7.35-7.08 (m, 15H, CHAr), 6.76 (d, J = 8.1 Hz, 1H, CHAr), 6.75 (s, 1H, C=CHNBn), 5.32 (d, J = 5 Hz,
2H, NCH2Ph) 4.00 (dd, J = 4.0, 7.5 Hz, 1H, NHTs), 3.66 (dd, J = 8.5, 11.5 Hz, 1H, CH2NHTs), 3.54
(dd, J = 4.0, 11.0 Hz, 1H, CH2NHTs), 2.38 (s, 3H, tosyl), 1.73 (s, 3H, PhC(CH3)CH2). 13C NMR (75
MHz, CDCl3): δ 145.5, 143.2, 137.4, 137.3, 136.1, 129.6, 128.9, 128.5, 127.7, 127.1, 127.0, 126.9,
126.6, 126.6, 125.9, 121.9, 120.9, 119.1, 118.8, 110.0, 51.5, 50.1, 43.1, 27.1, 21.5. HRMS: m/z; calcd
for C31H30N2O2SNa: 517.1926 [M+ Na]+; found: 517.1951.

N-(2-(1-Allyl-1H-indol-3-yl)-2-phenylpropyl)-4-methylbenzenesulfonamide 120

Following the general procedure 6, using 130 mg, 0.452 mmol of aziridine 98 and 23.7 mg, 0.151
mmol of 529. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v),
clear oil product (51.0 mg, 73% yield) was obtained. IR (KBr): ν = 3299, 2360, 1635. 1539, 1466,
1399, 1328, 1186, 1161, 1093, 1061, 812, 739, 699, 663.

H NMR (500 MHz, CDCl3): δ 7.50 (d, J
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= 8.0 Hz, 2H, CHAr), 7.29-7.16 (m, 8H, CHAr), 7.12 (t, J = 7.5 Hz, 1H, CHAr), 7.05 (s, 1H,
C=CHNCH2CH=CH2), 6.78-6.72 (m, 2H, CHAr), 6.06-6.00 (m, 1H, NCH2CH=CH2), 5.25 (d, J = 10.0
Hz, 1H, NCH2CH=CH2), 5.14 (d, J = 17.0 Hz, 1H, NCH2CH=CH2), 4.50 (d, J = 1.5 Hz, 2H,
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NCH2CH=CH2), 4.02 (dd, J = 8.0, 4.0 Hz, 1H, NHTs), 3.66 (dd, J = 11.0, 8.0 Hz, 1H, CH2NHTs),
3.54 (dd, J = 11.0, 4.0 Hz, 1H, CH2NHTs), 2.39 (s, 3H, tosyl), 1.73 (s, 3H, PhC(CH3)CH2). 13C NMR
(75 MHz, CDCl3): δ 145.6, 143.2, 137.2, 136.2, 133.3, 129.6, 128.6, 128.5, 127.0, 126.6, 126.5,
125.9, 121.7, 120.8, 119.0, 118.4, 117.6, 109.8, 51.6, 48.9, 43.1, 27.2, 21.5. HRMS: m/z; calcd for
C27H28N2O2Na: 467.1769 [M+Na]+; found: 467.1788.

N-(2-(5-Bromo-1-methyl-1H-indol-3-yl)-2-phenylpropyl)-4-methylbenzenesulfonamide
121

Following the general procedure 6, using 101 mg, 0.352 mmol of aziridine 98 and 25.0 mg, 0.117
mmol of 522. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v),
clear oil product (53.4 mg, 91% yield) was obtained. IR (KBr): ν = 3289, 2916, 1705, 1653, 1573,
1488, 1420, 1317, 1161, 1093, 1060, 1029, 813, 792, 765, 700, 668. 1H NMR (500 MHz, CDCl3): δ
7.47 (d, J = 8.5 Hz, 2H, CHAr), 7.26-7.12 (m, 9H, CHAr), 7.04 (s, 1H, C=CHNCH3), 6.80 (s, 1H, ,
CHAr), 4.01 (dd, J = 9.0, 4.0 Hz, 1H, NHTs), 3.77 (s, 3H, NCH3), 3.65 (dd, J = 8.5, 11.0 Hz, 1H,
CH2NHTs), 3.41 (dd, J = 4.0, 11.5, 1H, CH2NHTs), 2.41 (s, 3H, tosyl), 1.71 (s, 3H, PhC(CH3)CH2).
C NMR (75 MHz, CDCl3): δ 145.2, 143.4, 136.4, 135.8, 129.7, 129.1, 128.6, 127.2, 126.9, 126.8,
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126.5, 124.7, 122.9, 117.5, 112.4, 111.0, 51.4, 42.9, 33.1, 27.3, 21.6. HRMS: m/z; calcd for
C25H24BrN2O2S: 495.0742 [M-H]-; found: 495.0720.

N-(2-(5-Iodo-1-methyl-1H-indol-3-yl)-2-phenylpropyl)-4-methylbenzenesulfonamide
122

Following the general procedure 6, using 83.0 mg, 0.288 mmol of aziridine 98 and 25.0 mg, 0.0961
mmol of 523. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v),
clear oil product (23.0 mg, 44% yield) was obtained. IR (KBr): ν = 3272, 2973, 1701, 1636, 1542,
1471, 1418, 1330, 1160, 1091, 895, 814, 766, 701, 666. 1H NMR (500 MHz, CDCl3): δ 7.47 (d, J =
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8.0 Hz, 2H, CHAr), 7.39 (d, J = 8.5 Hz, 1H, CHAr), 7.26-7.20 (m, 5H, CHAr), 7.12 (d, J = 7.5 Hz, 2H,
CHAr), 7.06 (d, J = 8.5 Hz, 1H, CHAr), 7.02 (m, 1H, CHAr), 6.99 (s, 1H, C=CHNCH3), 4.91-3.99 (m,
1H, NHTs), 3.77 (s, 3H, NCH3), 3.65 (dd, J = 11.0, 8.5 Hz, 1H, CH2NHTs), 3.41 (dd, J = 11.0, 3.5 Hz,
1H, CH2NHTs), 2.42 (s, 3H, tosyl), 1.71 (s, 3H, PhC(CH3)CH2). 13C NMR (75 MHz, CDCl3): δ 145.1,
143.4, 136.8, 135.8, 130.1, 129.8, 129.1, 128.7, 128.5, 128.0, 126.8, 126.7, 126.4, 117.2, 111.5, 82.7,
51.4, 42.9, 33.0, 27.3, 21.7. HRMS: m/z; calcd for C25H24IN2O2S: 543.0603 [M-H]-; found: 543.0595.

N-(2-(5-Fluoro-1-methyl-1H-indol-3-yl)-2-phenylpropyl)-4-methylbenzenesulfonamide
123

Following the general procedure 6, using 143 mg, 0.496 mmol of aziridine 98 and 25.0 mg, 0.165
mmol of 526. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v),
clear oil product (50.4 mg, 70% yield) was obtained. IR (KBr): ν = 3272, 2984, 1700, 1653, 1496,
1490, 1448, 1416, 1325, 1241, 1161, 1083, 1022, 886, 800, 764, 715, 665. 1H NMR (500 MHz,
CDCl3): δ 7.47 (d, J = 8.0 Hz, 2H, CHAr), 7.23-7.13 (m, 8H, CHAr), 7.07 (s, 1H, C=CHNCH3), 6.87
(dt, J = 8.5, 2.0 Hz, 1H, CHAr), 6.27 (dd, J = 10.0, 2.0 Hz, 1H, CHAr), 4.07-4.05 (m, 1H, NHTs), 3.77
(s, 3H, NCH3), 3.65 (dd, J = 11.0, 8.5 Hz, 1H, CH2NHTs), 3.43 (dd, J = 11.0, 3.5 Hz, 1H, CH2NHTs),
2.39 (s, 3H, tosyl), 1.70 (s, 3H, PhC(CH3)CH2). 13C NMR (75 MHz, CDCl3): δ 157.0 (d, J = 234 Hz)
145.3, 143.5, 135.8, 134.4, 129.6, 129.5, 128.5, 126.9, 126.7, 126.5, 125.7 (d, J = 10 Hz) 117.6 (d, J
= 5 Hz) 110.2 (d, J = 9 Hz) 110.0 (d, J = 7 Hz) 105.5 (d, J = 24 Hz), 51.3, 42.9, 33.2, 27.2, 21.5.
HRMS: m/z; calcd for C25H24FN2O2S: 435.1543 [M-H]-; found: 435.1559.

N-(2-(5-Methoxy-1-methyl-1H-indol-3-yl)-2-phenylpropyl)-4-methylbenzenesulfonamid
e 124

Following the general procedure 6, using 131 mg, 0.457 mmol of aziridine 98 and 25.0 mg, 0.152
mmol of 524. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v),
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clear oil product (58.8 mg, 85% yield) was obtained. IR (KBr): ν = 3263, 2981, 1700, 1653, 1560,
1491, 1424, 1321, 1225, 1162, 1083, 1010, 814, 715, 659. 1H NMR (300 MHz, CDCl3): δ 7.46 (d, J =
8.0 Hz, 2H, CHAr), 7.25-7.13 (m, 8H, CHAr), 6.99 (s, 1H, C=CHNCH3), 6.80 (dd, J = 8.7, 2.4 Hz, 1H,
CHAr), 6.04 (d, J = 2.4 Hz, 1H, CHAr), 4.08-4.05 (m, 1H, NHTs), 3.75 (s, 3H, NCH3), 3.63 (dd, J =
10.8, 8.4 Hz, 1H, CH2NHTs), 3.49 (dd, J = 11.0, 3.6 Hz, 1H, CH2NHTs), 3.42 (s, 3H, OCH3), 2.38 (s,
3H, tosyl), 1.71 (s, 3H, PhC(CH3)CH2). 13C NMR (75 MHz, CDCl3): δ 153.2, 145.7, 143.2, 136.0,
133.1, 129.5, 128.4, 128.3, 126.9, 126.6, 126.5, 125.9, 117.1, 111.7, 110.1, 102.5, 55.3, 51.2, 42.9,
33.0, 27.2, 21.5. HRMS: m/z; calcd for C26H27N2O3S: 447.1718 [M-H]-; found: 447.1723.

N-(2-(1H-Indol-3-yl)-2-phenylpropyl)-4-methylbenzenesulfonamide 125

Following the general procedure 6, using 184 mg, 0.640 mmol of aziridine 98 and 25.0 mg, 0.213
mmol of 1H-indole. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane 40:60
(v/v), clear oil product (48.3 mg, 56% yield) was obtained. IR (KBr): ν = 3415, 2967, 1705, 1654,
1570, 1458, 1410, 1321, 1157, 1090, 1014, 961, 813, 742, 700, 662. 1H NMR (500 MHz, CDCl3): δ
8.21 (broad s, 1H, C=CHNH), 7.48 (d, J = 8.0 Hz, 2H, CHAr), 7.34 (d, J = 8.5 Hz, 1H, CHAr),
7.22-7.16 (m, 9H, CHAr & C=CHNH), 7.10 (t, J = 7.5 Hz, 1H, CHAr), 6.76-6.72 (m, 1H, CHAr),
4.07-4.05 (m, 1H, NHTs), 3.67 (dd, J = 11.5, 8.5 Hz, 1H, CH2NHTs), 3.53 (dd, J = 11.0, 4.0 Hz, 1H,
CH2NHTs), 2.38 (s, 3H, tosyl), 1.73 (s, 3H, PhC(CH3)CH2). 13C NMR (75 MHz, CDCl3): δ 145.5,
143.2, 137.0, 136.1, 129.6, 128.5, 126.9, 126.6, 126.6, 125.2, 123.0, 122.1, 120.6, 119.6, 119.3, 111.4,
51.5, 43.0, 27.1, 21.5. HRMS: m/z; calcd for C24H23N2O2S: 403.1480 [M-H]-; found: 403.1496.

General Procedure 7 for the Ring-Opening of 2-Aryl-N-Tosylaziridines with Indoles
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Aziridine (1.0 eq) was added to the solution of indole (1.5 eq) in the presence of PdCl2(MeCN)2 (0.1
eq) and p-benzoquinone (0.3 eq) at room temperature under the air. The resultant solution was stirred
at room temperature for 21 h, diluted with ethyl acetate (10 mL), washed with distilled water (3×10
mL), and the organic layer was dried over MgSO4 then evaporated under reduced pressure. The crude
product was then purified with column chromatography (ethyl acetate: hexane=40:60) to give the
targeted products

4-Methyl-N-(2-(1-methyl-1H-indol-3-yl)-2-phenylethyl) benzenesulfonamide 126

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oily product (57.2
mg, 77% yield) was obtained. IR (KBr): ν = 3743, 3277, 2364, 1741, 1551, 1482, 1424, 1370, 1317,
1213, 1157, 1095, 1050, 915, 868, 809, 763, 703. 1H NMR (300 MHz, CDCl3): δ 7.65 (d, J = 8.1 Hz,
2H, tosyl CHAr), 7.28-7.15 (m, 10H, , tosyl CHAr & CHAr), 6.98 (t, J = 7.8 Hz, 1H, CHAr), 6.76 (s, 1H,
C=CHNCH3), 4.38 (t, J = 6.0 Hz, 1H, NHTs), 4.30 (t, J = 7.5 Hz, 1H, CCH(Ph)CH2NHTs), 3.71 (s,
3H, NCH3), 3.66-3.50 (m, 2H, CH2NHTs), 2.42 (s, 3H, tosyl). 13C NMR (125 MHz, CDCl3): δ 143.4,
141.1, 137.2, 136.7, 129.7, 128.8, 127.9, 127.2, 127.0, 126.8, 126.7, 122.0, 119.2, 119.2, 113.9, 109.4,
47.5, 42.5, 32.8, 21.6. HRMS: m/z; calcd for C24H24N2O2SNa: 427.1456 [M+Na]+; found: 427.1469.

4-Methyl-N-(2-(1-methyl-1H-indol-3-yl)-2-(p-tolyl)ethyl)benzenesulfonamide 131

Following the general procedure 7, using 100 mg, 0.348 mmol of aziridine 517. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oily product (87.4
mg, 60% yield) was obtained. IR (KBr): ν = 3323, 2949, 2835, 2367, 1650, 1512, 1449, 1410, 1326,
1157, 1094, 1018, 813, 740, 660. 1H NMR (300 MHz, CDCl3): δ 7.65 (d, J = 7.8 Hz, 2H, tosyl CHAr),
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7.28-7.19 (m, 5H, tosyl CHAr & CHAr), 7.05(s, 4H, CHAr), 6.98 (t, J = 7.2 Hz, 1H, CHAr), 6.75 (s, 1H,
C=CHNCH3), 4.38 (t, J = 6.0 Hz, 1H, NHTs), 4.26 (t, J = 7.2 Hz, 1H, CCH(Ar)CH2NHTs), 3.71 (s,
3H, NCH3), 3.63-3.49 (m, 2H, CH2NHTs), 2.43 (s, 3H, tosyl), 2.29 (s, 3H, tolyl).13C NMR (75 MHz,
CDCl3): δ 143.4, 142.3, 138.0, 137.2, 136.8, 136.6, 129.7, 129.4, 127.8, 127.2, 126.7, 121.9, 119.2,
119.1, 114.1, 109.3, 47.5, 42.1, 32.8, 21.6, 21.0. HRMS: m/z; calcd for C25H26N2O2SNa: 441.1613
[M+Na]+; found: 441.1635.

N-(2-(4-Bromophenyl)-2-(1-methyl-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide
132

Following the general procedure 7, using 100 mg, 0.284 mmol of aziridine 518. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear liquid product (86.5
mg, 63% yield) was obtained. IR (KBr): ν = 3276, 2933, 2360, 1636, 1560, 1486, 1424, 1375, 1327,
1158, 1094, 1072, 1010, 813, 738, 661. 1H NMR (300 MHz, CDCl3): δ 7.63 (d, J = 8.4 Hz, 2H, tosyl
CHAr), 7.34 (d, J = 8.1 Hz, 2H, CHAr), 7.29-7.17(m, 4H, tosyl CHAr & CHAr), 7.06-6.96 (m, 4H, tosyl
CHAr & CHAr), 6.78 (s, 1H, C=CHNCH3), 4.55 (t, J = 6.0 Hz, 1H, NHTs), 4.28 (t, J = 7.8 Hz, 1H,
CCH(Ar)CH2NHTs), 3.72 (s, 3H, NCH3), 3.60-3.47 (m, 2H, CH2NHTs), 2.43 (s, 3H, tosyl). 13C NMR
(75 MHz, CDCl3): δ 143.5, 140.4, 137.3, 136.6, 131.7, 129.7, 129.7, 127.1, 126.7, 126.7, 122.1,
120.7, 119.3, 119.1, 113.3, 109.5, 47.3, 42.1, 32.8, 21.6. HRMS: m/z; calcd for C24H23BrN2O2SNa:
505.0561 [M+Na]+; found: 505.0591.

N-(2-(2-Chlorophenyl)-2-(1-methyl-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide
133

Following the general procedure 7, using 100 mg, 0.325 mmol of aziridine 519. Purified by
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chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear liquid product (81.3
mg, 57% yield) was obtained. IR (KBr): ν = 3281, 2958, 2356, 1641, 1599, 1565, 1473, 1424, 1375,
1325, 1155, 1094, 1015, 812, 739, 706, 658. 1H NMR (300 MHz, CDCl3): δ 7.65 (d, J = 8.1 Hz, 2H,
tosyl CHAr), 7.34-7.07 (m, 9H, tosyl CHAr & CHAr), 6.99 (t, J = 7.5 Hz, 1H, CHAr), 6.87 (s, 1H,
C=CHNCH3), 4.84 (t, J = 6.9 Hz, 1H, CCH(Ar)CH2NHTs), 4.57 (t, J = 7.0 Hz, 1H, NHTs), 3.72 (s,
3H, NCH3), 3.57 (app. t, J = 6.6 Hz, 2H, CH2NHTs), 2.42 (s, 3H, tosyl). 13C NMR (125 MHz, CDCl3):
δ 143.4, 138.7, 137.2, 136.6, 133.8, 129.8, 129.7, 129.0, 128.1, 127.2, 127.1, 127.0, 127.0, 122.1,
119.2, 119.1, 112.8, 109.4, 46.2, 38.7, 32.8, 21.5. HRMS: m/z; calcd for C24H23ClN2O2SNa: 461.1066
[M+Na]+; found: 461.1073.

N-(2-(4-Iodophenyl)-2-(1-methyl-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide 134

Following the general procedure 7, using 78.0 mg, 0.195 mmol of aziridine 520. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear liquid product (61.0
mg, 59% yield) was obtained. IR (KBr): ν = 3289, 2936, 1701, 1648, 1484, 1328, 1327, 1325, 1159,
1158, 1157, 1090, 1005, 900, 811, 742, 741, 672. 1H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 8.5 Hz,
2H, tosyl CHAr), 7.53 (d, J = 8.5 Hz, 2H, CHAr), 7.26-7.17 (m, 5H, tosyl CHAr & CHAr), 6.98 (t, J =
7.5 Hz, 1H, CHAr), 6.91 (d, J = 8.5 Hz, 2H, CHAr), 6.77 (s, 1H, C=CHNCH3), 4.55 (t, J = 6.0 Hz, 1H,
NHTs), 4.26 (t, J = 7.5 Hz, 1H, CCH(Ar)CH2NHTs), 3.70 (s. 3H, NCH3), 3.60-3.56 (m, 1H,
CH2NHTs), 3.51-3.47 (m, 1H, CH2NHTs), 2.42 (s, 3H, tosyl). 13C NMR (125 MHz, CDCl3): δ 143.5,
141.0, 137.7, 137.3, 136.7, 130.0, 129.7, 127.1, 126.7, 126.7, 122.1, 119.3, 119.1, 113.3, 109.5, 92.3,
47.2, 42.3, 32.8, 21.6. HRMS: m/z; calcd for C24H23IN2O2SNa: 553.0423 [M+Na]+; found: 553.0402.

173

4-Methyl-N-(2-(1-methyl-1H-indol-3-yl)-2-(naphthalen-2-yl)ethyl)benzenesulfonamide
135

Following the general procedure 7, using 50.0 mg, 0.155 mmol of aziridine 521. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear liquid product (55.0
mg, 78% yield) was obtained. IR (KBr): ν = 3290, 3058, 2935, 2319, 1607, 1470, 1420, 1326, 1156,
1093, 1013, 908, 858, 813, 736, 662. 1H NMR (300 MHz, CDCl3): δ 7.78-7.85 (m, 1H, CHAr), 7.70
(d, J = 8.4 Hz, 2H, tosyl CHAr), 7.63-7.61 (m, 3H, CHAr), 7.47-7.40 (m, 3H, CHAr), 7.30-7.15 (m, 5H,
CHAr & tosyl CHAr), 6.96 (t, J = 7.2 Hz, 1H, CHAr), 6.81 (s, 1H, C=CHNCH3), 4.52-4.46 (m, 2H,
NHTs & CCH(Ar)CH2NHTs), 3.78-3.70 (m, 1H, CH2NHTs), 3.70 (s, 3H, NCH3), 3.66-3.57 (m, 1H,
CH2NHTs), 2.41 (s, 3H, tosyl).

C NMR (75 MHz, CDCl3): δ 143.3, 138.6, 137.3, 136.8, 133.4,

13

132.5, 129.7, 128.5, 127.8, 127.6, 127.1, 126.7, 126.8, 126.4, 126.2, 125.8, 122.0, 119.2, 114.0, 109.4,
47.4, 42.7, 32.8, 21.5. HRMS: m/z; calcd for C28H26N2O2SNa: 477.1613 [M+Na]+; found: 477.1616.

N-(2-(1-Benzyl-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide 136

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), white solid product (52.8
mg, 60% yield) was obtained. m.p. 130-135 oC; IR (KBr): ν = 3290, 3030, 2255, 1599, 1550, 1496,
1453, 1399, 1327, 1157, 1093, 1074, 1017, 908, 814, 730, 699, 662. 1H NMR (300 MHz, CDCl3): δ
7.64 (d, J = 7.8 Hz, 2H, tosyl CHAr), 7.34-7.06 (m, 15H, CHAr & tosyl CHAr), 6.99 (t, J = 7.8 Hz,
1H, CHAr), 6.85 (s, 1H, C=CHNCH3), 5.25 (s, 2H, NCH2Ph), 4.38 (t, J = 5.7 Hz, 1H, NHTs), 4.33 (t,
J = 7.5 Hz, 1H, CCH(Ph)CH2NHTs), 3.70-3.48 (m, 2H, CH2NHTs), 2.42 (s, 3H, tosyl). 13C NMR (75
MHz, CDCl3): δ 143.4, 141.0, 137.3, 136.9, 136.8, 129.7, 128.8, 128.8, 128.0, 127.7, 127.1, 127.0,
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126.6, 126.0, 126.0, 122.2, 119.5, 119.4, 114.7, 109.9, 50.0, 47.5, 42.6, 21.6. HRMS: m/z; calcd for
C30H28N2O2SNa: 503.1769 [M+Na]+; found: 503.1778.

N-(2-(1-Allyl-1H-indol-3-yl)-2-phenylpropyl)-4-methylbenzenesulfonamide 137

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. The reaction was
carried out in DCM. Purified by chromatography on silica gel, eluting with ethyl acetate/hexane
40:60 (v/v), clear oil product (67.9 mg, 86% yield) was obtained. IR (KBr): ν = 3300, 3033, 2926,
1598, 1546, 1494, 1466, 1452, 1405, 1325, 1184, 1156, 1093, 1074, 1016, 990, 909, 813, 735, 731,
699, 663. 1H NMR (300 MHz, CDCl3): δ 7.66 (d, J = 8.4 Hz, 2H, tosyl CHAr), 7.33-7.16 (m, 10H,
CHAr & tosyl CHAr), 6.99 (t, J = 7.2 Hz, 1H, CHAr), 6.82 (s, 1H, C=CHNCH3), 6.01-5.92 (m, 1H,
NCH2CH=CH2), 5.20 (d, J = 10.2 Hz, 1H, NCH2CH=CH2), 5.08 (d, J = 17.1 Hz, 1H, NCH2CH=CH2),
4.66 (d, J = 5.4 Hz, 2H, NCH2CH=CH2), 4.40 (t, J = 6.0 Hz, 1H, NHTs), 4.31 (t, J = 7.8 Hz, 1H,
CCH(Ph)CH2NHTs), 3.70-3.48 (m, 2H, CH2NHTs), 2.44 (s, 3H, tosyl). 13C NMR (75 MHz, CDCl3):
δ 143.4, 141.0, 136.8, 136.7, 133.3, 129.9, 129.7, 128.8, 127.9, 127.1, 127.1, 127.0, 125.6, 122.0,
119.3, 117.5, 114.4, 109.8, 48.8, 47.5, 42.6, 21.6. HRMS: m/z; calcd for C27H28N2O2SNa: 453.1613
[M+Na]+; found: 453.1593.

N-(2-(5-Bromo-1-methyl-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide
138

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oil product (76.1
mg, 86% yield) was obtained. IR (KBr): ν = 3296, 2882, 1598, 1477, 1423, 1324, 1213, 1158, 1093,
1073, 908, 814, 793, 730, 701, 662. 1H NMR (500 MHz, CDCl3): δ 7.66 (d, J = 8.5 Hz, 2H, tosyl
CHAr), 7.30-7.22 (m, 7H, CHAr & tosyl CHAr), 7.16-7.13 (m, 3H, CHAr), 6.83 (s, 1H, C=CHNCH3),
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4.39 (t, J = 6.0 Hz, 1H, NHTs), 4.19 (t, J = 7.0 Hz, 1H, CCH(Ph)CH2NHTs), 3.71 (s, 3H, NCH3),
3.55 (app. q, J = 7.5 Hz, 2H, CH2NHTs), 2.46 (s, 3H, tosyl). 13C NMR (75 MHz, CDCl3): δ 143.6,
140.7, 136.7，135.9, 129.8, 128.9, 128.5, 127.9, 127.8, 127.2, 127.1, 124.9, 121.6, 113.6, 112.6, 110.9,
47.4, 42.2, 33.0, 21.6. HRMS: m/z; calcd for C24H24BrN2O2S : 483.0742 [M+H]+; found: 483.0733.

N-(2-(5-Iodo-1-methyl-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide 139

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oil product (69.9
mg, 72% yield) was obtained. IR (KBr): ν = 3751, 3651, 3275, 2880, 2362, 1650, 1541, 1475, 1422,
1326, 1158, 1093, 909, 813, 792, 732, 665. 1H NMR (500 MHz, CDCl3): δ 7.65 (d, J = 8.0 Hz, 2H,
tosyl CHAr), 7.51 (s, 1H, CHAr), 7.42 (d, J = 8.0 Hz, 1H, CHAr), 7.31-7.28 (m, 2H, CHAr), 7.26 (d, J =
8.0 Hz, 2H, CHAr), 7.23-7.20 (m, 1H, CHAr), 7.14 (d, J = 7.0 Hz, 2H, tosyl CHAr), 7.03 (d, J = 8.5 Hz,
1H, CHAr), 6.77 (s, 1H, C=CHNCH3), 4.42 (t, J = 6.0 Hz, 1H, NHTs), 4.18 (t, J = 7.5 Hz, 1H,
CCH(Ph)CH2NHTs), 3.69 (s, 3H, NCH3), 3.53 (app. q, J = 6.5 Hz, 2H, CH2NHTs), 2.46 (s, 3H, tosyl).
C NMR (75 MHz, CDCl3): δ 143.6, 140.7, 136.7, 136.3, 130.3, 129.9, 129.4, 128.9, 127.9, 127.8,
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127.6, 127.2, 127.1, 113.4, 111.4, 82.8, 47.5, 42.2, 32.9, 21.7. HRMS: m/z; calcd for C24H23IN2O2SNa:
553.0423 [M+Na]+; found: 553.0444.

N-(2-(5-Methoxy-1-methyl-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide
140

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oil product (39.8
mg, 50% yield) was obtained. IR (KBr): ν = 3281, 2938, 1623, 1599, 1491, 1452, 1424, 1326, 1266,
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1212, 1158, 1093, 1065, 1035, 815, 794, 734, 665. 1H NMR (500 MHz, CDCl3): δ 7.65 (d, J = 8.0 Hz,
2H, tosyl CHAr), 7.26 (d, J = 7.5 Hz, 4H, tosyl CHAr), 7.22-7.15 (m, 4H, CHAr), 6.85 (dd, J = 2.5, 8.5
Hz, 1H, CHAr), 6.72 (s, 1H, C=CHNCH3), 6.70 (d, J = 2.0 Hz, 1H, CHAr), 4.40 (t, J = 6.0 Hz, 1H,
NHTs), 4.28 (t, J = 7.5 Hz, 1H, CCH(Ph)CH2NHTs), 3.72 (s, 3H, NCH3), 3.69 (s, 3H, OCH3),
3.64-3.61 (m, 1H, CH2NHTs), 3.54-3.50 (m, 1H, CH2NHTs), 2.43 (s, 3H, tosyl). 13C NMR (75 MHz,
CDCl3): δ 153.8, 143.4, 141.0, 136.7, 132.1, 132.3, 129.7, 128.8, 127.9, 127.3, 127.1, 127.0, 113.3,
112.1, 110.1, 101.0, 55.8, 47.3, 42.6, 32.9, 21.5. HRMS: m/z; calcd for C25H26N2O3SNa: 457.1567
[M+Na]+; found: 457.1562.

N-(2-(7-Iodo-1-methyl-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide 141

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oil product (73.8
mg, 76% yield) was obtained. IR (KBr): ν = 3292, 2919, 1599, 1550, 1482, 1451, 1405, 1324, 1303,
1156, 1089, 1065, 1028, 838, 813, 737, 699, 665. 1H NMR (500 MHz, CDCl3): δ 7.65 (d, J = 8.0 Hz,
2H, tosyl CHAr), 7.62 (d, J = 7.0 Hz, 1H, CHAr), 7.27-7.20 (m, 6H, CHAr & tosyl CHAr), 7.14 (d, J =
7.5 Hz, 2H, CHAr), 6.75 (s, 1H, C=CHNCH3), 6.64 (t, J = 8.0 Hz, 1H, CHAr), 4.42 (t, J = 6.0 Hz, 1H,
NHTs), 4.27 (t, J = 7.5 Hz, 1H, CCH(Ph)CH2NHTs), 4.09 (s, 3H, NCH3), 3.63-3.57 (m, 1H,
CH2NHTs), 3.52-3.46 (m, 1H, CH2NHTs), 2.43 (s, 3H, tosyl). 13C NMR (75 MHz, CDCl3): δ 143.5,
140.6, 136.8, 136.0, 134.4, 129.8, 129.7, 129.3, 128.8, 127.8, 127.2, 127.1, 120.9, 119.3, 113.5, 73.0,
47.4, 42.1, 36.8, 21.6. HRMS: m/z; calcd for C24H23IN2O2SNa: 553.0423 [M+Na]+; found: 553.0433.

N-(2-(5-Fluoro-1-methyl-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide
142
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Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oil product (46.4
mg, 60% yield) was obtained. IR (KBr): ν = 3283, 2933, 1598, 1490, 1452, 1424, 1325, 1158, 1093,
909, 814, 794, 730, 701, 669, 665, 659. 1H NMR (500 MHz, CDCl3): δ 7.65 (d, J = 8.0 Hz, 2H, tosyl
CHAr), 7.29-7.14 (m, 8H, CHAr & tosyl CHAr), 6.92 (dt, J = 2.0, 9.0 Hz, 1H, CHAr), 6.86 (s, 1H,
C=CHNCH3), 6.79 (dd, J = 2.0, 9.5 Hz, 1H, CHAr), 4.36 (t, J = 6.0 Hz, 1H, NHTs), 4.20 (t, J = 7.5 Hz,
1H, CCH(Ph)CH2NHTs), 3.72 (s, 3H, NCH3), 3.58-3.52 (m, 2H, CH2NHTs), 2.44 (s, 3H, tosyl). 13C
NMR (75 MHz, CDCl3): δ 157.5 (d, J = 234 Hz), 143.6, 140.8, 136.6, 133.9, 129.8, 128.8, 128.3,
127.8, 127.1, 127.0, 126.9, 113.7 (d, J = 4.6 Hz), 110.4 (d, J = 26.7 Hz), 110.1 (d, J = 11.5 Hz), 104.1
(d, J = 23 Hz), 47.3, 42.4, 33.1, 21.5. HRMS: m/z; calcd for C24H23FN2O2SNa: 423.1543 [M+Na]+;
found: 423.1525.

N-(2-(7-Formyl-1-methyl-1H-indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide
143

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oil product (34.0
mg, 43% yield) was obtained. 17% inseparable benzoquinone was found by 1H NMR. IR (KBr): ν =
3275, 2876, 1684, 1546, 1461, 1415, 1324, 1243, 1223, 1157, 1094, 1045, 909, 814, 729, 702, 682,
677, 670, 665, 662. 1H NMR (500 MHz, CDCl3): δ 10.2 (s, 1H, O=CH), 7.66 (d, J = 8.5 Hz, 2H,
tosyl CHAr), 7.53 (d, J = 7.5 Hz, 1H, CHAr), 7.28-7.22 (m, 6H, CHAr & tosyl CHAr), 7.15 (d, J = 8.0
Hz, 2H, CHAr), 7.10 (t, J = 7.5 Hz, 1H, CHAr), 6.83 (s, 1H, C=CHNCH3), 4.47 (t, J = 6.0 Hz, 1H,
NHTs), 4.33 (t, J = 8.0 Hz, 1H, CCH(Ph)CH2NHTs), 4.04 (s, 3H, NCH3), 3.63-3.59 (m, 1H,
CH2NHTs), 3.53-3.50 (m, 1H, CH2NHTs), 2.43 (s, 3H, tosyl). 13C NMR (125 MHz, CDCl3): δ 190.9,
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143.6, 140.6, 136.8, 134.3, 130.7, 130.1, 130.1, 129.8, 129.0, 127.9, 127.3, 127.2, 126.2, 123.0, 118.8,
115.3, 47.6, 42.3, 39.1, 21.6. HRMS: m/z; calcd for C25H24N2O3SNa: 455.1405 [M+Na]+; found:
455.1413.

N-(2-(1H-Indol-3-yl)-2-phenylethyl)-4-methylbenzenesulfonamide 144

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oil product (54.3
mg, 76% yield) was obtained. IR (KBr): ν = 3438, 3329, 2360, 2157, 1968, 1653, 1491, 1457, 1402,
1317, 1150, 1093, 1012, 867, 808, 755, 699, 657. 1H NMR (500 MHz, CDCl3): δ 8.06 (broad s, 1H,
indole NH), 7.66 (d, J = 8.0 Hz, 2H, tosyl CHAr), 7.35 (d, J = 7.5 Hz, 1H, CHAr), 7.28-7.25 (m, 5H,
CHAr & tosyl CHAr), 7.22 (d, J = 7.0 Hz, 1H, CHAr), 7.18-7.15 (m, 3H, CHAr), 7.00 (t, J = 8 Hz, 1H,
CHAr), 6.97 (s, 1H, C=CHNCH3), 4.38 (t, J = 6.0 Hz, 1H, NHTs), 4.32 (t, J = 7.5 Hz, 1H,
CCH(Ph)CH2NHTs), 3.69-3.66 (m, 1H, CH2NHTs), 3.56-3.53 (m, 1H, CH2NHTs), 2.44 (s, 3H, tosyl).
C NMR (75 MHz, CDCl3): δ 143.5, 140.9, 136.8, 136.5, 129.7, 128.8, 127.9, 127.1, 127.0, 126.4,
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122.5, 121.9, 119.7, 119.2, 115.6, 111.2, 47.4, 42.6, 21.5. HRMS: m/z; calcd for C23H22N2O2SNa:
413.1300 [M+ Na]+; found: 413.1286.

4-Methyl-N-(2-phenyl-2-(1H-pyrrol-3-yl)ethyl)benzenesulfonamide 145

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), dark oil product (9.35 mg,
15% yield) was obtained. IR (KBr): ν = 3281, 2935, 1696, 1599, 1550, 1491, 1448, 1395, 1324, 1158,
1093, 1023, 812, 700, 658. 1H NMR (300 MHz, CDCl3): δ 7.81 (broad s, 1H, pyrrole NH), 7.62 (d, J
= 8.5 Hz, 2H, tosyl CHAr), 7.24-7.16 (m, 6H, CHAr & tosyl CHAr), 7.02 (d, J = 7.0 Hz, 2H, CHAr),
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6.59 (s, 1H, pyrrole), 6.07 (d, J = 2.5 Hz, 1H, pyrrole), 5.88 (s, 1H, pyrrole), 4.39 (t, J = 6.0 Hz, 1H,
NHTs), 4.04 (t, J = 7.5 Hz, 1H, CCH(Ph)CH2NHTs), 3.45-3.40 (m, 1H, CH2NHTs), 3.37-3.32 (m, 1H,
CH2NHTs), 2.37 (s, 3H, tosyl).

C NMR (75 MHz, CDCl3): δ 142.6, 138.8, 135.7, 129.6, 128.8,
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128.0, 127.0, 126.5, 126.1, 116.7, 107.5, 104.7, 46.4, 43.5, 20.5. HRMS: m/z; calcd for
C19H20N2O2SNa: 363.1143 [M+ Na]+; found: 363.1133.

4-Methyl-N-(2-phenyl-2-(2-phenyl-1H-indol-3-yl)ethyl)benzenesulfonamide 146

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine 26. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 40:60 (v/v), clear oil product (53.8
mg, 63% yield) was obtained. IR (KBr): ν = 3346, 2941, 1599, 1491, 1450, 1399, 1319, 1154, 1093,
1019, 922, 845, 813, 743, 700, 661. 1H NMR (500 MHz, CDCl3): δ 8.31 (broad s, 1H, indole NH),
7.44 (d, J = 8.5 Hz, 2H, tosyl CHAr), 7.40 (d, J = 8.0 Hz, 1H, CHAr), 7.35 (app. s, 6H, CHAr),
7.24-7.18 (m, 6H, CHAr & tosyl CHAr), 7.09 (d, J = 7.5 Hz, 2H, CHAr), 6.93 (t, J = 7.5 Hz, 1H, CHAr),
4.44 (dd, J = 6.0, 11.0 Hz, 1H, NHTs), 4.22 (app. d, J = 8.0 Hz, 1H, CCH(Ph)CH2NHTs), 3.76-3.72
(m, 1H, CH2NHTs), 3.64 (t, J = 11.0 Hz, 1H, CH2NHTs), 2.38 (s, 3H, tosyl). 13C NMR (75 MHz,
CDCl3): δ 143.1, 141.6, 137.7, 136.2, 136.2, 132.1, 129.6, 128.9, 128.7, 128.7, 128.4, 127.7, 127.0,
127.0, 126.7, 122.5, 120.2, 120.0, 111.5, 109.5, 46.7, 42.2, 21.5. HRMS: m/z; calcd for
C23H22N2O2SNa: 489.1613 [M+ Na]+; found: 489.1628.

Synthesis of (R)-126'

Following the general procedure 7, using 50.0 mg, 0.183 mmol of aziridine (R)-26', 36.0 mg, 0.275
mmol of 114 and 5.9 mg, 0.0549 mmol of BQ. Purified by chromatography on silica gel, eluting with
ethyl acetate/hexane 40:60 (v/v), clear oily product (55.5 mg, 75% yield, 98% ee) was obtained. Data
matched 126. [α]19D = -27.4 (c = 0.49 in CHCl3).
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General Procedure 8 for the Cycloaddition of Aziridines to 1,3-Dimethylindole 101

Synthesis

of

(3aR,8bS)

-4,8b-dimethyl-1-phenyl-3-tosyl-1,2,3,3a,4,8b-hexahydro

cyclopenta[b]indole 102

Aziridine 26 (114.7 mg, 0.420 mmol, 3.0 eq) was added to the solution of 1,3-dimethylindole 101
(20.6 mg, 0.140 mmol, 1.0 eq) in chloroform (1.5 ml) in the presence of PdCl2(MeCN)2 (3.60 mg,
0.0140 mmol, 10 mol%) at room temperature under the air. The resultant solution was stired at room
temperature for 21 h, diluted with ethyl acetate (10 mL), washed with distilled water (3×10 mL), and
the organic layer was dried over MgSO4 then evaporated under reduced pressure. The crude product
was then purified with column chromatography (ethyl acetate: hexane=20:80) to give white solid 102
(157 mg, 71%). Trans:cis = 6.5:1.0; m.p. 135-141oC; IR (KBr): ν = 3329, 2957, 1663, 1599, 1488,
1448, 1346, 1291, 1161, 1091, 1022, 892, 814, 753, 700, 668, 665, 613, 612. 1H NMR (300 MHz,
CDCl3): δ = 1H NMR (300 MHz, CDCl3) δ 7.87(d, J = 8.0 Hz, 2H, cis, tosyl CHAr), 7.83(d, J = 8.0
Hz, 2H, trans, tosyl CHAr), 7.39(d, J = 7.5 Hz, 2H, cis, tosyl CHAr), 7.36(d, J = 7.0 Hz, 2H, trans,
tosyl CHAr), 7.26-7.21(m, 6H, trans and cis, CHAr), 7.16(t, J = 8.0 Hz, 1H, cis, CHAr), 7.02(t, J = 8.0
Hz, trans, CHAr), 6.94-6.93 (m, 2H, cis, CHAr), 6.83(d, J = 7.5 Hz, 2H, trans, CHAr), 6.64 (t, J = 7.0
Hz, 1H, trans, CHAr), 6.53(t, J = 5.5 Hz, 2H, trans, CHAr), 6.36(d, J = 8.0 Hz, 1H, ci, CHAr s), 6.28(t,
J = 7.5 Hz, 1H, trans, CHAr), 5.57(d, J = 7.5 Hz, 1H, trans, CHAr), 5.37(s, 1H, trans, CH3NCHNTs),
5.07(s, 1H, cis, CH3NCHNTs), 3.85-3.77(m, 3H, trans and cis, (Ph)CHCH2NTs), 3.62-3.58(m, 1H,
cis, (Ph)CHCH2NTs), 3.41(t, J = 13.0 Hz, 1H, trans, (Ph)CHCH2NTs), 3.05(s, 3H, trans, NCH3),
3.04(s, 3H, cis, NCH3), 2.74-2.70(m, 1H, trans, (Ph)CHCH2NTs), 2.49(s, 3H, trans and cis, tosyl),
1.27 (s, 3H, cis, (CH3)CCH(Ph)CH2NTs), 0.49 (s, 3H, trans, (CH3)CCH(Ph)CH2NTs). 13C NMR (75
MHz, CDCl3): δ 150.8, 143.8, 137.1, 135.7, 132.5, 129.9, 128.8, 128.4, 127.9, 127.5, 127.3, 125.4,
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116.4, 104.9, 91.1, 56.7, 54.9, 51.2, 31.2, 25.9, 21.6.

13

C NMR signals reported for major isomer.

HRMS: m/z; calcd for C25H26N2O2SNa: 441.1613 [M+Na]+; found: 441.1620. Note: The
pyrroloindoline and its derivatives that were discussed in this thesis are numbered according to the
Hantzsch-Widman nomenclature.

Synthesis

of

(3aS,8aS)-3a,8-dimethyl-1-tosyl-3-vinyl-1,2,3,3a,8,8a-hexahydro-

pyrrolo[2,3-b]indole 104

Vinylaziridine 103 (50.0 mg, 0.224 mmol, 1.0 eq) was added to the solution of 1,3-dimethylindole
101 (50.0 μL, 0.336 mmol, 3.0 eq) in chloroform (2.3 ml) in the presence of PdCl2(MeCN)2 (5.8 mg,
0.0224 mmol, 10 mol%) at room temperature under the air. The resultant solution was stired at room
temperature for 21 h, diluted with ethyl acetate (10 ml), washed with distilled water (3×10 mL), and
organic layer was dried over MgSO4 and evaporated under reduced pressure. The crude product was
then purified with column chromatography (ethyl acetate: hexane=20:80) to give white solid 104
(21.0 mg, 17%). Trans:cis = 4.3:1.0 (Purified); m.p. 120-125oC; IR (KBr): ν = 2954, 1701, 1648,
1604, 1491, 1347, 1302, 1241, 1160, 1090, 1001, 904, 867, 813, 745, 742, 729, 668, 662. 1H NMR
(300 MHz, CDCl3): δ 7.72 (d, J = 8.1 Hz, 2H, trans and cis, tosyl CHAr), 7.27 (d, J = 7.8 Hz, 2H,
trans and cis, tosyl CHAr), 7.07-7.00 (m, 1H, trans and cis, CHAr), 6.81-6.76 (m, 1H, trans and cis,
CHAr), 6.59 (t, J = 7.5 Hz, 1H, cis, CHAr), 6.52 (t, J = 7.2 Hz, 1H, trans, CHAr), 6.40 (d, J = 8.1 Hz,
1H, cis, CHAr), 6.31 (d, J = 7.5 Hz, 1H, trans, CHAr), 5.54-5.42 (m, 1H, trans and cis, CH=CH2), 5.18
(s, 1H, trans and cis, CH3NCHNTs), 5.04 (d, J = 11.1 Hz, 1H, trans, CH=CH2), 5.01 (d, J = 9.6 Hz,
1H, cis, CH=CH2), 4.90 (d, J = 16.8 Hz, 1H, trans, CH=CH2), 4.86 (d, J = 16.8, 1H, cis, CH=CH2),
3.58-3.50 (m, 1H, trans and cis, CHCH2NTs), 3.16 (t, J = 9.9 Hz, 1H, cis, CHCH2NTs), 2.92 (s, 3H,
trans, NCH3), 2.91 (s, 3H, cis, NCH3), 2.80 (t, J = 12.0 Hz, 1H, trans, CHCH2NTs), 2.39 (s, 3H, trans
and cis, tosyl), 2.05-2.00 (m, 1H, trans and cis, CHCH2NTs), 1.10 (s, 3H, cis and trans,
(CH3)CHCH2NTs). 13C NMR (75 MHz, CDCl3): δ 150.8, 143.7, 137.0, 134.2, 133.0, 129.8, 127.7,
127.2, 125.1, 118.3, 116.7, 105.3, 90.8, 55.7, 54.6, 52.2, 31.2, 25.2, 21.6. 13C NMR signals reported
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for major isomer. HRMS: m/z; calcd for C21H24N2O2S Na: 369.1637 [M+Na]+; found: 369.1640.

Synthesis of 10627

A mixture of 102 (79 mg, 0.189 mmol, 1.0 eq), magnesium (906 mg, 37.8 mmol, 200 eq) and
ammonium chloride (2.02 g, 37.8 mmol, 200 eq) in anhydrous MeOH (10 mL) was sonicated for 6 h
at 30 oC. The reaction mixture then passed through a short pad of silica gel (1 cm), diluted with ethyl
acetate (30 mL) and washed with distilled water (3x20 mL). The organic phase was dried over
MgSO4 and concentrated in vacuo. The crude product was purified with column chromatography
(straight ethyl acetate) to afford 106 (28 mg, 56%) as a clear oily liquid. 106: 1H NMR (CDCl3, 500
MHz) δ 7.19-7.01 (m, 3H, CHAr), 6.99 (t, J = 7.5 Hz, 1H, Indole CHAr), 6.89-6.87 (m, 2H, CHAr),
6.34 (d, J = 8.0 Hz, 1H, Indole CHAr), 6.25 (t, J = 7.5 Hz, 1H, Indole CHAr), 5.72 (d, J = 7.0 Hz, 1H,
Indole CHAr), 4.70 (s, 1H, CH3NCHNH), 3.25 (dd, J = 10.0, 5.5 Hz, 1H, PhCHCH2NH), 3.18-2.11
(m, 2H, PhCHCH2NH & PhCHCH2NH), 2.90 (s, 3H, CH3N), 2.76 (broad s, 1H, NH). 1.50 (s, 3H,
(CH3)C(C6H5)CHCH2NH), 13C NMR (CDCl3, 125 MHz) δ 151.7, 138.2, 131.1, 129.1, 127.8, 127.7,
126.7, 125.4, 116.1, 104.6, 93.2, 59.4, 56.3, 50.6, 32.4, 27.3. IR ν(cm-1): 2923, 1738, 1604, 1496,
1452, 1386, 1342, 1297, 1216, 1155, 1123, 1051, 1022, 984, 912, 810, 742, 699. HRMS (ESI-TOF):
m/z 265.1714 [C18H20N2 + H]+, calcd. 265.1705.

General Procedure 9 for the Ring-Closure of β-Substituted Tryptamines
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Tryptamine (1.0 eq) was dissolved into acetonitrile in the presence of NaHCO3 (1.5 eq), and the
resulting

mixture

was

stirred

at

room

temperature

for

15

mins

under

the

air.

N-Fluorobenzenesulfonimide (1.2 eq) was then added to the mixture with stirring. After overnight,
the reaction mixture was diluted with ethylacetate (20 mL), washed with distilled water (3×10 mL),
dried over Na2SO4 and concentrated under the reduced pressure. The crude product was then purified
with the column chromatography (ethylacetate:hexane, 15:85) to give targeted compound.

3a-Fluoro-8-methyl-3-phenyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole 160

Following the general procedure 9, using 100 mg, 0.246 mmol of tryptamine 126. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 25:75 (v/v), clear oil product (43.5
mg, 43% yield) was obtained. Note: 8% Inseparable impurities present. IR (KBr): ν = 2922, 1705,
1612, 1493, 1472, 1454, 1431, 1346, 1317, 1306, 1265, 1236, 1159, 1107, 1092, 1020, 1013, 926,
814, 750, 735, 700, 667. 1H NMR (300 MHz, CDCl3): δ 7.85 (d, J = 8.1 Hz, 4H, trans and cis, tosyl
CHAr), 7.38 (d, J = 8.1 Hz, 4H, trans and cis, tosyl CHAr), 7.30-7.14 (m, 9H, trans and cis, CHAr),
7.05-7.03 (m, 2H, cis, , CHAr), 6.92 (d, J = 6.6 Hz, 2H, trans, CHAr), 6.70-6.62 (m, 2H, cis, CHAr),
6.47 (d, J = 8.1 Hz, 1H, trans, CHAr), 6.34 (t, J = 7.8 Hz, 1H, trans, CHAr), 5.85 (d, J = 7.5 Hz, 1H,
trans, CHAr), 5.65 (d, J = 19.8 Hz, 1H, trans, (CH3)NCHNTs), 5.36 (d, J = 23.4 Hz, 1H, cis,
(CH3)NCHNTs), 3.91-3.85 (m, 2H, , trans and cis, (Ph)CHCH2NTs), 3.75 (t, J = 11.7 Hz, 1H, cis,
(Ph)CHCH2NTs), 3.52 (t, J = 12.9 Hz, 1H, trans, (Ph)CHCH2NTs), 3.46-3.38 (m, 1H, cis,
(Ph)CHCH2NTs) 3.10 (s, 3H, cis, NCH3), 3.07 (s, 3H, trans, NCH3), 2.48 (s, 6H, trans and cis, tosyl).
C NMR (75 MHz, CDCl3): δ 152.7, 152.5, 144.3, 144.1, 136.4, 134.1, 134.0, 131.8, 131.8, 131.1,
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130.1, 129.9, 129.6, 128.4, 128.4, 128.3, 128.0, 128.0, 127.9, 127.4, 127.2, 126.8, 120.5, 118.9, 117.3,
117.2, 110.7, 108.9, 108.1, 106.7, 92.4 (J = 24 Hz), 89.1 (J = 30 Hz), 53.3 (J = 30 Hz), 51.7 (J = 25
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Hz), 50.3, 50.2, 33.8, 32.0, 29.7, 21.6. HRMS: m/z; calcd for C21H24N2O2S Na: 445.1362 [M+Na]+;
found: 445.1363.

8-Benzyl-3a-fluoro-3-phenyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole 161

Following the general procedure 9, using 70 mg, 0.338 mmol of tryptamine 136. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 25:75 (v/v), clear oil product (33.7
mg, 20% yield) was obtained. Note: 7% Inseparable impurities present. IR (KBr): ν = 3350, 1697,
1609, 1489, 1470, 1454, 1398, 1346, 1321, 1292, 1184, 1161, 1115, 1092, 1032, 1011, 924, 908, 812,
748, 731, 698, 664; m.p. 118-120oC; 1H NMR (500 MHz, CDCl3): δ 7.75 (d, J = 8.0 Hz, 2H, trans,
tosyl CHAr), 7.68 (d, J = 7.5 Hz, 2H, cis, tosyl CHAr), 7.40 (m, 2H, cis, CHAr), 7.38-7.20 (m, 19H,
trans and cis, tosyl CHAr & CHAr), 7.26 (t, J = 7.5 Hz, 1H, cis, CHAr), 7.14-7.03 (m, 2H, trans, CHAr),
6.92 (d, J = 8.0 Hz, 2H, trans, CHAr), 6.91-6.87 (m, 1H, cis, CHAr), 6.71 (d, J = 7.5 Hz, 1H, cis,
CHAr), 6.65 (t, J = 8.0 Hz, 1H, cis, CHAr), 6.50 (d, J = 8.0 Hz, 1H, cis, CHAr), 6.41 (d, J = 8.0 Hz, 1H,
trans, CHAr), 6.34 (t, J = 7.5 Hz, 1H, trans, CHAr), 5.85 (d, J = 21.0 Hz, 1H, trans, (Bn)NCHNTs),
5.67 (d, J = 23.4 Hz, 1H, cis, (Bn)NCHNTs), 5.07 (d, J = 11.7 Hz, 1H, cis, NCH2Ph), 4.70 (app. q, J
= 12.5 Hz, 2H, trans, NCH2Ph), 4.54 (d, J = 11.7 Hz, 1H, cis, NCH2Ph), 3.96-3.87 (dd, J = 3.0, 6.5
Hz, 2H, trans, (Ph)CHCH2NTs), 3.78 (t, J = 11.5 Hz, 1H, cis, (Ph)CHCH2NTs), 3.61 (t, J = 12.4 Hz,
1H, trans, (Ph)CHCH2NTs), 2.43 (s, 3H, trans, tosyl), 2.42 (s, 3H, cis, tosyl). 13C NMR (75 MHz,
CDCl3): δ 151.9, 151.9, 144.2, 143.5, 138.3, 137.8, 136.2, 134.1, 131.8, 131.8, 131.2, 130.1, 129.9,
129.8, 129.8, 129.7, 129.0, 128.9, 128.6, 128.6, 128.4, 128.4, 128.3, 128.0, 127.4, 127.4, 127.3, 127.3,
127.2, 127.1, 127.0, 126.6, 122.7 (J = 34 Hz), 120.5 (J = 14 Hz), 117.4, 110.3, 108.7, 107.1, 90.1 (J =
13 Hz), 87.7 (J = 18 Hz), 80.2, 64.5, 53.5 (J = 18 Hz), 50.3 (J = 13 Hz), 49.4, 48.6, 22.7, 21.6.
HRMS: m/z; calcd for C21H24N2O2S Na: 521.1675 [M+Na]+; found: 521.1666.

5-Bromo-3a-fluoro-3,8-dimethyl-3-phenyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b
]indole 162
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Following the general procedure 9, using 40 mg, 0.0804 mmol of tryptamine 121. Purified by
chromatography on silica gel, eluting with ethyl acetate/hexane 25:75 (v/v), clear oil product (30.3
mg, 73% yield) was obtained. IR (KBr): ν = 2926, 1603, 1489, 1447, 1422, 1383, 1344, 1265, 1157,
1107, 1090, 1067, 1022, 1011, 974, 941, 891, 866, 835, 812, 754, 735, 700, 664. 1H NMR (500 MHz,
CDCl3): δ 7.83 (d, J = 8.0 Hz, 2H, cis, tosyl CHAr), 7.75 (d, J = 8.5 Hz, 2H, trans, tosyl CHAr), 7.39
(d, J = 8 Hz, 2H, trans, tosyl CHAr), 7.37-7.25 (m, 13H, trans and cis, tosyl CHAr & CHAr), 7.19 (d, J
= 8.5 Hz, 1H, trans, CHAr), 7.04 (s, 1H, cis, CHAr), 6.50 (d, J = 8.5 Hz, 1H, cis, CHAr), 6.26 (d, J =
8.5 Hz, 1H, trans, CHAr), 5.87 (s, 1H, cis, CHAr), 5.53 (d, J = 16.5 Hz, 1H, trans, (CH3)NCHNTs),
5.22 (d, J = 26.5 Hz, 1H, cis, (CH3)NCHNTs), 4.09 (d, J = 9.5 Hz, 1H, cis, Ph(CH3)CCH2NTs), 3.73
(app. q, J = 6 Hz, 2H, trans, Ph(CH3)CCH2NTs), 3.65 (d, J = 9.5 Hz, 1H, cis, Ph(CH3)CCH2NTs),
3.10 (s, 3H, cis, NCH3), 3.00 (s, 3H, trans, NCH3), 2.47 (s, 3H, cis, tosyl), 2.43 (s, 3H, trans, tosyl),
1.54 (s, 3H, trans, Ph(CH3)CCH2NTs), 1.37 (s, 3H, cis, Ph(CH3)CCH2NTs).

13

C NMR (75 MHz,

CDCl3): δ 152.0, 145.2, 144.5, 143.7, 140.1, 138.0, 137.2, 134.3, 134.1, 133.2, 129.9, 129.8, 129.7,
129.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 127.5, 127.3, 127.1, 126.9, 126.8, 126.5, 126.5,
109.8 (J = 121 Hz), 107 (J = 61 Hz), 92.3 (J = 26 Hz), 86.8 (J = 31 Hz), 60.8, 56.4, 50.3 (J = 24 Hz),
34.4 (J = 65 Hz), 29.6, 23.8, 23.7, 23.1, 21.6, 21.5. HRMS: m/z; calcd for C21H24N2O2S Na: 537.0624
[M+Na]+; found: 537.0650.

General Procedure 10 for Boronic Acids Addition to 1-Tosyl-2-Vinyl Aziridine 103

In a typical experiment, Pd(OAc)2 (10 mol%), 1,10-phenanthroline (15 mol%) and AgSbF6 (10 mol%)
were dissolved in DCE (0.14 M). The resulting mixture was ultrasonically treated for 1 min, and then
stirred at room temperature for 1 min. 1-tosyl-2-vinylaziridine 103 (1.0 eq), arylboronic acid (1.5 eq),
KOAc (0.5 eq if needed) were then added. The mixture was then heated at 70 oC for 22 h, and then
diluted with ethyl acetate, passed through a short pad of silica gel, evaporated and finally purified
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with silica gel chromatography (typically 30% ethyl acetate/hexane) to give the allyl sulfonamide.

(E/Z)-4-Methyl-N-(4-phenylbut-2-enyl)benzenesulfonamide 274

Following the general procedure 10, using 30 mg, 0.135 mmol of 1-tosyl-2-vinyl aziridine 103 and
phenylboronic acid with no addition of KOAc yielded the title compound as a clear oil (32 mg, 79%).
H NMR (500 MHz, CDCl3) δ 7.88-7.71 (m, 2H, E and Z isomer, tosyl) 7.31-7.19 (m, 4H, E and Z
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isomer, tosyl & CHAr overlap), 7.24-7.22 (m, 1H, E and Z isomer, CHAr), 7.10-7.06 (m, 2H, E and Z
isomer, CHAr), 5.80-5.65 (m, 1H, E and Z isomer, CH=CHCH2Ph), 5.48-5.35 (m, 1H, E and Z isomer,
CH=CHCH2Ph), 4.48 (s, 1H, E and Z isomer, TsNH), 3.70 (t, J = 7.0 Hz, 2H, Z isomer,
CH2CH=CHCH2Ph), 3.54 (t, J = 7.0 Hz, 2H, E isomer, CH2CH=CHCH2Ph), 3.28 (d, J = 7.0 Hz, 2H,
Z isomer, CH2CH=CHCH2Ph), 3.26 (d, J = 7.0 Hz, 2H, E isomer, CH2CH=CHCH2Ph), 2.43 (s, 3H, E
and Z isomer, tosyl). 13C NMR (125 MHz, CDCl3) δ 143.5, 143.4, 139.7, 139.6, 137.0, 133.5, 132.8,
129.7, 129.7, 128.6, 128.5, 128.2, 127.2, 126.5, 126.3, 125.9, 124.9, 45.2, 40.1, 38.5, 33.4, 21.5. IR
ν(cm-1): 3274, 2920, 1599, 1404, 1325, 1119, 1093. HRMS (ES): m/z 302.1203. [C17H19NO2S + H]+,
calcd. 302.1215.

(E/Z)-4-Methyl-N-(p-methylphenylbut-2-enyl)benezenesulfonamide 281

Following the general procedure 10, using 25 mg, 0.112 mmol of 1-tosyl-2-vinyl aziridine 103 with
tolylboronic acid yielded the title compound as a clear oil (14.2 mg, 40%). 1H NMR (500 MHz,
CDCl3) δ 7.75 (d, J = 8.5 Hz, 2H, Z isomer, tosyl CHAr), 7.73 (d, J = 9.0 Hz, 2H, E isomer, tosyl
CHAr), 7.32-7.28 (m, 2H, E and Z isomer, tosyl CHAr & CHAr), 7.08-7.07 (m, 2H, E and Z isomer,
CHAr), 6.97-6.95 (m, 2H, E and Z isomer, CHAr), 5.73-5.67 (m, 1H, E and Z isomer, CH=CHCH2Ar),
5.44-5.39 (m, 1H, E and Z isomer, CH=CHCH2Ar), 4.28-4.27 (m, 1H, E and Z isomer, TsNH), 3.71 (t,
J = 6.5 Hz, 1H, Z isomer, CH2CH=CHCH2Ar) 3.55 (t, J = 6 Hz, E isomer, CH2CH=CHCH2Ar)
3.27-3.23 (m, 2H, E and Z isomer, CH2CH=CHCH2Ar) 2.43 (s, 3H, E and Z isomer, tosyl) 2.31 (s,
3H, E and Z isomer, tolyl).13C NMR (125 MHz, CDCl3) δ 143.6, 136.6, 135.8, 133.2, 129.8, 129.7,
129.3, 129.2, 128.4, 128.1, 127.2, 127.2, 124.6, 45.2, 40.3, 38.2, 32.6, 22.0, 21.7. IR ν(cm-1): 3239,
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2923, 1663, 1436, 1408, 1327, 1159, 1094. HRMS (ES): m/z 338.1197 [C18H21N1O2S1 + Na]+, calcd.
338.1191.

(E/Z)-4-Methyl-N-(4-ethoxycarbonylphenylbut-2-enyl)benezenesulfonamide 282

Following the general procedure 10, using 25 mg, 0.112 mmol of 1-tosyl-2-vinyl aziridine 103 and
4-(ethoxycarbonyl)phenylboronic acid yielded the title compound as a clear oil (39.3 mg, 94%). 1H
NMR (500 MHz, CDCl3) δ 7.77-7.71 (m, 2H, E and Z isomer, CHAr), 7.32-7.26 (m, 2H, E and Z
isomer, tosyl CHAr), 7.09-7.06 (2H, m, E and Z isomer, tosyl CHAr), 6.99- 6.94 (2H, m, E and Z
isomer, CHAr), 5.80-5.65 (m, 1H, E and Z isomer, CH=CHCH2Ar), 5.48-5.35 (m, 1H, E and Z isomer,
CH=CHCH2Ar), 4.34 (m, 3H, E and Z isomer, OCH2CH3 & TsNH), 3.70 (t, J = 7.0 Hz, 1H, Z isomer,
CH2CH=CHCH2Ar) 3.54 (t, J = 7.0 Hz, E isomer, CH2CH=CHCH2Ar) 3.40 (d, J = 7.0 Hz, Z isomer,
CH2CH=CHCH2Ar) 3.36 (d, J = 7.0 Hz, E isomer, CH2CH=CHCH2Ar ) 2.42 (s, 3H, Z isomer) 2.41
(s, 3H, E isomer) 1.42(t, J = 7.0 Hz, E and Z isomer, OCH2CH3).13C NMR (125 MHz, CDCl3) δ
166.8, 166.7, 145.1, 145.0, 143.8, 143.7, 137.2, 137.1, 132.5, 131.9, 130.1, 130.0, 129.9, 128.8, 128.7,
128.4, 127.4, 127.4, 127.0, 126.0, 61.1, 45.3, 40.3, 38.6, 33.6, 21.8, 21.7, 14.6. IR ν(cm-1): 3142,
2976, 2921, 2903, 1700, 1609, 1442, 1179, 1107. HRMS (ES): m/z 396.1237 [C20S1O4N1H23 + Na]+,
calcd. 396.1245.

(E/Z)-4-Methyl-N-(4-chlorophenylbut-2-enyl)benezenesulfonamide 283

Following the general procedure 10, using 25 mg, 0.112 mmol of 1-tosyl-2-vinyl aziridine 103 and
4-chlorophenylboronic acid yielded the title compound as a clear oil (21.4 mg, 57%). 1H NMR (500
MHz, CDCl3) δ 7.78 (d, J = 8.5 Hz, 2H, Z isomer, tosyl CHAr), 7.76 (d, J = 9.0 Hz, 2H, E isomer,
tosyl CHAr), 7.33 (app. d, J = 8.5 Hz, 2H, E and Z isomer, tosyl CHAr), 7.30-7.24 (m, 2H, E and Z
isomer, CHAr), 7.04 (app. d, J = 8.5 Hz, 2H, E and Z isomer, CHAr), 5.74- 5.61 (m, 1H, E and Z
isomer, CH=CHCH2Ar), 5.48-5.35 (m, 1H, E and Z isomer, CH=CHCH2Ar), 4.35-4.34 (m, 1H, E
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and Z isomer, TsNH), 3.72 (t, J = 7.0 Hz, 1H, Z isomer, CH2CH=CHCH2Ar), 3.60 (t, J = 7.0Hz, 1H,
E isomer, CH2CH=CHCH2Ar), 3.32 (d, J = 7.5 Hz, 2H, Z isomer, CH2CH=CHCH2Ar), 3.28 (d, J =
7.0 Hz, 2H, E isomer, CH2CH=CHCH2Ar), 2.42 (s, 3H, E and Z isomer, tosyl). 13C NMR (125 MHz,
CDCl3) δ 143.6, 138.0, 137.9, 132.8, 132.2, 132.1, 129.9, 129.8, 129.7, 129.6, 128.7, 128.6, 127.2,
127.2, 126.4, 125.4, 45.1, 40.1, 37.8, 32.8, 21.6. IR ν(cm-1): 3263, 2971, 2923, 1598, 1490, 1404,
1326, 1185, 1093. HRMS (ES): m/z 358.0637 [C17S1O2N1Cl1H18 + Na]+, calcd. 358.0644.

(E/Z)-4-Methyl-N-(3-nitrophenylbut-2-enyl)benezenesulfonamide 284

Following the general procedure 10, using 25 mg, 0.112 mmol of 1-tosyl-2-vinyl aziridine 103 and
4-nitrophenylboronic acid yielded the title compound as a green oil (34.9 mg, 90%). 1H NMR (500
MHz, CDCl3) δ 8.10-8.08 (m, 1H, E and Z isomer, CHAr), 7.98 (app. s, 1H, E and Z isomer, CHAr),
7.81-7.76 (m, 2H, E and Z isomer, tosyl CHAr), 7.48-7.47 (2H, m, E and Z isomer, CHAr), 7.35-7.32
(m, 2H, E and Z isomer, tosyl CHAr), 5.77-5.63 (m, 1H, E and Z isomer, CH=CHCH2Ar), 5.58-5.55
(m, 1H, Z isomer, CH=CHCH2Ar), 5.54-5.47 (m, 1H, E isomer, CH=CHCH2Ar), 4.72 (br. t, J = 5.0
Hz, Z isomer, TsNH), 4.67 (br. t, J = 6.0 Hz, E isomer, TsNH), 3.75 (t, J = 6.5 Hz, 1H, Z isomer,
CH2CH=CHCH2Ar), 3.62 (t, J = 6.5 Hz, E isomer, CH2CH=CHCH2Ar), 3.49 (d, J = 8.0 Hz, 1H, Z
isomer, CH2CH=CHCH2Ar), 3.42 (d, J = 6.5 Hz, 2H, E isomer, CH2CH=CHCH2Ar), 2.46 (s, 3H, E
and Z isomer, tosyl). 13C NMR (125 MHz, CDCl3) δ 148.6, 144.0, 143.9, 141.9, 141.8, 137.2, 137.0,
135.0, 134.8, 131.6, 131.0, 130.4 130.0, 129.9, 129.7, 129.6, 127.9, 127.4, 127.3, 126.8, 123.6, 123.3,
121.7, 45.2, 40.3, 38.2, 33.2, 21.8. IR ν(cm-1): 3410, 2921, 1591, 1383, 1044. HRMS (ES): m/z
347.1059 [C17S1O4N2H18 + H]+, calcd. 347.1066.

(E/Z)-4-Methyl-N-(4-fluorophenylbut-2-enyl)benezenesulfonamide 285

Following the general procedure 10, using 25 mg, 0.112 mmol of 1-tosyl-2-vinyl aziridine 103 and
189

4-fluorophenylboronic acid yielded the title compound as a clear oil (26.8 mg, 75%). 1H NMR (500
MHz, CDCl3) δ 7.79 (d, J = 8.5 Hz, 2H, Z isomer, tosyl CHAr), 7.77 (d, J = 8.0 Hz, 2H, E isomer,
tosyl CHAr), 7.32 (d, J = 8 Hz, 2H, Z isomer, tosyl CHAr), 7.28 (d, J = 8.5 Hz, 2H, E isomer, tosyl
CHAr) 7.08-7.06 (m, 2H, E and Z isomer, CHAr), 7.00-6.97 (m, 2H, E and Z isomer, CHAr), 5.80-5.65
(m, 1H, E and Z isomer, CH=CHCH2Ar), 5.50-5.38 (m, 1H, E and Z isomer, CH=CHCH2Ar),
4.42-4.38 (m, 1H, E and Z isomer, TsNH), 3.73 (t, J = 6.9 Hz, 1H, Z isomer, CH2CH=CHCH2Ar),
3.60 (t, J = 6.2 Hz, 1H, E isomer, CH2CH=CHCH2Ar), 3.32 (d, J = 7.5 Hz, 2H, Z isomer,
CH2CH=CHCH2Ar), 3.29 (d, J = 7.0 Hz, Z isomer, CH2CH=CHCH2Ar), 2.43 (s, 3H, E and Z isomer,
tosyl). 13C NMR (125 MHz, CDCl3) δ 161.7 (d, J = 244 Hz), 161.7 (d, J = 242 Hz), 143.8, 143.7,
137.3, 137.1, 135.5 (d, J = 2.8 Hz), 135.3 (d, J = 2.8 Hz), 133.4, 132.7, 130.1 (d, J = 8.4 Hz), 130.0,
129.9 (d, J = 9.0 Hz), 129.8, 127.4, 127.4, 126.3, 125.3, 115.5 (d, J = 20.5 Hz), 115.4 (d, J = 21.4 Hz),
45.3, 40.3, 37.8, 32.8, 21.8. IR ν(cm-1): 3421, 2971, 1655, 1378, 1089, 1047, 881. HRMS (ES): m/z
358.0694 [C17SO2NClH18 + K]+, calcd. 358.0679.

(E/Z)-4-Methyl-N-(4-(1-(phenylsulfonyl)-1H-indol-3-yl)but-2-en-1-yl)benzenesulfonami
de 286

Following the general procedure 10, using 25 mg, 0.112 mmol of 1-tosyl-2-vinylaziridine 103 and
4-nitrophenylboronic acid yielded the title compound as a green oil (20.4 mg, 38%). 1H NMR (500
MHz, CDCl3) δ 7.97 (d, J = 8.0 Hz, 1H, E and Z isomer, CHAr) 7.85 (d, J = 8.0 Hz, 2H, E and Z
isomer, CHAr) 7.73-7.70 (m, 2H, E and Z isomer, CHAr), 7.52-7.50 (m, 1H, E and Z isomer, CHAr),
7.43-7.40 (m, 3H, E and Z isomer, CHAr), 7.37-7.36 (m, 1H, E and Z isomer, CHAr), 7.33-7.21 (m, 4H,
E and Z isomer, CHAr & C=CHN), 5.82-5.76 (m, 1H, E and Z isomer, TsHNCH2CH=CH), 5.56-5.51
(m, 1H, E and Z isomer, TsHNCH2CH=CH), 4.34-4.33 (m, 1H, E and Z isomer, TsNH), 3.74 (t, J =
6.5 Hz, 1H, Z isomer, TsHNCH2CH=CH), 3.59 (t, J = 6.0 Hz, 1H, E isomer, TsHNCH2CH=CH),
3.36-3.34 (m, 2H, E and Z isomer, TsHNCH2CH=CHCH2), 2.45 (s, 3H, E isomer, tosyl), 2.44 (s, 3H,
Z isomer, tosyl).
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C NMR (125 MHz, CDCl3) δ 143.8, 143.8, 138.4, 137.2, 137.0, 135.6, 134.0,

131.2, 130.8, 130.7, 130.6, 130.0, 129.9, 129.5, 129.5, 127.4, 127.0, 126.9, 126.4, 125.2, 125.1, 123.4,
123.4, 123.1, 121.3, 121.1, 119.8, 119.6, 114.0, 45.3, 40.3, 28.0, 23.3, 21.7. IR ν(cm-1): 3315, 2973,
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2875, 1627, 1455, 1379, 1088, 1045, 881. HRMS (ES): m/z 503.1230 [C25S2O4N2H24 + Na]+, calcd.
503.1075.

(E/Z)-4-Methyl-N-(3-methoxyphenylbut-2-enyl)benezenesulfonamide 287

Following the general procedure 10, using 25 mg, 0.112 mmol of 1-tosyl-2-vinylaziridine 103 and
4-methoxyphenylboronic acid yielded the title compound as a clear oil (15.6 mg, 42%). 1H NMR
(500 MHz, CDCl3) δ 7.75 (d, J = 8.5 Hz, 2H, E and Z isomer, tosyl CHAr), 7.30 (d, J = 8.5 Hz, 2H, E
and Z isomer, tosyl CHAr), 7.19 (t, J = 8 Hz, 1H, E and Z isomer, CHAr), 6.75-6.73 (dd, J = 8.5, 2.0
Hz, 1H, E and Z isomer, CHAr), 6.67 (d, J = 7.5 Hz, E and Z isomer, CHAr) 6.64 (s, 1H, E and Z
isomer, CHAr) 5.77-5.72 (m, 1H, E and Z isomer, CH=CHCH2Ar), 5.50-5.45 (m, 1H, E and Z isomer,
CH=CHCH2Ar), 4.39 (br s, 1H, E and Z isomer, TsNH), 3.83 (s, 3H, E isomer, OCH3), 3.82 (s, 3H, Z
isomer, OCH3), 3.74 (t, J = 7.0 Hz, 1H, Z isomer, CH2CH=CHCH2Ar), 3.59 (t, J = 7.0 Hz, 1H, E
isomer, CH2CH=CHCH2Ar), 3.26 (d, J = 7.0 Hz, 2H, Z isomer, CH2CH=CHCH2Ar) 3.27 (d, J = 7.0
Hz, 2H, E isomer, CH2CH=CHCH2Ar), 2.46 (s, 3H, E and Z isomer, tosyl). 13C NMR (125 MHz,
CDCl3) δ 160.2, 160.0, 143.6, 143.4, 141.4, 137.2, 137.1, 130.0, 129.9, 129.8, 129.6, 127.4, 127.3,
126.2, 125,2, 121.1, 120.8, 114.5, 114.2, 111.9, 55.4, 45.2, 40.1, 38.5, 33.4, 21.5. IR ν(cm-1): 3257,
2919, 1600, 1490, 1454, 1325, 1259, 1159, 1094, 1045. HRMS (ES): m/z 354.1131 [C18SO3N1H21 +
Na]+, calcd. 354.1140.

(E/Z)-4-Methyl-N-(3.4-dimethoxyphenylbut-2-enyl)benezenesulfonamide 288

Following the general procedure 10, using 25 mg, 0.112 mmol of 1-tosyl-2-vinyl aziridine 103 and
3,4-dimethoxyphenylboronic acid yielded the title compound as a clear oil (10.1 mg, 25%). 1H NMR
(500 MHz, CDCl3) δ 7.78-7.72 (m, 2H, E and Z isomer, tosyl CHAr), 7.31-7.28 (m, 2H, E and Z
isomer, tosyl CHAr), 6.78 (d, J = 8 Hz, 1H, E and Z isomer, CHAr), 6.64- 6.62 (m, 2H, E and Z isomer,
CHAr), 5.73-5.68 (m, 1H, E and Z isomer, CH=CHCH2Ar), 5.45-5.40 (m, 1H, E and Z isomer,
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CH=CHCH2Ar), 4.36 (t, J = 5.5 Hz, 1H, E and Z isomer, TsNH), 3.85 (s, 6H, E and Z isomer, OCH3),
3.71 (t, J = 6.5 Hz, 2H, Z isomer, CH2CH=CHCH2Ar), 3.56 (t, J = 5.5 Hz, 1H, E isomer,
CH2CH=CHCH2Ar), 3.27 (d, J = 7.0 Hz, 2H, Z isomer, CH2CH=CHCH2Ar), 3.23 (d, J = 6.5 Hz, E
isomer, CH2CH=CHCH2Ar), 2.43 (s, 3H, E and Z isomer, tosyl).13C NMR (125 MHz, CDCl3) δ
149.4, 149.3, 147.7, 143.8, 143.7, 137.1, 137.0, 134.0, 133.2, 132.6, 132.2, 130.0, 129.9, 127.4, 127.3,
125.8, 124.9, 120.6, 120.1, 111.9, 111.8, 111.5, 111.4, 56.2, 56.1, 45.5, 40.3, 38.4, 33.0, 21.6. IR
ν(cm-1): 3243, 2919, 1616, 1515, 1328, 1139. HRMS (ES): m/z 384.1238 [C19H23NSO4 + Na]+, calcd.
384.1245.

Synthesis of 2-((4-phenylbut-2-en-1-yl)amino)isoindoline-1,3-dione 296

Pd(OAc)2 (7.30 mg, 0.0327 mmol, 10 mol%), 1,10-phenanthroline (8.80 mg, 0.0490 mmol, 15
mol%), AgSbF6 (10.9 mg, 0.0327 mmol, 10 mol%) were dissolved in anhydrous dichloroethane (2.8
mL). The resulting mixture was stirred for 30mins at room temperature. 2-(2-vinylaziridin-1-yl)
isoindoline-1,3-dione (70 mg, 0.327 mmol, 1.0 eq), phenylboronic acid (59.8 mg, 0.490 mmol, 1.5 eq)
and potassium acetate (11.1 mg, 0.117 mmol, 0.5 eq) were subsequently added. The mixture was then
stirred at room temperature for 17hrs, and then diluted with ethyl acetate, passed through a short pad
of silica gel (1 cm), evaporated and finally purified with silica gel chromatography (30% ethyl
acetate/n-pentane) to give the yellow solids (67.2 mg, 70%). 1H NMR (500Mz, CDCl3) δ 7.83-7.81
(m, 2H, CHAr), 7.73-7.72 (m, 2H, CHAr), 7.16-7.13 (m, 2H, CHAr), 7.10-7.08 (m, 1H, CHAr),
7.05-7.01 (m, 2H, CHAr), 5.83-5.78 (m, 1H, PhCH2CH=CH), 5.74-5.68 (m, 1H, PhCH2CH=CH) 3.86
(d, J = 6.0 Hz, 2H, NHCH2CH=CH, cis), 3.66 (d, J = 5.5 Hz, 2H, NHCH2CH=CH, trans), 3.38 (d, J
= 7.5 Hz, 2H, PhCH2CH=CH, cis), 3.30 (d, J = 6.5 Hz, 2H, PhCH2CH=CH, trans). 2.70 (broad s, 1H,
NHCH2CH=CH). 13C NMR (125 MHz, CDCl3) δ 166.7, 166.7, 140.0, 139.7, 135.3, 135.1, 134.2,
133.7, 131.1, 130.2, 128.4, 128.4, 128.2, 128.0, 126.0, 126.0, 124.9, 124.5, 123.6, 123.5, 123.4, 53.2,
47.8, 38.8, 33.4. IR ν(cm-1): 2989, 2362, 1773, 1717, 1560, 1507, 1457, 1376, 1192, 1127, 1084, 883,
712. HRMS (ES): m/z 315.1109 [C18H16N2O2+Na]+, calcd. 315.1101.
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Synthesis of N-(2-hydroxybut-3-en-1-yl)-4-methylbenzenesulfonamide 301

To a mixture of PdCl2 (0.400mg, 0.0023mmol, 1 mol%), 1,10-phenanthroline (0.80g, 0.0045mmol, 2
mol%) in DMSO/H2O (2ml, 1:1, v/v) added vinylaziridine 103 (50mg, 0.224mmol, 1.0 eq). The
resulting reaction mixture was then stirred at ambient temperature in the air for overnight, diluted
with ethyl acetate (30 mL) and washed it with water (3×10 mL).The organic layer was then dried
over Na2SO4, filtrated and concentrated under reduced pressure to give clear oily liquid (47.6mg,
88%). Note Data matched that reported previous.11 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8 Hz,
2H, tosyl CHAr), 7.51 (d, J = 8.0 Hz, 2H, tosyl CHAr), 5.79-5.72 (m, 1H, (OH)CHCHCH2), 5.29 (d, J
= 17.0 Hz, 1H, (OH)CHCHCH2), 5.17 (d, J = 10.5 Hz, 1H, (OH)CHCHCH2), 5.15 (s, 1H, NHTs),
4.22 (app. s, 1H, (OH)CHCHCH2), 3.14-3.09 (m, 1H, CH2CH(OH)), 2.89-2.83 (m, 1H, ,
CH2CH(OH)), 2.83 (s, 1H, OH), 2.42 (s, 1H, tosyl). 13C NMR (CDCl3, 75 Hz) δ 143.5, 136.8, 136.4,
129.6, 126.9, 117.0, 71.1, 48.0, 21.4.

General Procedure 11 for Palladium-Catalysed Coupling of Vinylcyclopropanes with
Boronic Acids in Water

To a 10 mL Schlenck flask equipped with a stir bar, was added Pd(OAc) 2 (1 mol%), the
vinylcyclopropane (1.0 eq), arylboronic acid (1.5 eq) and H2O (0.25 M wrt to the vinylcyclopropane).
The mixture was stirred at room temperature and after 8 h, it was extracted with ethyl acetate (3x10
mL). The combined organic layers were dried over MgSO4, filtered, and evaporated to dryness under
reduced pressure. The residue was purified by flash column chromatography (typically ethyl acetate:
Hexane, 20:80) or straight dichloromethane to furnish the corresponding coupling products. Data for
major isomer only reported.

(E)-Diethyl 2-(4-phenylbut-2-en-1-yl)malonate 452
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147.0 mg 452 was prepared in 84% yield via the general procedure 11 from 328 (127.7 mg, 0.2230
mmol, 1.0 eq), phenylboronic acid (110.2 mg, 0.3350 mmol, 1.5 eq) and palladium acetate (1.35 mg,
0.00223 mmol, 1 mol%); 1H NMR (300 MHz, CDCl3) δ 7.30-7.25 (m, 2H, CHAr), 7.20-7.13 (m, 3H,
CHAr), 5.74-5.65 (m, 1H, CH=CHCH2Ph), 5.53-5.43 (m, 1H, CH=CHCH2Ph), 4.19-4.13 (m, 4H,
OCH2CH3), 3.40 (t, J = 7.5 Hz, 1H, CH(CO2Et)2), 3.32 (d, J = 6.9 Hz, 2H, CH=CHCH2Ph), 2.62 (t, J
= 7.2 Hz, 2H, CHCH2CH=CHCH2Ph), 1.24 (t, J = 7.2 Hz, 6H, OCH2CH3).
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C NMR (75 MHz,

CDCl3) δ 169.0, 140.3, 132.4, 128.5, 128.4, 127.0, 126.0, 61.4, 52.2, 39.0, 31.8, 14.1. IR ν(cm-1):
1729, 1516, 1262, 1233, 1152, 1140, 1026. HRMS (ESI-TOF): m/z 313.1428 [C17H22O4 + Na]+, calcd.
313.1416.

(E)-Diethyl 2-(4-(3-nitrophenyl)but-2-en-1-yl)malonate 468

120 mg 468 was prepared in 95% yield via the general procedure 11 from 328 (80.0 mg, 0.377 mmol,
1.0 eq), 3-nitrophenylboronic acid (94.5 mg, 0.566 mmol, 1.5 eq) and palladium acetate (0.85 mg,
0.0038 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 8.06 (d, J = 7.5 Hz, 1H, CHAr), 8.01 (s, 1H,
CHAr), 7.50-7.44 (m, 2H, CHAr), 5.72-5.66 (m, 1H, CH=CHCH2Ar), 5.59-5.53 (m, 1H,
CH=CHCH2Ar), 4.23-4.14 (m, 4H, OCH2CH3), 3.43 (d, J = 6.5 Hz, 2H, CH=CHCH2Ar), 3.42 (t, J =
8.0 Hz, 1H, CH(CO2Et)2), 2.65 (t, J = 6.5 Hz, 2H, CHCH2CH=CHCH2Ar), 1.25 (t, J = 7.5 Hz, 6H,
OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 168.8, 148.3, 142.3, 134.8, 130.6, 129.2, 128.6, 123.3,
121.3, 61.4, 51.9, 38.4, 31.6, 14.0. IR ν(cm-1): 1734, 1730, 1528, 1351, 1153, 1031, 971, 733. HRMS
(ESI-TOF): m/z 358.1271 [C17H21NO6 + Na]+, calcd. 358.1267.

(E)-Diethyl 2-(4-(4-fluorophenyl)but-2-en-1-yl)malonate 470
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100 mg of 470 was prepared in 86% yield via the general procedure 11 from 328 (80.0 mg, 0.377
mmol, 1.0 eq), 4-fluorophenylboronic acid (79.2 mg, 0.566 mmol, 1.5 eq) and palladium acetate
(0.85 mg, 0.0038 mmol, 1 mol%); 1H NMR (300 MHz, CDCl3) δ 7.11-7.07 (m, 2H, CHAr), 6.95 (t, J
= 8.7 Hz, 2H, CHAr), 5.71-5.61 (m, 1H, CH=CHCH2Ar), 5.51-5.42 (m, 1H, CH=CHCH2Ar), 4.17 (q,
J = 7.2 Hz, 4H, OCH2CH3), 3.40 (t, J = 7.2 Hz, 1H, CH(CO2Et)2), 3.28 (d. J = 6.0 Hz, 2H,
CH=CHCH2Ar), 2.62 (t, J = 6.9 Hz, 2H, CHCH2CH=CHCH2Ar), 1.24 (t, J = 6.9 Hz, 6H, OCH2CH3).
C NMR (125 MHz, CDCl3) δ 169.0, 161.4 (d, J = 242.2 Hz), 135.9 (d, J = 2.9 Hz), 132.2, 129.8 (d,
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J = 7.6 Hz), 127.1, 115.1 (d, J = 21 Hz), 61.4, 52.1, 38.1, 31.7, 14.1. IR ν(cm-1): 1749, 1734, 1507,
1369, 1221, 1156, 1032, 971, 734. HRMS (ESI-TOF): m/z 331.1315 [C17H21FO4 + Na]+, calcd.
331.1322.

(E)-Diethyl 2-(4-(4-chlorophenyl)but-2-en-1-yl)malonate 472

118 mg of 472 was prepared in 96% yield via the general procedure 11 from 328 (80.0 mg, 0.377
mmol, 1.0 eq), 4-chlorophenylboronic acid (88.5 mg, 0.566 mmol, 1.5 eq) and palladium acetate
(0.85 mg, 0.0038 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 7.23 (d, J = 8.4 Hz, 2H, CHAr),
7.07 (d, J = 7.5 Hz, 2H, CHAr), 5.67-5.60 (m, 1H, CH=CHCH2Ar), 5.52-5.45 (m, 1H,
CH=CHCH2Ar), 4.17 (q, J = 7.2 Hz, 4H, OCH2CH3), 3.40 (t, J = 7.5 Hz, 1H, CH(CO2Et)2), 3.27 (d,
J = 6.3 Hz, 2H, CH=CHCH2Ar), 2.62 (t, J = 7.2 Hz, 2H, CHCH2CH=CHCH2Ar), 1.24 (t, J = 6.9 Hz,
6H, OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 168.9, 138.7, 131.8, 129.8, 128.8, 128.4,127.4, 61.4,
52.0, 38.2, 31.7, 14.1. IR ν(cm-1): 1744, 1729, 1491, 1370, 1266, 1231, 1176, 1154, 1091, 1029, 1015,
970, 855, 810, 735, 703. HRMS (ESI-TOF): m/z 347.1017 [C17H21ClO4 + Na]+, calcd. 347.1026.

(E)- Diethyl 2-(4-(2-chlorophenyl)but-2-en-1-yl)malonate 476

79.8 mg of 476 was prepared in 65% yield (some starting material was inseparable) via the general
procedure 11 from 328 (80.0 mg, 0.377 mmol, 1.0 eq), 2-chlorophenylboronic acid (88.5 mg, 0.566
mmol, 1.5 eq) and palladium acetate (0.85 mg, 0.0038 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3)
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δ 7.17 (d, J = 9.0 Hz, 1H, CHAr), 7.26-7.10 (m, 3H, CHAr), 5.73-5.63 (m, 1H, CH=CHCH2Ar),
5.51-5.42 (m, 1H, CH=CHCH2Ar), 4.15 (q, J = 6.9 Hz, 4H, OCH2CH3), 3.42 (d, J = 6.6 Hz, 2H,
CH=CHCH2Ar), 3.39 (t, J = 7.8 Hz, 2H, CH(CO2Et)2), 2.61 (t, J = 7.8 Hz, 2H,
CHCH2CH=CHCH2Ar), 1.23 (t, J = 6.9 Hz, 6H, OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 169.0,
138.0, 130.4, 130.3, 129.4, 127.7, 127.5, 126.8, 61.4, 52.1, 36.4, 31.8, 14.1. IR ν(cm-1): 1749, 1734,
1369, 1266, 1151, 1034, 736. HRMS (ESI-TOF): m/z 347.1031 [C17H21ClO4 + Na]+, calcd. 347.1026.

(E)- Diethyl 2-(4-(naphthalen-1-yl)but-2-en-1-yl)malonate 478

79.8 mg of 478 was prepared in 36% yield via the general procedure 11 from 328 (80.0 mg, 0.377
mmol, 1.0 eq), 1-naphthalenephenylboronic acid (97.4 mg, 0.566 mmol, 1.5 eq) and palladium
acetate (0.85 mg, 0.0038 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.0 Hz, 1H,
naph.), 7.84 (d, J = 7.5 Hz, 1H, naph.), 7.72 (d, J = 8.0 Hz, 1H, naph.), 7.51-7.45 (m, 2H, naph.),
7.41 (t, J = 7.0 Hz, 1H, naph.), 7.29 (d, J = 7.0 Hz, 1H, naph.), 5.85-5.81 (m, 1H, CH=CHCH2 naph.),
5.54-5.49 (m, 1H, CH=CHCH2 naph.), 4.18-4.07 (m, 4H, OCH2CH3), 3.77 (d, J = 6.0 Hz, 2H,
CH=CHCH2 naph.), 3.37 (t, J = 7.0 Hz, 1H, CH(CO2Et)2), 2.61 (t, J = 7.0 Hz, 2H,
CHCH2CH=CHCH2 naph.), 1.19 (t, J = 6.5 Hz, 6H, OCH2CH3).

C NMR (125 MHz, CDCl3) δ

13

168.9, 136.4, 133.9, 131.9, 131.9, 128.7, 127.3, 126.9, 126.1, 125.8, 125.6, 125.5, 124.0, 61.3, 52.1,
36.0, 31.8, 14.1. IR ν(cm-1): 1744, 1734, 1506, 1369, 1150, 1030, 970, 859, 777. HRMS (ESI-TOF):
m/z 363.1576 [C21H24O4 + Na]+, calcd. 363.1572.

(E)-Diethyl 2-(4-(3-acetylphenyl)but-2-en-1-yl)malonate 467
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78.7 mg of 467 was prepared in 61% yield via the general procedure 11 from 328 (80.0 mg, 0.377
mmol, 1.0 eq), 3-acetylphenylboronic acid (92.8 mg, 0.566 mmol, 1.5 eq) and palladium acetate (0.85
mg, 0.0038 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.0 Hz, 1H, CHAr), 7.73 (s,
1H, CHAr), 7.38-7.33 (m, 2H, CHAr), 5.70-5.65 (m, 1H, CH=CHCH2Ar), 5.53-5.49 (m, 1H,
CH=CHCH2Ar), 4.20-4.12 (m, 4H, OCH2CH3), 3.39 (t, J = 7.5 Hz, 1H, CH(CO2Et)2), 3.37 (d, J =
7.0 Hz, 2H, CH=CHCH2Ar), 2.62 (t, J = 7.0 Hz, 2H, CHCH2CH=CHCH2Ar), 2.59 (s, 3H, O=CCH3),
1.22 (t, J = 7.5 Hz, 6H, OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 198.3, 168.9, 140.8, 137.3, 133.3,
131.6, 128.6, 128.3, 127.6, 126.2, 61.4, 52.0, 38.7, 31.7, 26.7, 14.1. IR ν(cm-1): 1734, 1727, 1684,
1269, 1175, 1155, 969, 859, 797. HRMS (ESI-TOF): m/z 355.1518 [C19H24O5 + Na]+, calcd.
355.1521.

(E)- Diethyl 2-(4-(p-tolyl)but-2-en-1-yl)malonate 474

54.6 mg of 474 was prepared in 48% yield via the general procedure 11 from 328 (80.0 mg, 0.377
mmol, 1.0 eq), 4-methylphenylboronic acid (76.9 mg, 0.566 mmol, 1.5 eq) and palladium acetate
(0.85 mg, 0.0038 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 7.08 (d, J = 8.0 Hz, 2H, CHAr),
7.03 (d, J = 8.0 Hz, 2H, CHAr), 5.69-5.66 (m, 1H, CH=CHCH2Ar), 5.49-5.43 (m, 1H,
CH=CHCH2Ar), 4.21-4.12 (m, 4H, OCH2CH3), 3.39 (t, J = 7.5 Hz, 1H, CH(CO2Et)2), 3.28 (d, J =
7.5 Hz, 2H, CH=CHCH2Ar), 2.61 (t, J = 7.5 Hz, 2H, CHCH2CH=CHCH2Ar), 2.31 (s, 3H, tolyl),
1.24 (t, J = 7.5 Hz, 6H, OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 168.9, 137.2, 135.5, 132.6, 129.1,
128.4, 126.7, 61.4, 52.2, 38.5, 31.8, 21.0, 14.1. IR ν(cm-1): 1743, 1734, 1559, 1507, 1369, 1153, 1030,
970, 805. HRMS (ESI-TOF): m/z 327.1577 [C18H24O4 + Na]+, calcd. 327.1572.

(E)-Diethyl 2-(4-(4-(ethoxycarbonyl)phenyl)but-2-en-1-yl)malonate 469
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90.1 mg of 469 was prepared in 90% yield via the general procedure 11 from 328 (58.4 mg, 0.275
mmol, 1.0 eq), 4-ethoxycarbonylphenylboronic acid (80.1 mg, 0.413 mmol, 1.5 eq) and palladium
acetate (0.62 mg, 0.0028 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 8.5 Hz, 2H,
CHAr), 7.21 (d, J = 8.5 Hz, 2H, CHAr), 5.71-5.65 (m, 1H, CH=CHCH2Ar), 5.53-5.48 (m, 1H,
CH=CHCH2Ar), 4.36 (q, J = 7.5 Hz, 2H, (4-CO2CH2CH3)Ph), 4.22-4.12 (m, 4H, OCH2CH3), 3.40 (t,
J = 8.0 Hz, 1H, CH(CO2Et)2), 3.37 (d, J = 6.5 Hz, 2H, CH=CHCH2Ar), 2.63 (t, J = 7.0 Hz, 2H,
CHCH2CH=CHCH2Ar), 1.39 (t, J = 7.5 Hz, 3H, (4-CO2CH2CH3)Ph), 1.24 (t, J = 7.0 Hz, 6H,
OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 168.9, 166.6, 145.7, 131.4, 130.0, 129.7, 128.5, 127.8,
61.4, 60.8, 52.1, 38.9, 31.7, 14.4, 14.1. IR ν(cm-1): 1749, 1723, 1715, 1507, 1559, 1272, 1177, 1102,
1020, 857, 761, 703. HRMS (ESI-TOF): m/z 385.1622 [C20H26O6 + Na]+, calcd. 385.1627.

(E)-Diethyl 2-(4-(3-methoxyphenyl)but-2-en-1-yl)malonate 471

51.0 mg of 471 was prepared in 72% yield via the general procedure 11 from 328 (49.4 mg, 0.220
mmol, 1.0 eq), 3-methoxyphenylboronic acid (50.1 mg, 0.330 mmol, 1.5 eq) and palladium acetate
(0.50 mg, 0.0022 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 7.19 (t, J = 8.0 Hz, 1H, CHAr),
6.74-6.73 (m, 2H, CHAr), 6.69 (s, 1H, CHAr), 5.71-5.65 (m, 1H, CH=CHCH2Ar), 5.51-5.46 (m, 1H,
CH=CHCH2Ar), 4.22-4.14 (m, 4H, OCH2CH3), 3.79 (s, 3H, OCH3), 3.40 (t, J = 7.5 Hz, 1H,
CH(CO2Et)2), 3.29 (d, J = 6.5 Hz, 2H, CH=CHCH2Ar), 2.62 (t, J = 7.5 Hz, 2H,
CHCH2CH=CHCH2Ar), 1.24 (t, J = 7.0 Hz, 6H, OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 169.0,
159.7, 141.9, 132.1, 129.3, 127.0, 120.8, 114.1, 111.3, 61.3, 55.1, 52.1, 38.9, 31.7, 14.0. IR ν(cm-1):
1734, 1730, 1260, 1151, 1034, 970, 858, 779. HRMS (ESI-TOF): m/z 343.1519 [C18H24O5 + Na]+,
calcd. 343.1521.

(E)-Diethyl 2-(4-(3,4-dimethoxyphenyl)but-2-en-1-yl)malonate 473
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18.5 mg of 473 was prepared in 23% yield via the general procedure 11 from 328 (48.1 mg, 0.227
mmol, 1.0 eq), 3,4-dimethoxyphenylboronic acid (62.3 mg, 0.341 mmol, 1.5 eq) and palladium
acetate (0.510 mg, 0.00227 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 6.81-6.78 (m, 1H, CHAr),
6.70-6.67 (m, 2H, CHAr), 5.70-5.63 (m, 1H, CH=CHCH2Ar), 5.51-5.45 (m, 1H, CH=CHCH2Ar),
4.21-4.14 (m, 4H, OCH2CH3), 3.87 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.40 (t, J = 7.5 Hz, 1H,
CH(CO2Et)2), 3.26 (d, J = 6.5 Hz, 2H, CH=CHCH2Ar), 2.62 (t, J = 7.0 Hz, 2H,
CHCH2CH=CHCH2Ar), 1.24 (t, J = 7.0 Hz, 6H, OCH2CH3). 13C NMR (125 MHz, CDCl3) δ 169.0,
148.9, 147.4, 133.0, 132.6, 126.7, 120.3, 111.9, 111.3, 61.4, 56.0, 55.9, 52.2, 38.5, 31.7, 14.1. IR
ν(cm-1): 1729, 1727, 1515, 1262, 1233, 1153, 1140, 1025. HRMS (ESI-TOF): m/z 373.1618
[C19H26O6 + Na]+, calcd. 373.1627.

Diethyl 2-((2E,5E)-nona-2,5-dien-1-yl)malonate 475

64.1 mg of 475 was prepared in 59% yield via the general procedure 11 from 328 (82.4 mg, 0.388
mmol, 1.0 eq), 1-pentenylphenylboronic acid (66.4 mg, 0.582 mmol, 1.5 eq) and palladium acetate
(0.870 mg, 0.00388 mmol, 1 mol%); 1H NMR (300 MHz, CDCl3) δ 5.75-5.63 (m, 1H, Branched,
(CO2Et)2CHCH2CH=CH

&

CH2CH=CH(CH2)2CH3),

5.58-5.45

(m,

1H,

Linear

trans,

(CO2Et)2CHCH2CH=CH

&

CH2CH=CH(CH2)2CH3),

5.38-5.21

(m,

3H,

Linear

trans,

(CO2Et)2CHCH2CH=CH

&

CH2CH=CH(CH2)2CH3),

5.05-4.99

(m,

2H,

Branched,

(CO2Et)2CHCH2CH=CH & CH2CH=CH(CH2)2CH3), 4.19 (q, J = 6.9 Hz, 4H, Branched+Linear
trans, OCH2CH3), 3.38 (t, J = 7.5 Hz, 1H, Branched+Linear trans, (CO2Et)2CH), 2.68-2.65 (m, 2H,
Branched+Linear trans, CH=CHCH2CH=CH), 2.59 (t, J = 6.9 Hz, 2H, Branched+Linear trans,
(CO2Et)2CHCH2CH=CH), 2.02-1.93 (m, 2H, Branched+Linear trans, CH=CHCH2CH2CH3), 1.39 (m,
2H, Branched+Linear trans, CH=CHCH2CH2CH3), 1.26 (t, J = 7.2 Hz, 6H, Branched+Linear trans,
OCH2CH3), 0.88 (t, J = 7.2 Hz, 3H, Branched+Linear trans, CH=CHCH2CH2CH3). 13C NMR (125
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MHz, CDCl3) δ 169.0, 132.3, 131.3, 128.0, 125.8, 61.3, 52.2, 35.5, 34.7, 31.8, 22.6, 14.1, 13.7. IR
ν(cm-1): 1751, 1734, 1559, 1457, 1228, 1151, 1096, 1033, 968, 858. HRMS (ESI-TOF): m/z 305.1716
[C16H26O4 + Na]+, calcd. 305.1729. Note Proton signals for branched isomer reported where clearly
distinguished, this was not the case for the

13

C NMR hence only the major linear trans product is

reported.

(E)-2-(4-Phenylbut-2-en-1-yl)malononitrile 477

210 mg of 477 was prepared in a yield of 54% via the general procedure 11 from 530 (237 mg, 2.01
mmol, 1.0 eq), phenylboronic acid (368 mg, 3.01 mmol, 1.5 eq) and palladium acetate (4.50 mg,
0.0201 mmol, 1 mol%); 1H NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.0 Hz, 2H, cis+trans, CHAr),
7.24-7.16 (m, 3H, cis+trans, CHAr), 6.00-5.94 (m, 1H, cis+trans, CH=CHCH2Ph), 5.58-5.49 (m, 1H,
cis+trans, CH=CHCH2Ph), 3.69 (t, J = 6.0 Hz, 1H, cis+trans, (CN)2CH), 3.48 (d, J = 7.0 Hz, 2H, cis,
CH=CHCH2Ph), 3.38 (d, J = 6.5 Hz, 2H, trans, CH=CHCH2Ph), 2.86 (t, J = 7.5 Hz, 2H, cis,
CH2CH=CHCH2Ph), 2.70 (t, J = 7.0 Hz, 2H, trans, CH2CH=CHCH2Ph).

13

C NMR (125 MHz,

CDCl3) δ 139.1, 137.7, 136.0 (cis), 128.8 (cis), 128.7, 128.6, 128.4 (cis), 126.6 (cis), 126.5, 122.1,
121.1 (cis), 112.3, 38.8, 33.8, 33.7 (cis), 28.7 (cis), 23.4, 22.9 (cis). IR ν(cm-1): 2258, 1768, 1653,
1559, 1266, 1174, 1037, 971, 735, 699. HRMS (ESI-TOF): m/z 195.0914 [C13H12N2 - H]-, calcd.
195.0922. N.B. only visible cis signals highlighted in 13C NMR.

(E)-Diethyl 2-(2,4-diphenylbut-3-en-1-yl)malonate 485

64.8 mg of 485 was prepared in 82% yield via the general procedure 11 from 498 (64.3 mg, 0.223
mmol, 1.0 eq), phenylboronic acid (40.8 mg, 0.335 mmol, 1.5 eq) and palladium(II) acetate (0.500
mg, 0.002 mmol, 1 mol%). 1H NMR (CDCl3, 300 MHz, CHAr) δ 7.36-7.20 (m, 10H, CHAr), 6.44 (d, J
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= 15.9 Hz, 1H, PhCH=CHCH(Ph)CH2), 6.29 (dd, J = 15.9, 8.1 Hz, 1H, PhCH=CHCH(Ph)CH2), 4.17
(q, J = 7.2 Hz, 4H, OCH2CH3), 3.48 (app q, J = 8.1 Hz, 1H, PhCH=CHCH(Ph)CH2), 3.36 (t, J = 7.5
Hz, 1H, (CO2Et)2CH), 2.46-2.37 (m, 2H, PhCH=CHCH(Ph)CH2), 1.25 (app q, J = 6.9 Hz, 6H,
OCH2CH3).

13

C NMR (CDCl3, 75 MHz) δ 169.5, 169.4, 142.8, 137.1, 132.2, 130.6, 128.7, 128.5,

127.6, 127.4, 126.8, 126.2, 61.4, 50.2, 47.0, 34.6, 14.1, 14.0. IR ν(cm-1): 1744, 1734, 1369, 1150,
1028, 966, 859, 746, 693. HRMS (ESI-TOF): m/z 389.1745 [C23H26O4 + Na]+, calcd. 389.1729.

(E)-Diethyl 2-(2-(4-fluorophenyl)-4-phenylbut-3-en-1-yl)malonate 486

69.7 mg of 486 was prepared in 82% yield via the general procedure 11 from 498 (64.2 mg, 0.223
mmol, 1.0 eq), 4-fluorophenylboronic acid (46.8 mg, 0.334 mmol, 1.5 eq) and palladium acetate
(0.50 mg, 0.00223 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 7.33 (d, J = 7.5 Hz, 2H, CHAr),
7.30-7.27 (m, 3H, CHAr), 7.26-7.20 (m, 2H, CHAr), 7.01 (t, J = 8.5 Hz, 2H, CHAr), 6.41 (d, J = 16.0
Hz, 1H, PhCH=CHCH(Ar)CH2), 6.24 (dd, J = 15.5, 7.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.19-4.11
(m, 4H, OCH2CH3), 3.47 (app q, J = 7.5 Hz, 1H, (Ar)CHCH2CH(CO2Et)2), 3.33 (t, J = 7.0 Hz, 1H,
CH(CO2Et)2), 2.43-2.34 (m, 2H, (Ar)CHCH2CH(CO2Et)2), 1.25-1.21 (m, 6H, OCH2CH3). 13C NMR
(CDCl3, 125 MHz) δ 169.4, 169.3, 161.7 (d, J = 244 Hz), 138.6, 137.0, 132.0, 130.8, 129.1 (d, J = 8
Hz), 128.6, 127.5, 126.3, 115.5 (d, J = 30 Hz), 61.5, 50.2, 46.3, 34.7, 14.1, 14.1. IR ν(cm-1): 1750,
1729, 1507, 1221, 1158, 1027, 967, 832, 744, 693. HRMS (ESI-TOF): m/z 407.1642 [C23H25FO4 +
Na]+, calcd. 407.1635.

(E)-Diethyl 2-(2-(3-acetylphenyl)-4-phenylbut-3-en-1-yl)malonate 487

46.1 mg of 487 was prepared in 60% yield via the general procedure 11 from 498 (54.9 mg, 0.191
mmol, 1.0 eq), 3-acetylphenylboronic acid (46.9 mg, 0.286 mmol, 1.5 eq) and palladium acetate
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(0.430 mg, 0.00191 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 7.85 (s, 1H, CHAr), 7.81 (d, J =
7.5 Hz, 1H, CHAr), 7.47 (d, J = 7.5 Hz, 1H, CHAr), 7.42 (t, J = 8.0 Hz, 1H, CHAr), 7.33 (d, J = 7.5 Hz,
2H, CHAr), 7.28 (t, J = 7.5 Hz, 2H, CHAr), 7.22-7.19 (m, 1H, CHAr), 6.45 (d, J = 16.0 Hz, 1H,
PhCH=CHCH(Ar)CH2), 6.26 (dd, J = 16.0, 8.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.19-4.12 (m, 4H,
OCH2CH3), 3.56 (app q, J = 8.0 Hz, 1H, (Ar)CHCH2CH(CO2Et)2), 3.34 (t, J = 7.0 Hz, 1H,
CH(CO2Et)2), 2.60 (s, 3H, O=CCH3), 2.47-2.39 (m, 2H, , PhCH=CHCH(Ar)CH2), 1.26-1.21 (m, 6H,
OCH2CH3). 13C NMR (CDCl3, 125 MHz) δ 198.3, 169.5, 169.4, 143.9, 137.8, 137.0, 132.3, 131.7,
131.5, 129.2, 128.8, 127.8, 127.5, 127.2, 126.5, 61.8, 61.7, 50.4, 47.3, 34.7, 27.0, 14.3, 14.2. IR
ν(cm-1): 1749, 1734, 1727, 1684, 1559, 1507, 1369, 1267, 1151, 1027, 967, 693. HRMS (ESI-MS):
m/z 431.1834 [C25H28O5 + Na]+, calcd. 431.1834.

(E)-Diethyl 2-(2-(4-chlorophenyl)-4-phenylbut-3-en-1-yl)malonate 488

65.2 mg of 488 was prepared in 61 % yield via the general procedure 11 from 498 (63.9 mg, 0.222
mmol, 1.0 eq), 4-chlorophenylboronic acid (52.1 mg, 0.333 mmol, 1.5 eq) and palladium acetate
(0.500 mg, 0.00222 mmol, 1 mol%). 1H NMR (CDCl3, 300 MHz) δ 7.36-7.29 (m, 5H, CHAr),
7.23-7.18 (m, 4H, CHAr), 6.42 (d, J = 15.9 Hz, 1H, PhCH=CHCH(Ar)CH2), 6.23 (dd, J = 15.6, 7.8
Hz, 1H, PhCH=CHCH(Ar)CH2), 4.21-4.10 (m, 4H, OCH2CH3), 3.47 (app q, J = 7.8 Hz, 1H,
(Ar)CHCH2CH(CO2Et)2), 3.33 (t, J = 7.2 Hz, 1H, CH(CO2Et)2), 2.45-2.33 (m, 2H,
PhCH=CHCH(Ar)CH2), 1.24 (app q, J = 7.5 Hz, 6H, OCH2CH3).

C NMR (CDCl3, 125 MHz) δ

13

169.3, 169.2, 141.4, 136.9, 132.5, 131.6, 131.0, 129.0, 128.9, 128.6, 127.5, 126.3, 61.5, 50.2, 46.4,
34.5, 14.1, 14.0. IR ν(cm-1): 1750, 1729, 1490, 1369, 695. HRMS (ESI-TOF): m/z 423.1347
[C23H25ClO4 + Na]+, calcd. 423.1339.
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(E)-Diethyl 2-(2-(2-chlorophenyl)-4-phenylbut-3-en-1-yl)malonate 489

25.3 mg of 489 was prepared in 38% yield via the general procedure 11 from 498 (47.8 mg, 0.166
mmol, 1.0 eq), 2-chlorophenylboronic acid (38.9 mg, 0.249 mmol, 1.5 eq) and palladium acetate
(0.370 mg, 0.00166 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 7.37-7.33 (m, 3H, CHAr),
7.29-7.26 (m, 4H, CHAr), 7.22-7.15 (m, 2H, CHAr), 6.47 (d, J = 15.5 Hz, 1H, PhCH=CHCH(Ar)CH2),
6.23 (dd, J = 15.5, 8.0 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.17 (app q, J = 7.0 Hz, 4H, OCH2CH3),
4.11-4.06 (m, 1H, PhCH=CHCH(Ar)CH2), 3.37 (t, J = 7.0 Hz, 1H, CH(CO2Et)2), 2.49-2.38 (m, 2H,
PhCH=CHCH(Ar)CH2), 1.26 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.22 (t, J = 7.5 Hz, 3H, OCH2CH3). 13C
NMR (CDCl3, 125 MHz) δ 169.3, 169.3, 140.2, 137.0, 134.0, 131.5, 130.6, 130.0, 128.5, 128.2,
127.8, 127.5, 127.3, 126.3, 61.5, 50.2, 42.7, 33.8, 14.1, 14.0. IR ν(cm-1): 1750, 1734, 1369, 1153,
1034, 966, 749, 697. HRMS (ESI-TOF): m/z 423.1357 [C23H25ClO4 + Na]+, calcd. 423.1339.

(E)-Diethyl 2-(2-(4-(ethoxycarbonyl)phenyl)-4-phenylbut-3-en-1-yl)malonate 490

84.2 mg of 490 was prepared in 62% yield via the general procedure 11 from 498 (89.3 mg, 0.310
mmol, 1.0 eq), 4-ethoxycarbonylphenylboronic acid (90.2 mg, 0.465 mmol, 1.5 eq) and palladium
acetate (0.790 mg, 0.00310 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 8.00 (d, J = 8.5 Hz, 2H,
CHAr), 7.33 (d, J = 8.0 Hz, 4H, CHAr), 7.29-7.25 (m, 2H, CHAr), 7.22-7.19 (m, 1H, CHAr), 6.43 (d, J
= 15.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 6.25 (dd, J = 15.5, 8.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.36
(q, J = 7.5 Hz, 2H, CHAr OCH2CH3), 4.19-4.10 (m, 4H, OCH2CH3), 3.55 (app q, J = 7.5 Hz, 1H,
PhCH=CHCH(Ar)CH2), 3.31 (t, J = 7.5 Hz, 1H, CH(CO2Et)2), 2.46-2.38 (m, 2H,
PhCH=CHCH(Ar)CH2), 1.38 (t, J = 7.5 Hz, 3H) , CHAr OCH2CH3, 1.26-1.20 (m, 6H, OCH2CH3).
C NMR (CDCl3, 125 MHz) δ169.5, 169.4, 166.6, 148.3, 137.0, 131.5, 131.5, 130.2, 129.3, 128.8,

13

127.8, 127.8, 126.5, 61.7, 61.1, 50.3, 47.3, 34.6, 14.6, 14.3, 14.2. IR ν(cm-1): 1750, 1729, 1718, 1273,
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1104, 1020, 968, 855, 694. HRMS (ESI-MS): m/z 461.1942 [C26H30O6 + Na]+, calcd. 461.1940.

(E)-Diethyl 2-(2-(3-nitrophenyl)-4-phenylbut-3-en-1-yl)malonate 491

30.1 mg of 491 was prepared in 23% yield via the general procedure 11 from 498 (94.0 mg, 0.326
mmol, 1.0 eq), 3-nitrophenylboronic acid (81.7 mg, 0.488 mmol, 1.5 eq) and palladium acetate
(0.730 mg, 0.00326 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 8.14 (s, 1H, CHAr), 8.10 (d, J =
8.5 Hz, 1H, CHAr), 7.61 (d, J = 8.0 Hz, 1H, CHAr), 7.51 (t, J = 8.0 Hz, 1H, CHAr), 7.35 (d, J = 7.5 Hz,
2H, CHAr), 7.30 (t, J = 7.5 Hz, 2H, CHAr), 7.26-7.22 (m, 1H, CHAr), 6.48 (d, J = 16.0 Hz, 1H,
PhCH=CHCH(Ar)CH2), 6.23 (dd, J = 15.5, 8.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.21-4.11 (m, 4H,
OCH2CH3), 3.62 (app q J = 8.0 Hz, 1H, PhCH=CHCH(Ar)CH2), 3.35 (t, J = 7.5 Hz, 1H,
CH(CO2Et)2), 2.47-2.42(m, 2H, PhCH=CHCH(Ar)CH2), 1.28-1.22 (m, 6H, OCH2CH3).
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C NMR

(CDCl3, 75 MHz) δ 169.1, 169.0, 148.5, 145.2, 136.4, 133.8, 132.0, 130.3, 129.7, 128.6, 127.8, 126.3,
122.5, 122.0, 61.7, 61.6, 50.0, 46.8, 34.3, 14.0, 14.0. IR ν(cm-1): 1744, 1734, 1719, 1528, 1349, 1152,
1027, 968, 736, 694, 690. HRMS (ESI): m/z 434.1601 [C23H25NO6 + Na]+, calcd. 434.1580.

(E)-Diethyl 2-(4-phenyl-2-(p-tolyl)but-3-en-1-yl)malonate 492

61.1 mg of 492 was prepared in 84% yield via the general procedure 11 from 498 (55.3 mg, 0.192
mmol, 1.0 eq), 4-methylphenylboronic acid (39.2 mg, 0.288 mmol, 1.5 eq) and palladium acetate
(0.440 mg, 0.00192 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 7.31 (d, J = 8.5 Hz, 2H, CHAr),
7.25 (t, J = 7.5 Hz, 2H, CHAr), 7.19 (t, J = 8.0 Hz, 1H, CHAr), 7.12 (s, 4H, CHAr), 6.42 (d, J = 16.0
Hz, 1H, PhCH=CHCH(Ar)CH2), 6.27 (dd, J = 16.0, 8.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.22-4.10
(m, 4H, OCH2CH3), 3.44 (app q, J = 8.0 Hz, 1H, PhCH=CHCH(Ar)CH2), 3.34 (t, J = 8.0 Hz, 1H,
CH(CO2Et)2), 2.45-2.34 (m, 2H, PhCH=CHCH(Ar)CH2), 2.32 (s, 3H, tolyl), 1.28-1.20 (m, 6H,
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OCH2CH3). 13C NMR (CDCl3, 125 MHz) δ 169.5, 169.4, 139.8, 137.2, 136.3, 132.6, 130.4, 129.4,
128.5, 127.5, 127.3, 126.3, 61.4, 50.3, 46.6, 34.7, 21.1, 14.1. IR ν(cm-1): 1749, 1734, 1265, 1152,
1028, 967, 734, 703. HRMS (ESI-TOF): m/z 403.1871 [C24H28O4 + Na]+, calcd. 403.1885.

(E)-Diethyl 2-(2-(naphthalen-1-yl)-4-phenylbut-3-en-1-yl)malonate 493

94.4mg of 493 was prepared in 72% yield via the general procedure 11 from 498 (97.8 mg, 0.340
mmol, 1.0 eq), 1-naphthalenephenylboronic acid (87.6 mg, 0.509 mmol, 1.5 eq) and palladium
acetate (0.760 mg, 0.00340 mmol, 1 mol%). 1H NMR (CDCl3, 300 MHz) δ 8.20 (d, J = 8.4 Hz, 1H,
CHAr), 7.86 (d, J = 7.8 Hz, 1H, CHAr), 7.74 (d, J = 7.2 Hz, 1H, CHAr), 7.55-7.14 (m, 9H, CHAr), 6.53
(d, J = 15.9 Hz, 1H, PhCH=CHCH(Ar)CH2), 6.46 (dd, J = 15.9, 7.2 Hz, 1H, PhCH=CHCH(Ar)CH2),
4.36 (app q, J = 6.9 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.20 (q, J = 6.9 Hz, 2H, OCH2CH3), 4.17-4.07
(m, 2H, OCH2CH3), 3.49 (t, J = 7.2 Hz, 1H, CH(CO2Et)2), 2.61-2.54 (m, 2H, PhCH=CHCH(Ar)CH2),
1.26 (t, J = 7.2 Hz, 3H, OCH2CH3), 1.16 (t, J = 6.9 Hz, 3H, OCH2CH3). 13C NMR (CDCl3, 75 MHz)
δ 169.5, 169.5, 139.1, 137.0, 134.1, 131.8, 131.5, 131.3, 129.0, 128.5, 128.4, 127.4, 127.4, 126.3,
126.1, 125.6, 124.1, 123.2, 61.5, 50.3, 41.6, 34.5, 14.1, 14.0. IR ν(cm-1): 1749, 1729, 1369, 1151,
1027, 969, 778, 697. HRMS (ESI-TOF): m/z 439.1882 [C27H28O4 + Na]+, calcd. 439.1885.

(E)-Diethyl 2-(2-phenyl-4-(p-tolyl)but-3-en-1-yl)malonate 494

128.7 mg of 494 was prepared in 77% yield via the general procedure 11 from 481 (134.1 mg, 0.4440
mmol, 1.0 eq), phenylboronic acid (81.2 mg, 0.666 mmol, 1.5 eq) and palladium acetate (0.994 mg,
0.000444 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 7.31 (t, J = 7.0 Hz, 2H, CHAr), 7.27-7.14
(m, 5H, CHAr), 7.08 (d, J = 8.0 Hz, 2H, CHAr), 6.40 (d, J = 16.0 Hz, 1H, PhCH=CHCH(Ar)CH2),
6.22 (dd, J = 15.5, 8.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.18-4.11 (m, 4H, OCH2CH3), 3.46 (app q, J
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= 8.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 3.35 (t, J = 7.5 Hz, 1H, CH(CO2Et)2), 2.44-2.35 (m, 2H,
PhCH=CHCH(Ar)CH2), 2.31 (s, 3H, tolyl), 1.23 (app q, J = 9.0 Hz, 6H, OCH2CH3).
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C NMR

(CDCl3, 125 MHz) δ 169.5, 169.4, 143.1, 137.1, 134.3, 131.2, 130.5, 129.2, 128.7, 127.6, 126.7,
126.1, 61.4, 50.3, 47.0, 34.7, 21.1, 14.1, 14.0. IR ν(cm-1): 1749, 1730, 1653, 1507, 1457, 1369, 1150,
1097, 1030, 969, 853, 807, 761, 700. HRMS (ESI-TOF): m/z 403.1903 [C24H28O4 + Na]+, calcd.
403.1885.

(E)-Diethyl 2-(4-(2-chlorophenyl)-2-phenylbut-3-en-1-yl)malonate 495

177.1 mg of 495 was prepared in 80% yield via the general procedure 11 from 482 (218.1 mg, 0.6760
mmol, 1.0 eq), phenylboronic acid (123.6 mg, 1.014 mmol, 1.5 eq) and palladium acetate (1.501 mg,
0.006760 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 7.48 (d, J = 5.5 Hz, 1H, CHAr), 7.35-7.32
(m, 2H, CHAr), 7.27-7.22 (m, 3H, CHAr), 7.19-7.13 (m, 3H, CHAr), 6.83 (d, J = 16.0 Hz, 1H,
PhCH=CHCH(Ar)CH2), 6.26 (dd, J = 15.5, 8.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.20-4.12 (m, 4H,
OCH2CH3), 3.54 (app q, J = 8.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 3.37 (t, J = 8.0 Hz, 1H,
CH(CO2Et)2), 2.47-2.40 (m, 2H, PhCH=CHCH(Ar)CH2), 1.23 (app q, J = 6.5 Hz, 6H, OCH2CH3).
C NMR (CDCl3, 125 MHz) δ 169.4, 169.3, 142.6, 135.2, 135.1, 132.9, 129.6, 128.8, 128.4, 127.6,

13

126.9, 126.9, 126.8, 126.8, 61.5, 50.2, 47.3, 34.5, 14.1, 14.1. IR ν(cm-1): 1748, 1727, 1472, 1437,
1369, 1264, 1150, 1031, 966, 856, 750, 699. HRMS (ESI-MS): m/z 423.1348 [C23H25ClO4 + Na]+,
calcd. 423.1339.

(E)-Diethyl 2-(4-(4-bromophenyl)-2-phenylbut-3-en-1-yl)malonate 496

13.5 mg of 496 was prepared in 43% yield via the general procedure 11 from 484 (25.6 mg, 0.0715
mmol, 1.0 eq), phenylboronic acid (13.1 mg, 0.107 mmol, 1.5 eq) and palladium acetate (0.160 mg,
206

0.0000715 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 7.40 (d, J = 8.5 Hz, 2H, CHAr), 7.33 (t, J
= 8.0 Hz, 2H, CHAr), 7.26-7.22 (m, 3H, CHAr), 7.19 (d, J = 8.5 Hz, 2H, CHAr), 6.36 (d, J = 16.0 Hz,
1H, PhCH=CHCH(Ar)CH2), 6.27 (dd, J = 16.0, 7.5 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.19-4.11 (m,
4H, OCH2CH3), 3.47 (app q, J = 8.0 Hz, 1H, PhCH=CHCH(Ar)CH2), 3.31 (t, J = 7.0 Hz, 1H,
CH(CO2Et)2), 2.45-2.36 (m, 2H, PhCH=CHCH(Ar)CH2), 1.22 (app q, J = 6.5 Hz, 6H, OCH2CH3).
C NMR (CDCl3, 125 MHz) δ 169.4, 169.3, 142.5, 136.0, 133.2, 131.6, 129.4, 128.8, 127.8, 127.6,

13

126.9, 121.1, 61.5, 50.2, 47.1, 34.5, 14.1. IR ν(cm-1): 1734, 1694, 1646, 1551, 1515, 1462, 1370,
1223, 1154, 1034, 972, 858, 804, 695. HRMS (ESI-MS): m/z 467.0856 [C23H25BrO4 + Na]+, calcd.
467.0834.

(E)-Diethyl 2-(4-(4-methoxyphenyl)-2-phenylbut-3-en-1-yl)malonate 497

78.8 mg of 497 was prepared in 64% yield via the general procedure 11 from 483 (99.6 mg, 0.313
mmol, 1.0 eq), phenylboronic acid (57.2 mg, 0.470 mmol, 1.5 eq) and palladium acetate (0.700 mg,
0.000313 mmol, 1 mol%). 1H NMR (CDCl3, 500 MHz) δ 7.31 (t, J = 8.0 Hz, 2H, CHAr), 7.26 (t, J =
8.0 Hz, 4H, CHAr), 7.21 (t, J = 7.5 Hz, 1H, CHAr), 6.82 (d, J = 8.0 Hz, 2H, CHAr), 6.37 (d, J = 16.0
Hz, 1H, PhCH=CHCH(Ar)CH2), 6.13 (dd, J = 16.0, 8.0 Hz, 1H, PhCH=CHCH(Ar)CH2), 4.18-4.10
(m, 4H, OCH2CH3), 3.77 (s, 3H, OCH3), 3.45 (app q, J = 8.0 Hz, 1H, PhCH=CHCH(Ar)CH2), 3.35 (t,
J = 7.5 Hz, 1H, CH(CO2Et)2), 2.42-2.37 (m, 2H, PhCH=CHCH(Ar)CH2), 1.28-1.21 (m, 6H,
OCH2CH3). 13C NMR (CDCl3, 125 MHz) δ 169.5, 169.4, 159.0, 143.1, 130.1, 130.0, 129.9, 128.7,
127.6, 127.4, 126.7, 113.9, 61.4, 55.3, 50.3, 47.1, 34.7, 14.1. IR ν(cm-1): 1748, 1727, 1608, 1511,
1457, 1369, 1248, 1150, 1030, 967, 760, 700. HRMS (ESI-MS): m/z 419.1832 [C24H28O5 + Na]+,
calcd. 419.1834.
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General Procedure 12 for Decarboxylation of Targeted product 50012

A solution of 452 (108.6 mg, 0.374 mmol, 1.0 eq) and NaCl (30.0 mg, 0.512 mmol, 1.37 eq) in
DMSO (0.62 mL) and distilled water (25.4 μL) was heated at 170°C for 1 hr in a microwave.
Distilled water (20 mL) was added and the mixture was extracted with ethyl acetate (3 x 20 mL). The
combined organic phase was dried over Na2SO4 and concentrated in vacuo. The crude product was
purified with column chromatography (15% ethyl acetate in hexane) to afford 500 (49 mg, 60%) as a
brown oily liquid. 1H NMR (CDCl3, 500 MHz) δ 7.30-7.26 (m, 2H, CHAr), 7.20-7.16 (m, 3H, CHAr),
5.66-5.57 (m, 1H, PhCH2CH=CH), 5.55-5.46 (m, 1H, PhCH2CH=CH), 4.12 (t, J = 6.5 Hz, 2H,
OCH2CH3), 3.33 (d, J = 6.5 Hz, 2H, PhCH2CH=CH), 2.40-2.36 (m, 4H, PhCH2CH=CHCH2CH2),
1.25 (q, J = 6.5 Hz, 3H, OCH2CH3). 13C NMR (CDCl3, 125 MHz) δ 173.2, 140.7, 130.2, 129.7, 128.5,
128.4, 126.0, 60.3, 49.2, 39.0, 34.3, 27.8, 14.3. IR ν(cm-1): 1734, 1495, 1452, 1373, 1248, 1178, 1156,
1030, 968, 745, 698. HRMS (ESI-TOF): m/z 241.1208 [C14H18O2 + Na]+, calcd. 241.1204.
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Appendix

220

HPLC Chromatograms for ee Determination
Figure 1. HPLC chromatogram for racemic 126 (AD column: 90:10 Hexane-Isopropanol; 0.5
ml.min-1)

Figure

2.

HPLC

chromatogram

for

enantiopure

(R)-126'

(AD

column:

90:10

Hexane-Isopropanol; 0.5 ml.min-1)

221

Figure 3. HPLC chromatogram for enantiopure (R)-126' synthesised in the presence of BQ (AD
column: 90:10 Hexane-Isopropanol; 0.5 ml.min-1)
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